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ABSTRACT
The initial lesions observed in Crohn's disease typically occur over lymphoid 
aggregates in the large bowel and Peyer's patches in the small bowel, where 
M-cells are present. An increased presence of Adherent and Invasive 
Escherichia coli (AIEC) has been reported in Crohn's disease mucosa. Crohn's 
disease is common in westernised countries where low levels of soluble fibre 
are eaten and where the use of emulsifiers in processed food is common. It is 
possible that dietary factors may be implicated in the pathogenesis of the 
disease. The aims of this work were to establish if AIEC interact with 
intestinal M-cells, and to establish the effect that dietary factors have on 
these interactions.
Crohn's disease AIEC are translocated across M-cells significantly more than 
control E. coli K12, and translocation of Crohn's disease AIEC is significantly 
higher across M-cells than across control Caco2-cll monolayers. Soluble 
plantain fibre markedly reduced translocation of Crohn's disease AIEC across 
M-cells, as did soluble broccoli fibre. The food emulsifiers polysorbate-60 and 
polysorbate-80 led to increased translocation of Crohn's disease AIEC across 
Caco2-cll monolayers, but the effect was less clear across M-cell monolayers.
Crohn's disease AIEC demonstrated the ability to survive and replicate within 
macrophages at levels significantly greater than control E. coli K12. 
Combinations of the antibiotics ciprofloxacin, tetracycline, clarithromycin, 
trimethoprim and rifampicin were able to kill Crohn's disease AIEC within 
macrophages.
This work supports the hypothesis that M-cells play an important role the 
pathogenesis of Crohn's disease. The replication of AIEC within macrophages 
may result in the typical granulomatous lesions observed in Crohn's disease. 
The effect of soluble plant fibres on inhibition of bacterial translocation 
across M-cells represents a novel effect that might be an important 
mechanism by which dietary fibre could promote intestinal health.
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Chapter 1
Introduction, 
Hypothesis and 
Aims
1.1 CROHN'S DISEASE
Crohn's disease (CD) is a chronic inflammatory disorder affecting the 
gastrointestinal (Gl) tract. Typically, any part of the Gl tract can be involved, 
although most commonly the distal ileum and caecum are affected. The 
disease is characterised by uncontrolled inflammation of the intestinal 
mucosa, and deep inflammation with granulomata (in about 70% of cases). 
The mucosal immune system of patients becomes chronically activated, and 
the intestine remains chronically inflamed.
The symptoms of Crohn's disease vary amongst individual patients; the main 
gastrointestinal symptoms are cramp-like abdominal pain, diarrhoea, 
vomiting or weight loss.
The disease was independently described by Thomas Kennedy Dalziel in 1913 
[Dalziel 1913], and in 1932 by the American gastroenterologist Burrill Bernard 
Crohn, after whom the disease was named. Crohn, along with two colleagues, 
described a series of patients with inflammation of the terminal ileum, the 
area most commonly affected by the illness [Crohn et al. 2000].
Crohn's disease is currently of unknown aetiology. It is considered to be a 
multi-factorial disease, consisting of interplay between host genetics, 
aberrant immune responses to environmental factors and to the gut 
microbiota, and defects in the epithelial barrier.
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1.2 EPIDEMIOLOGY
1.2.1 Incidence and prevalence
Studies conducted across the UK (Aberdeen [Kyle 1992] and Cardiff [Thomas 
et al. 1995]), and some parts of Europe (Stockholm [Lapidus et al. 1997] and 
Örebro [Lindberg et al. 1991] in Sweden) suggest that the incidence of 
Crohn's disease rose during the 1950s and 1960s. More recently, some 
reports suggest that Crohn's disease incidences have been decreasing from 
north to south across Europe [Stewenius et al. 1995; Lapidus et al. 1997], 
whilst other studies have found comparable rates between Southern and 
Northern Europe [Shivananda et al. 1996]. There is considerable difficulty in 
establishing the true incidence of Crohn's disease across different European 
countries, due in part to historical and local differences in Crohn's disease 
diagnosis, and the difficulties in obtaining comparable retrospective data for 
analyses [Logan 1998].
Within the UK, epidemiological data derived from hospital led studies find 
the incidence of Crohn's disease to be 6.7 per 100,000 annually (range 1.6 to 
14.6), with a prevalence of 140 cases per 100,000 people (range 10 to 199) 
[Cummings et al. 2008]. Studies of the general practice population puts the 
incidence of Crohn's disease at 8.3 cases per 100,000 people annually, and 
the prevalence at 144.8 cases per 100,000 people [Rubin et al. 2000].
1.2.2 Sex, age and racial incidence
The onset of Crohn's disease has a bimodal distribution. The first and largest 
peak occurs between the ages of 15-30 years [Rubin et al. 2000]; around 10% 
of cases occur in individuals younger than 18 years of age [Hanauer 2006]. 
The second, much smaller peak is between 50 - 70 years [Andres et al. 1999].
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The disease tends to occur in peoples of a higher socioeconomic group 
[Andres et al. 1999; Loftus 2004]. People of Caucasian and Ashkenazic Jewish 
origin have higher rates of Crohn's disease than individuals of other 
backgrounds [Loftus 2004]. Whilst the incidence among ethnic or racial 
minority groups is still lower than that of Caucasians and Ashkenazic Jewish, 
the gap between the groups has been closing, with increased incidence of 
Crohn's disease over recent years in African Americans [Loftus 2004] and in 
second generation South Asians who have migrated to developed countries 
[Montgomery etal. 1999].
1.3 GENETIC FACTORS IMPLICATED IN CROHN'S DISEASE
1.3.1 Family occurrence
Several family association studies have demonstrated a genetic contribution 
to the pathogenesis of Crohn's disease [Weterman et al. 1984; Monsen et al. 
1991; Orholm et al. 1991; Halme et al. 2006]. In one such study from 
Denmark, analysis of 133 Crohn's disease patients revealed that first degree 
relatives had a 10-fold increased risk for Crohn's disease, after 
standardization for age and sex, compared to the general population [Orholm 
et al. 1991]. This was subsequently followed up by a much larger study 
several years later using a national database consisting of millions of patients, 
where similar outcomes were observed [Orholm et al. 1999].
The age at which Crohn's disease occurs also seems to be influenced 
genetically - patients with Crohn's disease and a family history tend to get 
their disease at an earlier age than patients without a family history [Van 
Kruiningen et al. 2007].
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In addition, twin studies have revealed that monozygotic twins with Crohn's 
disease have a much higher disease concondance (50%) of the disease than 
dizygotic twins (3.8%), indicating that genetic factors play an important role 
in Crohn's disease development [Halfvarson et al. 2003]. Similar findings have 
been observed from other independent groups [Burak et al. 1998; Orholm et 
al. 2000; Halme et al. 2006; Spehlmann et al. 2008].
1.3.2 The immune system
The immune system can be divided into two systems, namely the innate 
(non-specific) and the adaptive (specific), which operate at both the local 
(humoral) and systemic level [Wood, 2001]. The innate and adaptive immune 
systems work together through direct cell contact and through interactions 
involving chemical mediators, cytokines and chemokines. Aberrant 
functioning of the immune system has been implicated in Crohn's disease 
[van Lierop et al. 2009; Gersemann et al. 2009],
The epithelium within the intestine acts as the interface between the 
intestinal lumen and the intestinal tissue; it consists of a single layer of cells 
protected by a layer of mucus (produced by goblet cells) on the luminal 
surface [Macpherson et al. 2004]. Paneth cells within the epithelium produce 
antimicrobial peptides such as a-defensins [Ayabe et al. 2000], lysozyme 
[Chung et al. 1988; Cross et al. 1988] and phospholipase A2 [Talvinen et al. 
2001; Keshav 2006], all of which act as a first line defence against pathogens, 
and serve as part of the innate immune response. If Paneth cells come into 
direct contact with invading microbes or microbial molecules, production of 
further and higher amounts of antimicrobial peptides is induced [Ayabe et al. 
2000]. The released antimicrobial peptides have the ability to attract antigen- 
presenting cells and lymphocytes [Yang et al. 2002], in this way, Paneth cells
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play a role in both the innate immune response, and in activating the 
adaptive immune system.
In healthy individuals, Paneth cells are found only in the small intestine, in 
Crohn's disease, Paneth cells have been found to also develop in the colonic 
mucosa [Muller et al. 2005]. Altered antimicrobial peptide production by 
Paneth cells has been implicated in Crohn's disease by several independent 
groups [Lala at el. 2003; Wehkamp at el. 2005; Wang at el. 2007].
Innate immunity is often considered a first line defence against microbial 
infection; it serves to protect the host from infection by other organisms, in a 
non-specific manner, without any long lasting specific immunity [Medzhitov, 
2007; Wood, 2001]. The innate immune response involves several host cells 
and components, including epithelial barriers, phagocytes (neutrophils, and 
monocytes/macrophages), mast cells, Paneth cells, natural killer cells, the 
complement system, and innate immunity associated cytokines. Together 
these cells act to recognize and eliminate foreign antigens through 
phagocytosis. In Crohn's disease, this process is understood to be 
deregulated, and several genes have been identified which are thought to be 
involved in this process and which are closely linked to Crohn's disease 
susceptibility [The Wellcome Trust Case Control Consortium, 2007; Barrett et 
al. 2008; Fisher et al. 2008].
Conversely, the adaptive immune is triggered by the innate immune system 
and acts to recognize and remember specific pathogens, conferring long 
lasting specific immunity. Cells involved in the adaptive immune response 
involve B cell lymphocytes (which secrete antibodies) and memory T cells 
(also a lymphocyte cell). B cells mature mainly under the influence of bone 
marrow and give rise to lymphoid populations which, on contact with
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antigen, proliferate and differentiate into plasma cells. In turn, these plasma 
cells produce a humoural factor (an antibody) which is specific for the antigen 
and which is able to neutralise or eliminate the antigen. T lymphocytes 
mature under the influence of the thymus, and upon stimulation by antigen, 
give rise to cellular immunity -  this provides the immune system with a 
memory of the antigen after the infection has subsided) [Wood, 2001].
1.3.3 Susceptibility genes
The pathogenic mechanisms of Crohn's disease are poorly understood. Fine 
mapping as well as candidate gene studies have led to the identification of a 
number of susceptibility genes for Crohn's disease. A bioinformatics based 
approach has led to the identification of upwards of 30 genes which have 
been implicated in the pathogenesis of Crohn's disease [The Wellcome Trust 
Case Control Consortium, 2007; Barrett et al. 2008; Fisher et al. 2008].
Well documented genes thought to be associated with Crohn's disease 
include autophagy genes ATG16L1 (ATG16 autophagy-related 16-like 1) and 
IRGM (immunity-related guanosine triphosphatase). Other genes identified 
included NOD2/CARD15 (nucleotide-binding oligomerization domain 
containing 2 / caspase recruitment domain family, member 15), MST-1 
(macrophage stimulating 1, a protein that influences motile activity and 
phagocytosis by peritoneal macrophages) and interleukin-23 receptor 
(IL23R).
Recent work by Barrett et al. has identified several other gene loci to be 
associated with Crohn's disease [Barrett et al. 2008]. These newly identified 
loci contain genes such as PTPN2 and PTPN22 (protein tyrosine phosphate, 
nonreceptor types 2 and 22), LRRK2 (leucine-rich repeat kinase 2, a multi­
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domain protein expressed mainly in the cytoplasm of myeloid cells and 
monocytes, and potentially in autophagy [Plowey et al. 2008]), ITLN1 
(intelectin-1), CCR6 (chemokine receptor 6, a member of the G protein- 
coupled chemokine receptor family), IL12B (interleukin-12 B, this gene 
encodes a p40 subunit which forms part of both IL-12 and IL-23), STAT3 
(signal transducer and activator of transcription 3) and JAK2 (Janus kinase 2. 
The JAK-STAT signalling pathway is involved downstream of cytokine and 
growth factor signalling from cell surface receptors, it functions to signal to 
the nucleus to modify transcription of various genes).
The identified genes have been associated with a diverse range of cellular 
processes, from regulation of the intestinal epithelial barrier, innate immune 
responses, adaptive immune responses and cellular signalling, suggesting 
that a dysregulated immune response to commensal intestinal bacteria and 
possibly defects in mucosal barrier function or bacterial clearance may be 
involved in Crohn's disease pathogenesis [Sartor 2006].
1.3.3.1 Innate immune response
The gene products of NOD2/CARD15, NODI and TLR4 are involved in the 
recognition of bacterial products.
In 2001, positional cloning identified CARD15 (caspase recruitment domain 
family, member 15) / NOD2 (nucleotide-binding oligomerization domain 
containing 2) as the first confirmed Crohn's disease-susceptibility gene 
[Hugot et al. 2001; Ogura et al. 2001]. Since then, more than 30 variations in 
the NOD2 gene have been associated with an increased risk of Crohn's 
disease in the lower part of the small intestine (the ileum). This increased risk 
has been found only in Caucasian (white) populations.
8
The N0D2 protein is active in immune cells such as monocytes, macrophages, 
paneth cells, and dendritic cells; it acts as a cytoplasmic sensor of the 
bacterial peptidoglycan component muramyl dipeptide [Bonen et al. 2003; 
Voss et al. 2006]. Once activated, NOD2 activates NF-kB (nuclear factor- 
kappaB), which in turn regulates the activity of multiple genes, including 
genes that control immune responses and inflammatory reactions which help 
protect the intestine from bacterial invasion.
1.3.3.2 Intestinal epithelial barrier function
The NOD2 protein is also active in Paneth cells, found in the base of the 
crypts, particularly in the distal small intestine [Lala et al. 2003]. It can be 
envisaged that mutations in NOD2 would affect regulation of Paneth cell 
mediated responses against intestinal bacteria, and perhaps the intestinal 
barrier itself [Ogura et al. 2003].
The gene products of MDR1 (multidrug resistance gene), OCTN (organic 
carion transporters) [Reinhard et al. 2006] and DLG (discs large homolog) are 
thought to play a role in maintaining the intestinal epithelial barrier [Van 
Limbergen et al. 2007]. All have gene mutations which have been associated 
with Crohn's disease.
The MDR1 gene encodes an efflux pump of amphipathic toxins, it is highly 
expressed in distal small bowel and colon - genetic variants in MDR1 could 
interfere with mucosal detoxification [Satsangi et al. 1996; van Heel et al. 
2004]. Under specific pathogen-free conditions, MDR-1 knockout mice are 
susceptible to the development of a severe, spontaneous intestinal 
inflammation that is preventable by, and treatable with, antibiotics [Panwala 
et a!. 1998].
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DLG5 is a member of the caspase recruitment domain (CARD) interaction 
network family [Friedrichs et al. 2008] and of the membrane-associated 
guanylate kinase (MAGUK) family [Van Limbergen et al. 2007]. MAGUKs are 
known to form scaffolds for proteins involved in intraceullar signal 
transduction. DLG5 encodes a scaffolding protein involved in the 
maintenance of epithelial integrity [Stoll et al. 2004]; variants in DLG5 protein 
could therefore interfere with the epithelial barrier function.
1.3.3.3 Cellular signalling
A recent genome wide study [The Wellcome Trust Case Control Consortium, 
2007] found a highly significant association between Crohn's disease and the 
IL23R gene on chromosome lp31. This gene encodes a subunit of the 
receptor for the proinflammatory cytokine interleukin-23 [Duerr et al. 2006], 
which is pivotal in the differentiation of T helper (Thl7) cells. In animal 
models, the Thl7 T cell subset mediates chronic and autoimmune 
inflammatory conditions [Van Limbergen et al. 2007]. Variants of this gene 
can confer an increased risk of Crohn's disease development [Amre et al. 
2008; Taylor et al. 2008], whilst a relatively rare variant has been found to 
confer strong protection against developing Crohn's disease [Dubinsky et al. 
2007].
1.3.3.4 Autophagy
Significant associations between an intergenic region on 10q21.1 and a 
coding variant in ATG16L1 (ATG16 autophagy related 16-like 1) have been 
identified for Crohn's disease [Hampe et al. 2007; Rioux et al. 2007]. ATG16L1 
is highly expressed in intestinal epithelial and immune cells and is important 
for autophagy, a cellular process involved in the degradation and processing 
of bacteria [Hampe et al. 2007; Rioux et al. 2007]. Rioux et al. demonstrated 
that ATG16L1 was expressed in intestinal epithelial cell lines, and knockdown
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of the gene abrogates autophagy of Salmonella Typhimurium, suggesting that 
autophagy and host cell responses to intracellular microbes are involved in 
the pathogenesis of Crohn's disease [Rioux et al. 2007].
Several variations in or near the IRGM gene (5q33.1) have been associated 
with an increased risk of developing Crohn's disease. Variants in IRGM 
(immunity-related GTPase family, M), encoding a GTP-binding protein which 
induces autophagy, has also been shown to be associated with Crohn's 
disease [The Wellcome Trust Case Control Consortium, 2007]. The product of 
this gene is involved in elimination of intracellular bacteria, including 
Mycobacterium tuberculosis [Singh et al. 2006]. Reduced function and/or 
activity of this gene would be expected to prevent the immune system from 
destroying harmful bacteria effectively leading to persistence of intracellular 
bacteria. An abnormal immune response to bacteria in the intestinal walls 
may lead to chronic inflammation and the digestive problems characteristic 
of Crohn's disease.
1.4 EVIDENCE FOR BACTERIAL INVOLVEMENT IN CROHN'S DISEASE
1.4.1 The role of the faecal stream
Some of the clearest evidence to support a role for bacterial involvement in 
Crohn's disease comes from observations following surgery; the creation of a 
diverting ileostomy prevents postoperative recurrence, but disease often 
recurs rapidly following reanastomosis [Rutgeerts et al. 1991]. Fractionation 
of the faecal stream followed by selective réintroduction demonstrated 
exacerbation of inflammation by particles greater than 0.22 pm -  consistent 
with the involvement of a bacterial factor [Harper et al. 1985].
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1.4.2 Stool microbiology
1.4.2.1 Gut microbiota In the healthy individual
The normal human colonic microbiota is made up of a complex ecosystem of 
over 500 species of bacteria [Madsen et al. 1999; Prindiville et al. 2000]. 
These bacterial species comprise 95% of the cells in the human body [Dunne 
et al. 1999]. There is a gradual increase in the population along the small 
bowel, from approximately 104 colony forming units (CFU) per gram of 
luminal content in the jejunum to 107 in the distal ileum, with a 
predominance of Gram negative aerobes and some obligate anaerobes 
[Guarner et al. 2003]. Conversely, the human colon is heavily populated with 
anaerobes with bacterial counts in the region of 1014 per gram of luminal 
content [Egert et al. 2006].
Traditionally, culture methods together with phylogenetic classification have 
been used to identify and characterise faecal microbiota, but with the 
limitation that around 70 -  90% of bacteria are, to date, unculturable 
[Eckburg et al. 2005]. More modern methods have allowed for 
characterisation of 16S rRNA sequence diversity [Rinttila et al. 2004] and the 
use of denaturing gradient gel electrophoresis in combination with PCR 
[Bibiloni et al. 2005] have allowed for insight and detection of the normal 
microflora, and changes in response to disease [Andersson et al. 2008].
In the healthy gut, Firmicutes (low-G+C Gram positives), Bacteroides and 
Actinobacteria (high-G+C Gram positives) are the most common species 
[Backhed et al. 2005]. Probably the single most common is Bacteroides spp., 
which account for the majority of intestinal obligate anaerobes in the colon 
with counts of between 1010 and 1011 cells per gram of intestinal contents. E. 
coli is the predominant facultative anaerobe of the human colonic microbiota
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[Boudeau et al. 1999] but accounts for less than 0.7% of the total human 
microbiota.
1.4.2.2 Gut microbiato alterations in Crohn's disease
Sokol et al. used fluorescent in situ hybridization adapted to flow cytometry 
to demonstrate that the bacterial composition of fecal samples from 13 
patients with active Crohn's disease had significantly lower levels of 
Clostridium leptum compared to healthy subjects [Sokol et al. 2006], whilst 
Manichanh et al. demonstrated a significant reduction in the Firmicutes 
phylum in Crohn's disease compared to healthy control patients [Manichanh 
et al. 2006].
1.4.3 Role of Mycobacterium avium subsp paratuberculosis (MAP)
In 1913, Dalziel, a Scottish physician, likened the clinical appearance of 
chronic intestinal enteritis in man (later defined as Crohn's disease) with the 
appearance of Johne's disease in cattle (paratuberculosis) as - 'the 
histological characters and naked-eye appearances are as similar [in cattle] as 
may be to those we have found in man' [Dalziel 1989]. This suggested for the 
first time the idea that Crohn's disease might be caused by a specific 
organism, like Johne's disease, which is caused by Mycobacterium avium 
subspecies paratuberculosis (MAP). Since then, others have noted the clinical 
and pathological similarities between Johne's and Crohn's disease [Chiodini 
1989; Greenstein 2003].
Since then however, the literature has been divided on whether MAP is a 
causative agent in Crohn's disease, with several dozen studies providing 
evidence to either prove or disprove the association of MAP with Crohn's 
disease [Sartor 2005]. Whilst MAP has been detected in Crohn's disease
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tissue by culture, PCR and by FISH analysis by some groups [Chiodini et al. 
1984; Sanderson etal. 1992; Hulten et al. 2001; Sechi et al. 2001; Autschbach 
et al. 2005], not all groups have been able to detect the presence of MAP 
with reported detection rates ranging from 0 -  100% in Crohn's disease tissue 
[Mishina et al. 1996; Behr et al. 2006]. However, MAP has been cultured from 
the blood of Crohn's disease patients [Naser et al. 2004] and has been found 
to elicit increased serological responses in Crohn's disease patients [Olsen et 
al. 2001; Naser etal. 2004].
MAP is known to persist in the food chain in both meat and milk [Millar et al. 
1996; Mishina et al. 1996; Corti et al. 2002; Grant et al. 2002], so a ready 
source of potential infection exists. Despite this, there is a lack of 
epidemiological data supporting transmissible infection of MAP in Crohn's 
disease [Abubakar et al. 2007], disease status is not exacerbated by 
immunosuppressive agents [Sartor 2005], and there is no therapeutic 
response to traditional antimycobacterial antibiotics [Thomas et al. 1998]. A 
large scale meta-analysis by Feller et al. did find an association between MAP 
and Crohn's disease, but it was found that the 'role [of MAP] in the aetiology 
of Crohn's disease remains to be defined' [Feller et al. 2007].
1.4.3 Mucosal E. coli in Crohn's disease
Schultsz et al. detected E. coll adherent to the rectal mucosa in Crohn's 
disease which possessed adherence factors, but did not detect any 
differences in frequency of E. coll in either control or diseased samples 
[Schultsz et al. 1997]. Subsequently the same group, by use of In situ 
hybridisation, demonstrated a marked increase in bacterial 16S ribosomal 
DNA within the overlying mucus of diseased rectal mucosal biopsies 
compared to controls [Schultsz etal. 1999].
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Darfeuille-Michaud et al. demonstrated that early and chronic ileal lesions of 
Crohn's disease are often colonised by mucosally-associated E. coli strains 
devoid of the virulence genes that are generally associated with 
enteropathogenic strains of E. coli [Darfeuille-Michaud et ol. 1998]. Since 
then, nine independent studies have revealed an increased presence of 
mucosa-associated E. coli in Crohn's disease [Darfeuille-Michaud et al. 2004; 
Martin et al. 2004; Ryan et al. 2004; Mylonaki et al. 2005; Swidsinski et al. 
2005; 2006; Baumgart et al. 2007; Kotlowski et al. 2007; Sasaki et al. 2007]. 
This group of E. coli have been designated as a new pathotype, termed 
adherent-invasive E. coli (AIEC) [Darfeuille-Michaud 2002].
1.4.3.1 AIEC characteristics
AIEC do not possess any of the known genetic invasive determinants 
described for enteroinvasive (EIEC) or enteropathogenic E. coli (EPEC) and 
Shigella strains [Darfeuille-Michaud 2002]. Despite this, they have been 
shown to both adhere and invade into several in vitro intestinal cell lines 
[Darfeuille-Michaud et al. 2004; Martin et al. 2004] although there is little or 
no direct evidence for their presence within normal human intestinal 
epithelial cells in human tissue whereas they can be found within tissue 
macrophages [Liu et al. 1995; Ryan et al. 2004].
The AIEC have been shown to stimulate the release of the pro-inflammatory 
chemokine interleukin-8 (IL-8) from epithelial cells in vitro [Martin et al. 2004; 
Eaves-Pyles et al. 2008; Subramanian et al. 2008]. The AIEC preferentially 
belong to phylogenic groups B2 and D that are associated with uropathic, 
avian and extraintestinal virulent E. coll strains (Uropathogenic (UPEC), avian 
pathogenic (APEC) and Extraintestinal pathogenic (ExPEC)) [Kotlowski et al. 
2007]. In addition to their association with human Crohn's disease, these
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AIEC have been shown to be associated with granulomatous colitis in boxer 
dogs [Simpson et al. 2006].
One ileal isolate, LF82 has been investigated in detail; it has been reported to 
replicate extensively within mature phagolysosomes of macrophages [Bringer 
et al. 2006]. It has been found that deletion of the genes yfgL and Nlpl (both 
of which encode lipoproteins) from E. coli LF82 lead to a decrease in invasive 
ability of LF82 [Barnich et al. 2004; Rolhion et al. 2005]. LF82 has also been 
shown to adhere to primary ileal epithelial cells isolated from Crohn's disease 
patients. The adherence was dependent on type 1 pili expression on the 
bacterial surface and on carcinoembryonic antigen-related cell adhesion 
molecule 6 (CEACAM6) expression on the apical surface of ileal epithelial cells 
[Barnich et al. 2007], it was found that the process could be blocked by 2% d - 
mannose.
It should be noted that the demonstration of the presence of AIEC within 
diseased tissue does not automatically suggest a pathogenic role for these 
organisms. Other factors may be involved in promoting mucosal dysbiosis, 
such as glycosylation changes [Rhodes 1996], overexpression of fibronectin 
[Isenmann et al. 2002] and carcinoembryonic antigen expression [Greenstein 
et al. 1982], which may promote recruitment of bacteria including E. coli to 
the mucosa.
1.4.4 Intra-mucosal bacteria in Crohn's disease
E. coli, Listeria, and Group F Streptococci have been demonstrated within 
macrophages in Crohn's disease tissue [Liu et at. 1995]; however, not all 
groups have been able to identify Listeria in Crohn's disease patients through 
either PCR detection [Chiba et al. 1998; Chen et al. 2000] or
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immunohistochemistry [Walmsley et al. 1998]. Walmsley et al. however were 
able to observe E. coli on the luminal surface of epithelium and in ulcers in 
35% of Crohn's disease patients [Walmsley et al. 1998].
1.4.5 Other bacterial species identified in Crohn's disease
Tiveljung et al. in 1999 demonstrated by in situ hybridisation, an increase in 
Helicobacter spp.-, Mycobacterium paratuberculosis-, Listeria 
monocytogenes- and E. coli-like 16S rDNA sequences in Crohn's disease 
compared with control biopsies [Tiveljung et al. 1999].
1.4.6 Role of the adaptive immune response to bacterial antigens in Crohn's 
disease pathogenesis
Crohn's disease has been associated with elevated adaptive immune 
responses to gut microbiota. Crohn's disease patients are known to have 
antibodies against E. coli outer-membrane porin C (OmpC), Pseudomonas 
fluorescens-associated sequence 12, bacterial flagellin and Saccharomyces 
cerevisiae (ASCA) [Landers et al. 2002], indicating a loss of host-tolerence 
against these bacterial species and products. The presence of anti-OmpC and 
anti-12 antibodies has been shown to be associated with a complicated 
disease pattern amongst Crohn's disease patients [Arnott etal. 2004].
Marks et al. reported a substantially diminished IL-8 response by peripheral 
blood monocyte-derived macrophages from Crohn's disease patients to pro- 
inflammatory stimuli [Marks et al. 2006]. It was found that the defective IL-8 
response was associated with a reduced recruitment of neutrophils to sites of 
mucosal injury (the biopsy site), and the defect in IL-8 response was absent in 
healthy controls. It has also been observed that macrophages from smokers
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(who have a higher risk of developing Crohn's disease) lack the ability to kill 
Legionella pneumophila [Matsunaga et al. 2001]. Diseases such as the 
inherited conditions chronic granulomatous disease and glycogen storage 
disease type lb  are associated with a Crohn's disease like intestinal disease; 
both these conditions are well characterised as having defects in phagocyte 
killing of bacteria [Isaacs et al. 1985; Sanderson et al. 1991].
1.4.7 Animal models
Several animal models exist which replicate to some extent the human 
phenotype of Crohn's disease, and which indicate the importance of gut 
microbiota for the disease [Wirtz et al. 2007]. These mouse models typically 
have defects in epithelial integrity/permeability, or defects in the innate or 
adaptive immune system.
Several Crohn's disease associated genes, such as OCTN1, OCTN2, DLG5, 
NOD2/CARD15 and ATG16L1 have been shown to be related to the biological 
function of epithelial cells, and mutations in these genes could potentially 
lead to increased intestinal permeability.
An interesting mouse model which provides direct evidence for the 
importance of an intact epithelial barrier is that of transgenic/chimeric mice 
expressing a dominant negative mutant form of the cell adhesion molecule 
N-cadherin, along the crypt villus axis [Hermiston et al. 1995]; these mice 
develop a chronic inflammatory bowel disease in areas of chimeric/leaky 
epithelium.
In addition, missense mutations in the gene for keratin 8, a major 
intermediate filament protein present in intestinal enterocytes, have been
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identified in a subset of patients with Crohn's disease [Owens et al. 2004], 
Mice deficient for keratin 8 develop colonic hyperplasia and colitis as a result 
of epithelial rather than immune cells defects [Baribault et al. 1994]. 
Treatment with antibiotics markedly decreased intestinal inflammation, 
implying that luminal bacteria play a role in Crohn's disease [Baribault et al. 
1994],
The multidrug resistance (MDR) gene 1, encoding P-glycoprotein 170, is 
responsible for drug resistance to chemotherapy in certain types of cancer, is 
expressed in the intestinal epithelium and subsets of hematopoietic cells 
[Ambudkar et al. 2003]. M drla'~  mice display spontaneous bowel 
inflammation triggered by the bacterial microbiota [Panwala et al. 1998].
SAMPl/YitFc (senescence-accelerated mouse - Samp) mice develop 
spontaneous inflammation in the terminal ileum [Matsumoto et al. 1998], a 
common site of inflammation in Crohn's disease. Germ-free housed SAMP 
mice develop intestinal inflammation spontaneously; however they do so to a 
lesser extent than when housed in conventional conditions, implying that 
both epithelial permeability and the microflora are important factors in 
inflammation.
Several mouse models implicate a defective innate immune system in 
association with aberrant inflammation. Innate immune cells recognise 
foreign organisms through patter recognition receptors (PRRs) which 
recognise pathogen-associated molecular patterns (PAMPs). PRRs include Toll 
like receptos (TLR), nucleotide-binding oligomerization domain-like (NOD- 
like) receptors (NLRs) and C-type lectin receptors (CLRs) [Akira et al. 2004; 
Inohara et al. 2003]. Generally, the interaction between PPRs and PAMPs
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results in the activation of innate immune cells such as dendritic cells and 
macrophages which function to eliminate the foreign organism.
Mice with a mutant STAT3 gene (signal transducter and activator of 
transcription 3) in macrophages and neutrophils develop a spontaneous 
enterocolitis [Takeda et al. 1999]. When crossed with TLR4-/- or MyD88-/- 
mice the double deficient mice developed significantly less colitis, indicating 
the critical requirement of the bacterial microflora [Kobayashi et al. 2003].
STAT 3 is also involved in the signal transduction pathway of Interleukin-10 
(IL-10). Interleukin-10 (IL-10) is an anti-inflammatory cytokine. IL-10 gene- 
deficient mice develop a patchy chronic enterocolitis with massive infiltration 
of lymphocytes, activated macrophages, and neutrophils [Kuhn et al. 1993]. 
This colitis develops when the mice are reared in conventional animal care 
facilities; conversely, they do not develop colitis when reared in germ-free 
conditions, again suggesting that luminal bacteria are a significant factor in 
the onset and chronicity of inflammation [Madsen et al. 1999]. These mice 
demonstrate significant alterations in the species and the levels of bacteria 
colonizing the colon, suggesting that genetic factors in the host may be 
critical in controlling bacterial colonization [Madsen 2001].
Further studies in this mouse model have revealed that increased mucosal 
adherence in the colon precedes the development of colitis, and that this 
increase is coupled with a reduction of colonic luminal Lactobacillus spp.. 
Restoring the levels of Lactobacillus spp. to those of the normal mouse colon 
resulted in a reduced concentration of adherent bacteria, a reduction in 
bacteria translocated across the epithelial cell layer, and attenuation of the 
colitis [Madsen et al. 1999; Madsen et al. 1999; Schultz et al. 2000].
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1.5 ENVIRONMENTAL FACTORS IMPLICATED IN CROHN'S DISEASE
1.5.1 General observations
Several lines of evidence implicate environmental factors as risk factors or 
association with Crohn's disease development. Factors such as diet, smoking, 
occupation and wealth all appear to have a connection to Crohn's disease 
development.
Poor sanitary conditions and exposure to infection appear to protect against 
Crohn's disease, in common with diseases such as multiple sclerosis, 
rheumatoid arthritis and asthma. Children who have been raised in more 
spacious conditions have a higher risk of developing Crohn's disease than 
those raised in more cramped conditions [Krishnan et al. 2002] whilst people 
in higher socioeconomic groups have a higher risk of Crohn's disease 
development [Krishnan et al. 2002]. Additionally, Crohn's disease is more 
common in 'white-collar' professionals in sedentary indoors jobs compared 
with 'blue-collar' professionals who work outside [Sonnenberg 1990].
In addition, there has been clear emergence of Crohn's disease in the 
economically developed nations of Western Europe and North America 
during the past century, whilst incidence remains low in less economically 
developed countries [Calkins et al. 1986]. Dramatic increases in incidence 
observed during the 1950s and 1960s [Miller et al. 1974] and during the 
remainder of the 20th century in developed countries support the theory that 
environmental factors may contribute substantially to Crohn's disease 
development [Krishnan et al. 2002].
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1.5.2 Dietary factors
There are several lines of evidence which suggest that the diet may play an 
important role in the development and prevalence of Crohn's disease. 
Malnutrition is known to worsen the course of disease progression in Crohn's 
disease, since both macronutrient and micronutrient deficiencies lead to 
impaired inflammatory and immune intestinal response [Sanderson et al. 
2005]. There is good evidence supporting the benefits of enteral nutritional 
feeding with elemental or whole protein feed as either primary or adjuvant 
therapy for Crohn's disease [Ricour et al. 1977; Morin et al. 1982]. Several 
studies have attributed these benefits in part to a decrease in systemic 
inflammatory markers as a consequence of enteral feed [O'Morain et al. 
1984; Thomas et al. 1993; Akobeng et al. 2007]. Others report that enteral 
feeding directly affects intestinal inflammation by regulating gene expression 
in the gut epithelium [Sanderson et al. 2005; de Jong et al. 2007], as well as 
modulating intestinal inflammatory and immune mediators production [Fell 
2005; Genton et al. 2005; Sanderson et al. 2005; Menezes et al. 2006; de 
Jong et al. 2007; Yamamoto et al. 2007]. In some studies however, the use of 
enteral feeding was less effective than conventional therapies such as 
steroids or aminosalicylates [Zachos et al. 2007]. The consumption of fruits, 
vegetables and dietary fibre has been found to be protective against Crohn's 
disease development [Amre et al. 2007].
Increased intake of dietary sugar has long been linked as a risk factor for 
increased occurrence of Crohn's disease [Martini et al. 1976; Miller et al. 
1976; Thornton et al. 1979; Mayberry et al. 1980; Silkoff et al. 1980; 
Katschinski et al. 1988]. There is also evidence to suggest that frequent fast- 
food intake confers a 3- to 4-fold greater risk for developing Crohn's disease 
[Persson et al. 1992], whilst consumption of long-chain omega-3 fatty acids
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has been reported to be negatively associated with Crohn's disease [Amre et 
al. 2007].
There has been a rapid recent rise in Crohn's disease in Japan [Yao et at. 
2000] which has paralled the introduction and uptake of a western style diet 
and an increase in animal fat consumption there [Shoda et al. 1996; 
Sakamoto et al. 2005]. Indeed, it has been observed that an increase in 
dietary fat intake can counteract the benefits obtained from an elemental 
diet in the treatment of Crohn's disease in Japan [Bamba et al. 2003].
Additionally, there has been a relatively recent increase in Crohn's disease 
development amongst migrants to 'First-world' countries [Montgomery et al. 
1999], it is possible that this may in part be due to a change of diet in the new 
home country.
1.5.3 Smoking
Probably the most convincing example of the influence of the environment 
upon the development of Crohn's disease is that of smoking tobacco. In 1984, 
a case-control study by Somerville et al. reported that the relative risk of 
developing Crohn's disease was 4.8 for those who smoked before disease 
onset, and 3.5 for those with a current smoking habit [Somerville et al. 1984], 
In other studies, it has been found that smoking tobacco increases the need 
and frequency of surgery [Lindberg et al. 1992; Breuer-Katschinski et al. 
1996], the frequency of progression to complicated disease (defined by 
development of strictures or fistulae [Mahid et al. 2007]), penetrating 
intestinal complications [Lindberg et al. 1992; Louis et al. 2003; Picco et al. 
2003], and a higher relapse rate [Cosnes et al. 1999; Lakatos et al. 2005], 
whilst cessation of smoking improves the disease course [Thomas et al.
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1998]. Smoking is known to affect both systemic and mucosal immunity, 
affecting both innate and immune functions, such as altering the ratio of T- 
helper to T-suppressor cells [Sopori 2002] and affecting the ability of 
macrophages to kill bacteria [King et al. 1988; Matsunaga et al. 2001].
1.6 PATHOPHYSIOLOGY OF CROHN'S DISEASE
1.6.1 Initial presentation
There is controversy surrounding the site of the initial lesion in Crohn's 
disease. It has been suggested that it may be the granuloma, which can be 
found within the mucosa despite entirely normal overlying epithelium 
[Makiyama et al. 1984; Wakefield et al. 1991]. Conversely, there is a growing 
body of evidence suggesting that the initial lesions of Crohn's disease are in 
fact the aphthous lesions.
Lockhart-Mummery and Morson [Lockhart-Mummery et al. 1960; Morson 
1972] reported as far back as the 1960s that an early microscopic change in 
Crohn's disease was ulceration of lymphoid follicles and Peyer’s patches in 
the terminal ileum. These ulcerations have subsequently been termed 
aphthous lesions, after the Greek word aptha, roughly translated as an 
inflamed spot [Kinjo et al. 2004]. These aphthous lesions under endoscopic 
examination appear as superficial ulcers, 1-5 mm in diameter, with 
surrounding erythema. Aphthoid lesions can be found in 70% of Crohn's 
disease patients [Rickert et al. 1980], and have been described as as early 
endoscopic signs of Crohn's disease recurrence in the neoterminal ileum 
following ileocolonic anastomosis [Rutgeerts et al. 1984].
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In Crohn's disease of the large bowel, aphthoid lesions frequently occur over 
lymphoid aggregates [Fujimura et al. 1996], whilst in Crohn's disease of the 
small bowel, these lesions typically occur over Peyer's patches [Rickert et al. 
1980; Rutgeerts et al. 1984; Olaison et al. 1992] which are structured 
collections of lymphoid follicles [Van Kruiningen et al. 2002]. Interestingly, 
Van Kruiningen et al. noted that there is an age related increase in the 
frequency of Peyer's patches, which correlates well with the increase in 
Crohn's disease with age [Van Kruiningen et al. 1997].
As Crohn's disease progresses, it is thought that the aphthous lesions enlarge 
to form stellate ulcers and ultimately, deeper longitudinal and transverse 
linear ulcers [Hizawa et al. 1994]. Intervening regions of mucosa not affected 
by ulceration can create the typical cobblestone appearance characteristic of 
Crohn's disease. These findings have been confirmed by endoscopic and 
radiographic studies in the small intestine [Olaison et al. 1992; Matsumoto et 
al. 2000], but are less obvious in colonic Crohn's disease [Ni et al. 1986].
1.6.3 M-cells and bacterial sampling of the lumen
Since the initial lesions which are often observed in Crohn's disease occur in 
the region of lymphoid aggregates in the large bowel, and Peyer's patches in 
the small bowel, it is possible that M-cells present in the 'dome' epithelia that 
overlies Peyer's patches and lymphoid follicles might play an important role 
in the pathophysiology of Crohn's disease.
1.6.3.1 Peyer's patches
Peyer's patches are named after the 17th-century Swiss anatomist Hans 
Conrad Peyer and are located along the antimesenteric side of the small 
intestine [Corr et al. 2008]. The Peyer's patches consists of the Peyer's patch
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lymphoid follicle (containing B- and T- lymphocytes), follicular dendritic cells 
and macrophages; overlying the Peyer's patches is the follicle-associated 
epithelium (FAE) [Neutra et al. 2001], a one-cell-thick layer composed of 
enterocytes and specialized epithelial cells termed M-cells [Owen et al. 
1974]. The FAE forms the interface between the intestinal lymphoid system 
and the intestinal luminal environment.
1.6.3.2 M-cells - origin
The origin of M-cells within the FAE is unclear and is the subject of much 
debate. Intestinal epithelial cells in the FAE originate from stem cells in the 
crypts located between villi and the dome epithelium -  within the crypts, 
there are two distinct axes of migration and differentiation [Heath 1996]. 
Cells on the villous side of the crypt migrate upwards to form the villi, 
differentiating into absorptive enterocytes, goblet cells and endocrine cells as 
they migrate upwards [Sierro et al. 2000], where upon reaching the tip of the 
villus, they are shed into the intestinal lumen [Sierro et al. 2000; Kiesslich et 
al. 2007]. Cells on the FAE side of the crypt migrate into the dome epithelia, 
where they differentiate into absorptive enterocytes and M-cells [Gavrieli et 
al. 1992].
It is not known if cells within the crypt commit to become M-cells early on, or 
if the formation of M-cells occurs as a result of transformation from existing 
enterocytes within the dome FAE [Nicoletti 2000]. A well established in vitro 
M-cell culture system demonstrates that enteroyctes can be converted into 
M-cells by murine Peyer's patch lymphocytes [Kerneis et al. 1997] or Raji B 
lymphocyte cells [Gullberg et al. 2000; des Rieux et al. 2007]. However, since 
this model utilises adenocarcinoma cells (Caco2) that do not behave like 
normal enterocytes, it is difficult to know if this in vitro M-cell model is a true 
indication for the In vivo situation. Indeed, one group has reported that B
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cells are not absolutely required for the generation of M-cells from Caco2 
cells -  they found the presence of M-like cells in lymphocyte untreated Caco- 
2 monolayers [Blanco et al. 2006].
Gerbert et al. demonstrated the presence specialised dome epithelia 
associated crypts which differed from ordinary crypts in size, shape, cellular 
composition and location. Within these specialised crypts, Gerbert et al. was 
able to identify the presence M-cell precursor cells using histological and 
ultrastructural techniques, indicatinglthat in vivo M-cells arise from a distinct 
cell lineage [Gebert et al. 1999].
It has also been shown that M-cells numbers increase in response to 
microbial challenge. Smith et al. showed that in mouse FAE, the number of 
M-cells present increased upon transfer of germ-free mice into conventional 
housing [Smith et al. 1987], with several in vitro studies (using mouse or 
rabbit biopsies) confirming these findings [Savidge et al. 1991; Borghesi et al. 
1996; Borghesi et al. 1999]. In contrast, Gebert et al. show that increased 
uptake of particles after inoculation with bacteria depended on increased 
transport capacity in M cells already present in the FAE, and not upon the 
formation of new M-cells [Gebert et al. 2004].
It should be noted that whilst much of the literature suggests M-cells are only 
present within the FAE, there is a growing body of evidence reporting the 
presence of M-cells within villus epithelial cells and cryptopatches in mice 
[Iwatsuki et al. 2002; Jang et al. 2004] and in villus epithelial cells in non­
human primates [Takahashi et al. 2008].
Interestingly, villus M-cells within mice were increased following cholera 
toxin treatment, implying generation of the M-cell phenotype in response to
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potentially pathogenic challenge [Terahara et al. 2008], whist in the Rhesus 
Macaques monkey, oral poliovirus was spatiotemporally internalized into 
villous M-like cells and engulfed by macrophage-like cells in the lamina 
propria.
1.6.33 M-cells - structure
M-cells are structurally distinct from the surrounding intestinal enterocytes, 
At the apical surface, M-cells have a poorly organized brush border with short 
irregular microvilli, in contrast to enterocytes which have a highly organized 
brush border, with uniform densely packed microvilli [Kerneis et al. 1997]. M- 
cells also lack the thick glycocalyx which is common on surrounding 
enterocytes; it is thought that this provides the M-cell with greater access to 
antigens in the gut lumen. The dome epithelium also lacks goblet cells, thus 
Peyer's patches and lymphoid follicles have little or no overlying mucus layer, 
allowing the M-cell greater access to antigens in the gut lumen.
1.6.3.4 M-cell markers
Positive markers of M-cells in mice are Ulex europaeus 1 (UEA-1) and 
Psophocarpus tetragonolobus (winged bean; WBA) lectins [Clark et al. 1993; 
Giannasca et al. 1994], conversely, there are a lack of true definite positive 
markers for human M-cells. In order to identify markers of human M-cells, 
recent work has utilized microarray analysis of Caco-2 cells differentiated to 
M-like cells and established, via microarrary technology, that galectin 9 is 
apically expressed on M-cells and has promise as an M-cell marker [Pielage et 
al. 2007]. In addition, monoclonal antibodies specific against single 
carbohydrate epitopes have also been used to identify M-cells in humans 
[Neutra 1999]. It has also been shown that M-cells express sialyl Lewis A 
antigen on their apical and subcellular membranes [Giannasca et al. 1999], 
although these results could not be reproduced [Wong et al. 2003; Keita et al.
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2006]. Human M-cells are known to lack certain enterocyte apical surface 
glycoproteins, such as alkaline phosphatase and sucrase-isomaltase activity, 
which are typical to the brushborder of enterocytes, and both have been 
used as negative markers for M-cells [Gebert et al. 1996].
1.6.3.5 Functional M-cells
M-cells are known to take up and transport luminal antigens, including 
proteins, viruses, bacteria, small parasites, and microspheres [Ermak et al. 
1995; Neutra et al. 1996; Gebert et al. 1996; Wolf et al. 1984],
Antigens are taken up at the M-cell apical surface and are internalised into 
endosomal tubules and vesicles and large multivesicular bodies that lie 
between the apical membrane and the intraepithelial pocket (formed from 
invaginations of the basolateral membrane of the M-cell) [Mestecky et al. 
2004]. The large vesicles contain the late endosome / lysosome membrane 
marker Igp20, have an acidic pH [Allan et al. 1993] and contain the 
endosomal protease cathepsin E [Finzi et al. 1993]. The presence of acidic 
endosomal-lysosomal compartments within M-cells, and the fact that M-cells 
express MHC class II molecules [Allan et al. 1993] suggests that M-cells may 
be involved in antigen processing and presentation.
Following uptake, the antigens are subsequently released from the M-cells 
into the extracellular 'pocket' region [Mestecky et al. 2004], where 
processing and initiation of immune responses can occur [Kraehenbuhl et al. 
1992; Neutra et al. 1996; Neutra et al. 1996]. It is likely that here antigens are 
captured by immature dendritic cells in the subepithelial dome (SED) regions 
[Kelsall et al. 1996]. Indeed, live attenuated S. typhimurium and Listeria 
monocytogenes have been detected in SED dendritic cells [Hopkins et al. 
2000; Pron etal. 2001].
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In Peyer's patches and isolated lymphoid follicles, the site of antigen entry 
into M-cells and subsequent capture by immature dendritic cells occurs in 
close proximity to organised T-cell and B-cell zones. It has been observed that 
dendritic cells in the SED are able to deliver antigens to adjacent 
interfollicular T-cell regions where antigen presentation would be expected 
to occur [Iwasaki and Kelsall 2000]. It is now generally agreed that oral 
tolerance is established and maintained at the level of T cells [Strobel et al. 
1998; Strober et al. 1998; Wardrop et al. 1999]. Recent studies have 
identified dendritic cells as key players in the direct or indirect (by way of T 
cells) induction of oral tolerance [Mowat et al. 2003; Nagler-Anderson et al. 
2001; Viney et al. 1998; Weiner et al. 2001].
Although M-cells are able to transport luminal antigens [Ermak et al. 1995; 
Neutra et al. 1996; Gebert et al. 1996; Wolf et al. 1984], noninvasive strains 
of S typhimurium cannot penetrate M cells and are avirulent [Jones et al. 
1994]. The ability of an antigen to generate an immune response in the 
gastrointestinal tract could be one of the most critical factors in determining 
whether mucosal immunity or tolerance is induced. Mucosal tolerance may 
be the most common immune response because it is necessary to maintain 
homeostasis. The normal host must readily establish unresponsiveness to 
commensal bacteria, food antigens, and allergens.
As M-cells are capable of taking up antigen from the lumen and then 
delivering it to the intestinal lymphoid system, they act as gateway or a portal 
to the mucosal immune system and this function has been exploited by many 
invading pathogens. For example, some strains of Salmonella Typhimurium 
have been found to target to M-cells where they cause extensive membrane 
ruffling and FAE damage [Sansonetti et al. 1999], and possible destruction of
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the M-cells to perpetuate infection [Jensen et al. 1998], whereas pathogens 
such as Listeria monocytogenes and Shigella flexneri have been found to be 
internalized into M cells in a much less disruptive manner [Jensen et al. 
1998]. M-cells have been also been found to transport Vibrio cholerae [Owen 
et al. 1986; Kerneis et al. 1997], The transport of microorganisms through M- 
cells has been shown to be temperature-dependent, with transport being 
inhibited at 25°C or lower [des Rieux et al. 2005], indicating that transport is 
an active, not passive process. In addition, M-cells have been shown to 
transport particulates including latex beads, carbon particles and liposomes 
and macromolecules including ferritin, horseradish peroxidase, cholera toxin­
binding subunit, lectins and antivirus antibodies [Gebert et al. 1996].
1.6.3.6 E. coli and M-cells
Several papers have reported E. coli adhesion to or translocation through M- 
cells. Enteropathogenic E. coli (EPEC) strain E2348/69 has been found to bind 
specifically to in vitro generated M-cells [Pielage et al. 2007], whilst Martinez- 
Argudo et al. reported increased translocation of enteropathogenic E. coli 
(EPEC) across in vitro derived M-cells [Martinez-Argudo et al. 2007]. Other E. 
coli strains found to adhere to M-cells include E. coli 0:124, enteroaggregative 
(EAEC) and diffuse-adhering E. coli (DAEC), enterotoxigenic E. coli (ETEC) 
[Cantey et al. 1981]. All of these E. coli are classic enteric pathogens.
The use of Ussing chambers provides a useful tool to study in vitro human 
intestinal epithelium [Soderholm et al. 1998]. An interesting study by Keita et 
al. utilised the FAE of macroscopically normal ileum from patients with 
longstanding Crohn's disease and control patients to test the translocation of 
E. coli across the FAE. They observed that the FAE of Crohn's disease patients 
showed increased E. coli K-12 (chemically killed) adhesion following FAE 
exposure in Ussing chambers, and increased translocation of live E. coli
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HB101 through cells of the FAE in Crohn's disease [Keita et al. 2008]. The 
paper eloquently demonstrated an increased bacterial load of non- 
pathogenic E. coli within the FAE, raising the possibility that cells within the 
FAE may also transport AIEC [Gullberg et al. 2006].
The FAE has also been implicated as a site of initiation of pro-inflammatory 
immune responses in rats. One paper suggests that chronic stress, known to 
affect the course of Crohn's disease, can modulate the FAE of rats. Rats under 
chronic psychological stress displayed increased E. coli K12 passage across 
FAE, but not across villus epithelium. This implies that stress could lead to 
increased antigen exposure in Peyer's patches, which may alter 
proinflammatory immune responses [Velin et al. 2004].
1.6.4 Epithelial barrier integrity in Crohn's disease
A tightly regulated epithelial barrier is critical to healthy functioning of the 
gut. Whilst M-cells provide one route by which this barrier may be breached, 
recent research suggests another alternative. Epithelial cells of the small 
intestine migrate to the tip of the villus where they are shed into the lumen, 
in a process associated with both phosphorylation of myosin light chains 
(thought to be involved in wound healing) and apoptosis [Bullen et al. 2006]. 
There is a relatively high rate of cell turnover at the tip of the villus, and it has 
been observed in mice that during this process gaps within the cell layer can 
be formed. Despite this, the epithelial barrier function is maintained at the 
apical pole of the epithelial layer [Watson et al. 2005]. It has since been 
observed that these cellular gaps in the epithelial layer also occur in humans 
[Kiesslich et al. 2007]. Whilst it can be assumed that these gaps are a normal 
component of the intestinal barrier, it does raise the possibility that
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dysregulation in this area could provide easy access for luminal 
microorganisms to the intestinal lymphoid system.
Several groups report a defect in intestinal barrier function to be associated 
with Crohn's disease. In one study, by Soderholm et al. [Soderholm et al. 
1999], intestinal permeability of Crohn's disease patients together with their 
healthy first degree relatives and spouses, with healthy unrelated volunteers 
serving as a control group was investigated. The authors reveal that intestinal 
permeability is determined by both environmental and genetic factors, and 
that Crohn's disease patients had higher baseline intestinal permeability than 
control patients [Soderholm et al. 1999]. Work by the same group also 
revealed that the non-inflamed ileal mucosa from patients with Crohn's 
disease have increased epithelial permeability to ovalbumin protein. The 
authors suggest that this may lead to an increase of antigen load the lamina 
propria, which could be an initiating pathogenic event in Crohn's disease 
[Soderholm et al. 1999]. More recently, Buhner et al. demonstrated that in 
first degree relatives of Crohn's disease patients, there was a significant 
association between high mucosal permeability and the presence of a 
common Crohn's disease associated mutation in CARD15, 3020insC [Buhner 
et al. 2006]. One recent study has implicated dihydroxy bile acids as a 
negative modulator of intestinal permeability. Normal human colon biopsies 
mounted in Ussing chambers had increased E. coll uptake into the lamina 
propria in the presence of pM concentrations of dihydroxy bile acids. This 
study indicats that bile acids could contribute to the development of 
intestinal inflammation by promoting bacterial uptake in the colon [Munch et 
al. 2007].
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1.7 TREATMENT OF CROHN'S DISEASE
1.7.1 Drugs
Drugs of the corticosteroid family (eg prednisolone) are commonly used to 
treat Crohn's disease due to their anti-inflammatory effects on 
immunoregulatory T cells [Paliogianni et al. 1993], monocytes [Breuninger et 
al. 1993], macrophages [Linden et ol. 1994] and dendritic cells [de Jong et al. 
1999]. Drugs such as methotrexate or azathioprine are sometimes used as a 
treatment to suppress the immune system. Infliximab is a chiral monoclonal 
IgGl antibody to tumour necrosis factor, used in more severe cases of 
Crohn's disease [Rutgeerts et al. 2006; Van Assche et al. 2006; Juillerat et al. 
2007],
1.7.2 Antibiotics
Several chronic granulomatous diseases have been successfully treated with 
antibiotics, including Whipple's disease, malakoplakia, and granulomatous 
colitis of Boxer dogs [Van Kruiningen 1995], suggesting that antibiotic 
treatment might be beneficial for Crohn's disease. Several independent trials 
have investigated this hypothesis, and revealed interesting findings.
In active Crohn's disease, metronidazole has been shown to be a useful 
treatment for patients with colonic Crohn's disease; 6/22 patients 
investigated in randomized double-blind cross-over trial showed significant 
improvement following antibiotic treatment [Blichfeldt et al. 1978].
Ciprofloxacin, in a randomised trial against active Crohn's disease, was found 
to be as effective as a treatment as mesalazine for treating mild to moderate 
relapses of Crohn's disease [Colombel et al. 1999], whilst a study by Leiper et
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al. demonstrated that clarithromycin treatment for 3 months was ineffective 
in active Crohn's disease, but that a possible benefit was detected at 1 
month, with the suggestion being that the initial beneficial effect of the 
antibiotic could be attenuated by subsequent bacterial resistance [Leiper et 
al. 2008].
Treatment with both metronidazole and ciprofloxacin led to clinical remission 
following a 12-week treatment period in 45.5% of patients investigated, 
compared with 63% for those patients receiving steroid treatment [Prantera 
et al. 1996]; however, a retrospective study of this combination of antibiotics 
found no benefit compared to single antibiotic therapy; 70.6% of patients 
taking the two antibiotics achieved clinical remission, 72.8% with 
metronidazole alone, and 69.0% with ciprofloxacin alone [Prantera et al. 
1998]. A meta-analysis, conducted by Rahimi et al., examined 6 randomized, 
placebocontrolled trials conducted with metronidazole, ciprofloxacin and 
cotrimoxazole -  they concluded that patients receiving antibacterial therapy 
were 2.257 times more likely to have clinical improvement compared with 
those receiving placebo [Rahimi et al. 2006].
Ornidazole, in an open trial, led to 75% clinical remission following 4 weeks of 
treatment [Triantafillidis et al. 1996], and treatment with rifaximin for 16 
weeks also decreased disease activity [Guslandi 2005].
Treatment with the antimycobacterials rifampicin and / or ethambutol did 
not lead to clinical remission [Shaffer et al. 1984], nor did Rifampicin and / or 
Isoniazid and / or ethambutol treatment [Swift et al. 1994; Thomas et al. 
1998].
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1.7.3 Probiotics
Probiotics are viable microorganisms that confer therapeutic benefit beyond 
their nutritional value. Data from human studies suggest the presence of 
intestinal dysbiosis in Crohn's disease, and therefore the use of probiotic 
could provide a rational approach to redress this balance, and perhaps aid 
treatment. Clinical trials conducted so far using probiotic microorganisms 
have revealed some interesting results.
Trials using Saccharomyces boulardii as a probiotic agent led to a significant 
reduction in the frequency of bowel movements in Crohn's disease patients 
[Plein et al. 1993] in a randomized double-blind placebo-controlled trial, 
whilst the rate of relapse or in Crohn's disease was significantly reduced 
when Saccharomyces boulardii was used in combination with mesalamine as 
a treatment strategy to maintain remission [Guslandi 2000].
Lactobacillus GG led to a significant improvement of clinical activity and 
intestinal permeability in children with mildly active Crohn's disease [Gupta 
et al. 2000].
E. coli strain Nissle 1917 has been tested as a potential probiotic for use in 
Crohn's disease in several randomized double-blind trials. One such trial 
measured maintenance of remission in Crohn's disease following surgery, 
where is was observed that, whilst there was no difference in the number of 
patients obtaining remission from symptoms, there were fewer relapses for 
patients on probiotic medication, implying a potential use in maintenance 
therapy [Malchow 1997].
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1.8 SUMMARY
There is convincing evidence supporting the concept that Crohn's disease is a 
multi-facto rial disease and that genetically susceptible hosts have aberrant 
immune responses and loss of tolerance to environmental factors which 
contribute to the mucosal inflammation. Functional defects in the epithelial 
barrier have been suggested which allow inappropriate or unusual access of 
both bacterial and other microbial antigens to the lamina propria, as a 
possible consequence of inflammation, and also allowing further propagation 
of inflammation already seen. In the healthy homeostatic gut, commensal 
bacteria encountering the lamina propria would typically mediate a poor 
inflammatory response due to induction of host tolerance. In Crohn's disease, 
it is plausible that defects in innate and/or adaptive immune cells somehow 
lose this tolerance, and give rise to a non self-limiting chronic inflammation 
as a result of bacterial / other antigens encountering the lamina propria. It is 
possible that AIEC may play an important role in any of these processes.
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PATHOGENESIS
1. Crohn's disease AIEC may play a role In Crohn's disease pathogenesis 
by adhering to and invading into intestinal epithelial cells, from where 
an aberrant immune response can be initiated.
2. Since the initial lesions of Crohn's disease frequently occur in the 
region of M-cells, typically over lymphoid aggregates in the large 
bowel, and over Peyer's patches in the small bowel, AIEC may be 
translocated at these points to the underlying lamina propria, leading 
to formation of aphthous lesions. This process may be exacerbated by 
dietary components which affect intestinal barrier function.
3. The processes of AIEC adhesion, invasion and translocation to the gut 
may be prevented by dietary components, such as dietary fibre. This 
may have considerable therapeutic potential.
4. Crohn's disease may occur as a result of defective clearance of 
ingested gut microbiota by phagocytes. AIEC may survive and replicate 
with macrophages resulting in the granulomatous lesions of Crohn's 
disease. Antibiotics may be used to inhibit these processes.
1.9 HYPOTHESIS FOR THE ROLE OF AIEC IN CROHN'S DISEASE
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1.10 AIMS
1. To assess AIEC adhesion and invasion to colonic epithelial cell lines in 
vitro.
2. To determine if AIEC can be translocated across intestinal M-cells in 
vitro.
3. To assess the role of dietary components such as dietary non-starch 
polysaccharides (NSP) and food emulsifiers on AIEC translocation 
across M-cells.
4. To assess the ability of AIEC to survive within macrophages
5. To assess the efficacy of combination antibiotic treatment against 
internalised AIEC within macrophages.
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Chapter 2
Methods
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2.1 MATERIALS
Unless otherwise stated, all chemicals used herein were purchased from 
Sigma-Aldrich (Sigma-Aldrich Company Ltd, Gillingham, UK). Bacto™ agar, 
Bacto™ tryptone and Bacto™ yeast extract for use in bacterial culture were 
obtained from BD Biosciences (Becton, Dickinson and Company, Oxford, UK). 
Transwell® filters used in M-cell generation were obtained from Millipore 
(Millipore (UK) Limited, Watford, UK). Osmium tetroxide, glutaraldehyde, and 
araldite resin, all used in sample preparation for electron microscopy, were 
obtained from Agar Scientific (Stansted, United Kingdom).
All plastics used for human cell culture were obtained from Corning® (Corning 
Incorporated, Corning, USA) as were plastics used in liquid bacterial culture. 
Solid bacterial culture was performed using plastics obtained from Sterilin 
(Sterilin Limited, Caerphilly, UK).
Soluble non-starch polysaccharides (plantain, broccoli, leek, and apple) used 
in bacterial cell adhesion and translocation assays were provided by Provexis 
pic (Liverpool, UK). The food emulsifiers (polysorbate-60 and polysorbate-80) 
were obtained from Sigma-Aldrich (Sigma-Aldrich Company Ltd, Gillingham, 
UK).
The antibiotic clarithromycin was obtained from Abbott (Abbott Laboratories 
Ltd., Queenborough, United Kingdom), all other antibiotics were obtained 
from Sigma-Aldrich (Sigma-Aldrich Company Ltd, Gillingham, UK).
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2.2 BACTERIAL STRAINS AND GROWTH CONDITIONS
2.2.1 Crohn's disease and control patient population E. coli isolation
E. coll were previously isolated from patients with Crohn's disease or from a 
control population comprising of patients with irritable bowel syndrome (IBS) 
and sporadic polyps, as described elsewhere [Martin 2004; Martin et al. 
2004]. Briefly, colonic biopsy specimens were washed in PBS and treated with 
500 pL 0.016% dithiotreitol (DTT) solution for 15 minutes to remove the 
overlying mucus layer; 50 pL of the resultant DTT solution was plated onto 
MacConkey agar and incubated at 37°C for 24 hours -  bacterial growth on 
this plate was assumed to that of mucus-associated bacteria. Following 
dithiothreitol treatment, the biopsy samples were transferred into 1.5 mL 
Eppendorf tubes containing either 500 pL sterile saline or 500 pL gentamicin 
(50 pg / mL) to kill any extracellular bacteria, for 30 minutes. The biopsies 
were then serially washed in PBS. The gentamicin treated biopsy was then 
lysed in sterile distilled and de-ionised water, and again, the supernatant 
plated onto MacConkey agar and incubated at 37°C for 24 hours -  bacteria 
on this plate were assumed to be intracellular bacteria. The supernatant from 
the PBS treated biopsy was then plated onto MacConkey agar and incubated 
at 37°C for 24 hours, bacteria on these plates were assumed to be adherent 
to the biopsy cell surface.
Following the 24 hour incubation, the bacterial colonies were characterised 
morphologically by Gram staining, and Gram-negative rods were further 
characterised by using API20E bacterial identification kits (Bio-Merieux, 
Marcy L'Etolie, France). In all, thirteen of these E. coli isolates, representing 
six from the control group, and seven from the Crohn's disease group, were 
selected for further study in this work; their known characteristics are 
summarised in Appendix 1.
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2.2.2 Bacteria from other sources
In addition to the colonic E. coli isolates previously identified in our lab, 
several other bacterial strains were utilised from other sources as controls in 
some experimental work. These included the ileal Crohn's disease mucosa- 
associated E. coli isolate LF82, kindly donated by Professor A. Darfeuille- 
Michaud (Pathogenie Bacterienne Intestinale, Laboratorie de Bacteriologie, 
Faculte de Pharmacie, Clermont-Ferrand, France). LF82 had previously been 
described as an adherent and invasive E. coli (AIEC) as it was found to adhere 
to and invade into Intestine-407 (1407) epithelial cells lines in vitro, and was 
found to replicate within both epithelial cells and macrophages [Boudeau et 
al. 1999; Darfeuille-Michaud 2002]. In addition, E. coli K12, obtained from the 
American Type Culture Collection (ATCC®) (LGC Standards, Middlesex, UK; 
ATCC® Number 10798 [Tompkins et al. 1997]) was used as a control in 
bacterial translocation across M-cell and control Caco2-cll monolayers to 
indicate low level rates of translocation, as was the probiotic E. coli Nissle 
1917, a kind gift from Dr C Enders (ArdeyPharm, Herdecke, Germany). 
Salmonella Typhimurium LT2 and Shigella sonnei were a kind gift from Dr C. 
Winstanley (School and Infection and Host Defence, Faculty of Medicine, 
University of Liverpool, England) and were used as positive controls in M-cell 
translocation assays.
2.2.3 Bacterial growth conditions
2.2.3.1 Solid agar culture
For most assays, bacteria were simply grown from frozen stocks onto solid 
Luria-Bertani (LB) agar plates (Appendix 2) at 37°C, for 24 hours. Following 
this, a group of approximately 5 colonies were removed from the plate, 
suspended in sterile saline, centrifuged at 10,000 x g for 10 minutes, and 
washed three times in sterile saline. E. coli were then suspended to an OD at
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550nm of 0.825, equivalent to 1 x 106 E. coli per pL, and used immediately as 
the assay required.
2.23.2 Broth-based culture
Bacteria were grown as for solid agar culture; following the 24 hour 
incubation at 37°C, a single colony was removed and suspended in 10 mL of 
LB broth (Appendix 2). This was then incubated at 37°C in an orbital incubator 
(Sanyo, Gallenkemp PLC, Loughborough, UK) at 200 rpm overnight. Following 
this, 10 mL of fresh LB broth was then inoculated with 100 pL of the bacterial 
suspension, and incubated in the orbital incubator at 37°C for approximately 
2 hours until Log phase growth was achieved. The bacterial suspension was 
then centrifuged at 10,000 x g for 10 minutes, and washed three times in 
sterile saline. E. coli were then suspended to an OD at 550nm of 0.825, 
equivalent to 1 x 106 E. coll per pL (based on McFarland standards, Pro-Lab 
Diagnostics, Cheshire, UK), and used immediately as the assay required.
2.2.33 Sterile PBS culture
Bacteria were grown as for solid agar culture; following the 24 hour 
incubation at 37°C, a single colony was removed and suspended in lOOpL 
sterile PBS, and left at room temperature for 72 -  96 hours. The bacterial 
suspension was then centrifuged at 10,000 x g for 10 minutes, and washed 
three times in sterile saline. E. coll were then suspended to an OD at 550nm 
of 0.825, equivalent to 1 x 106 E. coll per pL, and used immediately as the 
assay required.
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2.3 CELL CULTURE: CELL LINE MAINTANENCE
2.3.1 Culture of Caco2 cells
The adherent human colonic epithelial cell line Caco2 (ATCC® Number HTB- 
37, [Trainer et al. 1988]) was maintained at 20% -  80% confluency in DMEM 
supplemented with 10% FCS, 100 U / mL penicillin, 100 pg / mL streptomycin 
and 8 mM glutamine (complete DMEM). Cells were maintained at 37°C in a 
humidified atmosphere of 5% C02, 95% air. Used at sub confluent levels, 
these cells are models of isolated colonic epithelial cells. Upon reaching 
confluencey, the cells express characteristics of enterocytic differentiation, 
and thus are models of the colonic epithelial barrier. These cells are 
heterogenous for microvillar length and microvillar aggregation
2.3.2 Culture of Caco2-cll cells
The adherent human colonic epithelial cell line Caco2-cll was a kind gift from 
Dr E. Gullberg (Colorectal Surgery Unit, Department of Surgery, University 
Hospital, SE-581 85 Linköping, Sweden [Gullberg et al. 2000]). These cells 
were maintained at 20% -  80% confluency in DMEM supplemented with 10% 
FCS, 100 U / mL penicillin, 100 pg / mL streptomycin and 8 mM glutamine 
(complete DMEM). Cells were maintained at 37°C in a humidified atmosphere 
of 5% C02, 95% air.
Like the Caco2 parent cell line, upon reaching confluencey, these Caco2-cll 
cells express characteristics of enterocytic differentiation, and thus are 
models of the colonic epithelial barrier. In addition, this cell line has exclusive 
apical villin localisation. Twenty-one days post confluency, Caco2-cll cells 
form a polarized monolayer with an apical brush border (BB) morphologically 
comparable to that of the human colon. The isolated BB contains the
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microvillar proteins villin, fimbrin, sucrase-isomaltase, myosin-1, fodrin and 
myosin II, at levels similar to that of the human enterocyte. These cells are 
still heterogenous for microvillar length and microvillar aggregation
2.3.3 Culture of Raji B cells
Raji B cells were a kind gift from Mrs C. Thomas (School of Clinical Sciences, 
University of Liverpool, Liverpool, UK. L69 3BX; ATCC® Number CCL-86, 
[Pulvertaft 1964]). These non-adherent cells are a cell line model of B 
lymphocytes, and were used to facilitate transformation of Caco2-cll cells 
into cells with an M-cell phenotype. The Raji B cells were maintained at 10 -  
30% confluency in Roswell Park Memorial Institute-1640 media (RPMI-1640) 
supplemented with 10% FCS, 100 U / mL penicillin, 100 pg / mL streptomycin 
and 4 mM glutamine (complete RPMI-1640). Cells were maintained at 37°C in 
a humidified atmosphere of 5% C02, 95% air.
2.3.4 Culture of J774-1A cells
The murine macrophage-like cell J774-A1 was obtained from the ATCC 
(ATCC® Number TIB-67 [Ralph et al. 1975]). Cells were maintained at 25 -  
50% confluency, in RPMI-1640 media supplemented with 10% foetal calf 
serum (FCS), 100 U / mL penicillin, 100 pg / mL streptomycin and 4 mM 
glutamine (complete RPMI-1640). Cells were maintained at 37°C in a 
humidified atmosphere of 5% C02, 95% air.
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2.4 BACTERIAL ADHERENCE AND INVASION OF INTESTINAL EPITHELIAL 
CELLS
2.4.1 Cell lines
Three intestinal cell line models were used to establish bacterial adhesion 
and invasion into intestinal epithelial cells: 1407, Caco2, and Caco2-cll. 1407 
were selected as they had previously been used by Darfeuille-Michaud and 
colleagues as a reference epithelial cell line for AIEC adherence and invasion 
[Boudeau et al. 1999] and by Martin and colleagues [Martin et al. 2004]. 
Caco2 and Caco2-cll cells were selected as a model of colonic epithelial cells.
2.4.2 Plant fibres
Soluble plant non-starch polysaccharides (NSP) have previously been 
investigated for their ability to block the attachment of adherent and invasive 
E. coll (AIEC) to intestinal epithelial cells in vitro (1407 and HT-29 cells) [Martin 
et al. 2004]. Soluble NSP from plantains were found to be particularly potent 
(plantains are a banana family (Musa) member that are usually cooked as a 
vegetable). Soluble plant fibres contain a wide range of oligosaccharide 
structures and might have the ability to inhibit a wide range of bacteria- 
epithelial interactions. The plant NSPs tested here, namely apple, plantain 
[Musa spp i.e. the banana family], broccoli and leek were provided by 
Provexis PLC. The plant NSP were dissolved in DMEM (without FCS, penicillin, 
streptomycin and glutamine) at a concentration of 500 mg / mL, followed by 
sterilisation through a 0.2 pm filter, and then used at a final concentration of 
0 -5 0  mg / mL.
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2.4.3 In vitro invasion assays
Seven colonic Crohn's disease AIEC isolates, six control patient AIEC, the ileal 
AIEC isolate LF82, and E. coli K12 (Appendix 1) were tested for their ability to 
invade the intestinal cell line 1407, and the colonic cell lines Caco2 and Caco2- 
c ll cells. Shigella sonnei was also used with the intention that it would act as 
a positive control for invasion.
Cells were maintained as described earlier. After cells had reached 
confluency levels of approximately 60%, they were detached from their flasks 
by treatment with 1 x trypsin-EDTA solution (0.05% trypsin (v/v), 0.02% EDTA 
(w/v) in PBS) and seeded into 24-well tissue culture treated plates (Costar, 
High Wycombe, UK), at a density of 1 x 105 cells per well in 1 mL; cells were 
maintained in complete DMEM for 24 hours. The cells were then washed 
twice with sterile PBS prewarmed to 37°C, and the media replaced with fresh 
complete DMEM but lacking antibiotics. E. coli, prepared as per 'solid agar 
culture', were added at a concentration of 1 x 106 E. coli per well (1:10 
dilution of an OD 0.825 at 550nm solution, 10 pL of the resultant solution 
were added per well). E. coli were incubated with cells in wells for 4 hours at 
37°C, 5% C02 in a humidified atmosphere. Wells were then washed three 
times in sterile PBS. To determine bacterial invasion, wells were treated with 
fresh culture medium containing gentamicin at 100 pg / mL to kill any 
extracellular bacteria. After one hour at 37°C, the wells were washed three 
times in sterile PBS. Cells were lysed by adding deionised water containing 1% 
Triton-XlOO (v/v) for 5 minutes to release internalised bacteria. Eight 10-fold 
dilutions of the cell lysate were performed, and 50pL from each was plated 
onto LB agar plates in triplicate. Plates were incubated at 37°C for 24 hours, 
and colony forming units (CFU) counted. One colony forming unit originates 
from a single bacterium which has proliferated to become a visible colony.
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2.4.4 In vitro adhesion assays
Three colonic Crohn's disease AIEC isolates, three control patient AIEC, the 
ileal AIEC isolate LF82, and E. coli K12 (Appendix 1) were tested for their 
ability to adhere to the intestinal cell line 1407. The method to determine 
bacterial adhesion follows the same protocol as determining bacterial 
invasion, with the omission of the gentamicin step, with bacteria and cells 
incubated together for a total of 4 hours.
2.4.5 Adhesion and invasion assays in the presence of soluble non-starch 
polysaccharides (NSPs)
Several strains of E. coli were subjected to further investigation to determine 
if the presence of soluble non-starch polysaccharides (NSP) such as plantain 
or broccoli could prevent or disrupt bacterial adhesion and invasion into 
Caco2-cll cells. The protocol was the same as for the standard invasion and 
adhesion assay described previously, with the exception that the cell media 
were supplemented with NSPs over a range of concentrations from Omg/mL 
-  50 mg / mL (w/v), and was added to the cells 30 minutes prior to the 
addition of the bacteria.
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2.5 M-CELL AND Caco2-CLl MONOLAYER GENERATION
2.5.1 Transwell® filter set up
The apical surface of 12mm (0.6 cm2) Transwell® filters (Millicell® Culture 
Plate Inserts with 3.0pm pores (Millicell, cat. No. PITP 012 50)) were coated 
with 13.56 pg Matrigel™ (Becton, Dickinson and Company, Oxford, UK) 
diluted in 300 pL ice-cold DMEM (without FCS, penicillin, streptomycin and 
glutamine). Transwells® were then left for 1 hour at room temperature in 
sterile conditions to allow the Matrigel™ to gel. Transwells® were then 
washed twice with DMEM.
2.5.2 Caco2-cll cell seeding
Caco2-cll cells were seeded into the apical Transwell® chamber at 5 x 105 
cells in 500 pL complete DMEM. Wells were placed in 12 well plates and 1500 
pL complete DMEM added to the basolateral aspect. Caco2-cll cells were left 
to adhere overnight, followed by replacement of all media with complete 
DMEM; subsequently, both apical and basolateral media was changed every 
other day. Caco2-cll cells were cultured for 14 - 16 days at 37°C in a 
humidified atmosphere of 5% C02, 95% air, until confluent monolayers were 
formed,
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2.5.3 Detection of confluent monolayers
2.5.3.1 Transepithelial Electrical Resistance (TEER)
Confluent Caco2-cll monolayers were monitored daily by measuring 
transepithelial electrical resistance (TEER) using an epithelial voltohmmeter 
(World Precision Instruments, Hertfordshire, UK). Cultures which had TEER, 
values < 300 Qcm2 at day 16 of culture were discarded and not used in any 
assay.
2.5.3.2 Light Microscopy
Twelve well plates with a growth area of 3.8 cm2 / well were coated with 
Matrigel at the same concentration as Transwell® filters (85.88 pg Matrigel™ 
in 1.9 mL ice cold DMEM per 12-well plate well) and left to gel for 1 hour at 
room temperature. Caco2-cll cells were seeded at a concentration of 1 x 106 
cells / mL, in a volume of 3.17 mL. The growth of the monolayers was 
monotored via light microscopy. This allowed direct visualisation of Caco2-cll 
cell growth on Matrigel™, since Caco2-cll cells growing on the Transwell® 
filter could not be easily monitored due to the filter itself preventing clear 
visualisation of the cells.
2.5.4 Caco2-cll monolayer formation
Upon reaching TEER, values > 300 Qcm2 at day 14 -  16 of culture, control 
Transwells® were then cultured for a further 4 - 6  days, with the apical and 
basolateral media changed each day. TEER was monitored throughout -  any 
cultures with TEER < 300 Qcm2 were discarded and not utilised for further 
study.
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2.5.5 M-cell monolayer generation
Raji B cells were removed from complete RPMI-1640 medium, centrifuged at 
1,000 x g for 5 minutes and resuspended in complete DMEM to a final 
concentration of 333,000 cells / mL; 1.5 mL of this medium was then added 
to the basolateral chamber of the Transwell®. Raji B -  Caco2-cll cells were 
cocultures together for a further 4 - 6 days. Apical and basolateral media was 
changed each day.
2.5.5 Monolayer preparation for assays
Prior to use, Caco2-cll and M-cell monolayers were removed from complete 
DMEM and Raji B cells, washed once in DMEM, and twice in sterile PBS at 
37°C, media was them replaced with DMEM without penicillin and 
streptomycin, and left for 1 hour before use.
2.6 BACTERIAL TRANSLOCATION ACROSS Caco-2 AND M-CELL MONOLAYERS
2.6.1 Translocation of bacterial species
The apical surface of Caco2-cll and M-cell monolayers was infected with 
lOpL bacterial suspension containing 1 x 107 bacterial colony forming units 
(CFU). Aliquots from the basolateral media were removed at appropriate 
time points (0 -  24 hours), and the bacterial load quantified; ten-fold 
dilutions of the basolateral media were performed, and 50 pL from each was 
cultured on LB agar plates, incubated at 37°C, 5% C02 and colony forming 
units were counted after 24 h.
Following removal of the required aliquots of basolateral media, all 
basolateral media was removed from surrounding the well, and from below
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the monolayer itself. The filter grown monolayers were then incubated for a 
further hour at 37°C, any Transwells® which had basolateral media present at 
this point were discard, as it was assumed that the basolateral media had 
leaked from the apical chamber -  as such, translocation data for these wells 
would be unreliable, and was discarded. In addition, TEER was monitored 
throughout, those wells with TEER < 300 Qcm2 at any point were discounted 
as this indicted disruption to the monolayer integrity.
Within each translocation assay, E. coli K12 (having a low translocation rate) 
and Crohn's disease AIEC HM605 (having a high translocation rate) were 
always included to assess interassay variability. Data was presented as the 
total number of bacterial species translocating across monolayers per cm of 
monolayer.
2.6.2 Preparation of dietary components.
Plant NSPs were prepared and used as described previously (section 2.4.2). 
The food emulsifiers polysorbate-80 and polysorbate-60 were diluted in 
DMEM (without FCS, penicillin, streptomycin and glutamine) at 37°C to 
ensure solubilisation at a concentration of 1% polysorbate-60 (v/v) and 0.1% 
polysorbate-80 (v/v). The polysorbates were then used at a final 
concentration of 0.1% - 0.0001% polysorbate-60 and 0.01% - 0.0001% (v/v) 
polysorbate-80 (the range predicted to be physiologically relevant).
2.6.3 Translocation in the presence of dietary components.
To assess the impact of dietary factors such as fibres and emulsifiers upon 
translocation, prior to infection with bacterial species, the apical surface of 
the monolayers were pre-incubated for 30 minutes with fibre or emulsifiers
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prior to infection. After this 30 minute pre-incubation period, monolayers 
were infected in the normal way, and bacterial translocation quantified as 
usual.
2.7 TRANSMISSION ELECTRON MICROSCOPY OF Caco2-CLl AND M-CELL 
MONOLAYERS
2.7.1 Sample preparation and embedding in resin
Transwells® containing Caco2-cll cells or M-cell monolayers before or during 
infection were prepared for transmission electron microscopy. Transwells® 
were washed 2 x 5minute PBS, and then fixed in 2% glutaraldehyde (w/v) and 
4% paraformaldehyde (w/v) in PBS for 1 h at RT. This was followed by 2 x 15 
minute PBS washes, then 1 hour at room temperature in 1% osmium 
tetroxide (v/v), and then 2 x 30 minute PBS and 1 overnight PBS wash. The 
following morning, the PBS was removed from the monolayers by 2 x 15 
minute sterile H20 washes. Monolayers were then serially dehydrated by a 
series of ethanol washes; 20 minutes in 30% ethanol, then 10 minutes each in 
60%, 70%, 80%, and 90% ethanol, finally followed by 2 x 15 minute washes in 
100% ethanol. The cell monolayer coated filter was then carefully removed 
from the Transwell®, using a scalpel, and cut into 3 mm wide strips (ensuring 
the cell monolayer is uppermost). Samples were then incubated for 30 
minutes in 50% ethanol, 50% araldite resin, and then for 1 hour in araldite 
resin. The samples were then transferred to moulds containing 100% resin, 
and baked in a dry oven at 60°C for 48 hours.
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2.7.2 Sample sectioning
Once polymerised, blocks were trimmed at the sample containing end to an 
area of 0.25mm2. Samples were then sectioned on a Reichert Ultracut E 
(Reichert Analytical Instruments, Depew, USA) using a diamond knife 
(DiATOME AG, Biel, Switzerland) to a thickness of 70nm. Samples were then 
mounted onto copper grids, and left to dry for at least 24 hours before 
staining.
2.7.3 Sample staining
Copper grids were incubated, sample side down, on lOOpL drops of Reynards 
Lead Citrate (Appendix 2) for 5 minutes, followed by 3 x 20 second vigorous 
washes in distilled water. Samples were then incubated, again, sample side 
down, on lOOpL drops of 5% uranyl acetate (w/v) for 5 minutes, followed by 
3 x 20 second vigorous washes in distilled water. Samples were left to air dry 
for at least 24 hours.
2.7.4 TEM analysis
Samples were examined using a FEI 120kV Tecnai G 2 Spirit BioTWIN 
transmission electron microscope (Biomedical Electron Microscopy Unit, 
University of Liverpool, Liverpool, UK).
2.8 MONOLAYER EXAMINATION BY IMMUNOBLOTTING
2.8.1 Sample preparation
Caco2-cll and M-cell monolayers were washed three time in sterile PBS, the 
PBS was removed and the monolayers immediately frozen at -80 °C overnight
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to lyse the cells. The cell lysates were then resuspended in 250 pL sample 
buffer, vortexed for 30 seconds to ensure a homogeneous sample and then 
boiled at 90 °C for 5 minutes.
2.8.2 Immunoblotting
Solubilised proteins were separated by SDS-PAGE on 10% resolving, 4% 
stacking polyacrylamide gel (Appendix 2) and electrotransferred to 
nitrocellulaose membrane for 1 hour, at 100 V, in 25 mM Tris, 192 mM 
glycine and 20% (v/v) methanol.
2.8.3 Aleuria aurantia lectin binding
Aleuria aurantia lectin (Catalog number B-1396; Vector laboratories, 
Peterborough, UK) has been found to target human M-cells [Roth-Walter et 
ol. 2004; Roth-Walter et al. 2005]. It has been used here to detect M-cell 
generation from Caco2-cll cells.
Following M-cell and Caco2-cll protein transfer onto nitrocellulaose 
membrane, the membrane was washed in 50 mM Tris, pH 7.5, 0.15M IMaCI, 
0.1% Tween-20 (v/v), blocked in buffer containing 1% BSA (w/v), incubated 
with a biotinylated Aleuria aurantia lectin diluted 1:2000 in buffer, washed in 
buffer, and detected using peroxidase-conjugated avidin (Bio-Rad, Hemel 
Hempstead, UK), and this detected using a chemiluminescence Super-signal 
immunoblotting detection kit (Pierce, Rockford IL, USA).
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2.8.4 Alkaline Phosphatase protein expression
Alkaline Phosphatase expression is known to be down regulated in M-cell 
cultures compared with Caco2 / Caco2-cll cultures [Gullberg et al. 2000; 
Tyrer et al. 2002; Lai et al. 2008]. For this reason, alkaline phosphatase 
expression was assessed as an indicator of M-cell generation from Caco2-cll 
cells.
Following M-cell and Caco2-cll protein transfer onto nitrocellulose 
membrane, the membrane was blocked with Tris-buffered saline (TBS) 
containing 1% (w/v) BSA, 0.1 % (v/v) Tween 20 for 1 hour. The membrane 
was then probed with the primary antibody; rabbit polyclonal to human 
intestinal alkaline phosphatase ([ab7322], Abeam; Cambridge, UK) diluted 
1:5000 in TBS -  0.1 % Tween 20 (v/v) (TBS Tween) for 1 hour, followed by 3 x 
20 minute washes in TBS Tween. Peroxidase-conjugated secondary anti­
rabbit Ig antibody at 1:5000 was used (Dako; Glostrup, Denmark). Alkaline 
phosphatase expression was detected using the Super-signal immunoblotting 
detection kit (Pierce; Rockford IL, USA).
2.8.5 Pan-actin expression to detect equal loading of protein samples
Equal loading of samples for western blot analysis was confirmed using a pan- 
actin antibody (1:500) (Antibody #4968; Cell Signalling Technology®; Danvers, 
MA, USA). Membranes were washed three time in TBS tween, incubated with 
the primary antibody for 1 hour, washed in TBS tween, followed by 
appropriate secondary antibody incubation for 1 hour, and detected again 
using the Super-signal immunoblotting detection kit.
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2.8.6 Antibody / Lectin detection
Following use of the Super-signal immunoblotting detection kit, membranes 
were examined using a Bio-Rad Fluor-S Multiimager (Bio-Rad Laboratories, 
California, USA), a quantitative imaging system for capturing high-resolution 
digital images. Using Quantity One® software (Bio-Rad Laboratories, 
California, USA), images were subjected to quantitative densitométrie 
analysis of protein bands.
2.9 BACTERIAL INTERACTIONS WITH J774-A1 MACROPHAGE CELLS
2.9.1 Bacterial replication within J774-A1 macrophage cells
Murine macrophage cells J774-A1 were seeded into 24-well tissue culture 
plates at density of 1 x 105 cells per well in 1 mL and maintained in complete 
media (RPMI-1640) for 24 hours. The wells were then washed three times in 
sterile PBS. E. coli were added at a concentration of 1 x 106 E. coli per well 
(1:10 dilution of a OD 0.825 at 550nm solution, lOpL of the resultant solution 
were added per well). E. coli were incubated with cells in wells for 2 hours at 
37°C, 5% C02 in a humidified atmosphere. Following this, wells were washed 
three times in sterile PBS to remove non-adherent bacteria. Wells were then 
treated with fresh culture medium containing gentamicin at 20 pg / mL for a 
further hour, to both kill any extracellular bacteria [Subramanian et al. 2008]. 
Following this, the media was removed and replaced with complete media 
lacking antibiotics, and left for a further 3h to allow replication of internalised 
bacteria. Subsequently, the wells were washed three times with sterile PBS, 
and the cells lysed by adding deionised water containgin 1% v/v Triton-XlOO 
(v/v) for 5 minutes to release internalised bacteria. Ten-fold dilutions of the 
cell lysate were performed, and 50pL from each was plated onto LB agar 
plates. Plates were incubated at 37°C for 24 hours, and colony forming units
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(CFU) counted, with a CFU taken to represent a single viable E. coli from 
within the macrophage cell. To calculate the percentage of replication, the 
viable CFU counts at the end of the three hour replication period were 
compared to viable CFUs obtained immediately after one hour of gentamicin 
treatment.
2.9.2 Efficacy of antibiotics against bacteria internalised within macrophage 
cells
To assess the efficacy of antibiotics against internalised bacteria, a 
representative Crohn's disease associated AIEC was selected. This E. coli, 
HM605, was then used for further study as it had previously been shown to 
replicate extensively within macrophages. Cells were infected and treated 
with gentamicin as described above. Following gentamicin treatment, cells 
were incubated with various antibiotics, such as rafampicin, clarithromycin, 
tetracycline, trimethoprim or ciprofloxacin, both as single treatments, and in 
combination with each other, for 3h. Antibiotics were tested at commonly 
observed peak serum concentrations (Cmax), and at 10% of Cmax. Cells were 
lysed and plated as described above to yield CFU and % killing of bacteria was 
determined as compared to control level survival.
2.9.3 Transmission electron microscopy (TEM) of macrophages
2.9.3.1 Sample preparation and embedding in resin
Subsequent to infection, as described above, J774-A1 cells were fixed in 2% 
glutaraldehyde and 4% paraformaldehyde (both Agar Scientific) in PBS, at 
room temperature (RT) for 1 hour. Cells were then washed in PBS for 
5minutes, and left overnight at 4°C in fresh PBS. The following morning, cells 
were again washed in PBS, followed by 2 x 15 minute washes in 0.15M
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glycine in PBS, followed by a 5 minute PBS wash. Cells were then gently 
scraped into an Eppendorf containing 1 mL PBS. Cells were then centrifuged 
at 5000 x g for 2 minutes. The resultant pellet was then suspended in 2% 
liquid agarose, centrifuged at 5000 x g for 2 minutes, and left upon ice until 
set. Samples were then cut into 2mm3 pieces. Samples were further fixed in 
1% osmium tetroxide, which also gives contrast when viewed under TEM, for 
a further 1 hour. This was followed by 2 x 30 minute PBS washes, 1 x 15 
minute distilled water wash, then 1 x 30 minute 30% ethanol in water 
(ethanol wash). The samples were then left for 1 hour in 30% ethanol 
containing an additional 0.5% urayl acetate. Following this step, the samples 
were washed for 10 minutes each in increasing strength ethanol washes 
(30%, 60%, 70%, 80%, 90%) followed by 2 x 15 minute washes in 100% 
ethanol. Samples were then washed in 1:1 acetone:ethanol mix for 10 
minutes, followed by a 30 minute 1:1 acetone:resin mix, and finally a 100% 
resin was added. Samples were placed in moulds 3mm x 4mm x 9mm along 
with fresh resin, and then polymerised in an oven at 60°C for 24 -  48 hours.
2.93.2 Sample sectioning
Once polymerised, blocks were trimmed at the sample containing end to an 
area of 0.25mm2. Samples were then sectioned as per section 2.7.2, stained 
as per section 2.7.3 and examined as per section 2.7.4.
2.9.4 Effect of antibiotics on macrophage viability
Murine macrophage cells J774-A1 were seeded into 24-well tissue culture 
plates at density of 1 x 105 cells per well in 1 mL and maintained in complete 
RPMI-1640 for 24 hours. The wells were then washed three times in sterile 
PBS. Antibiotics, at Cmax of each antibiotic, were then added to each well and 
incubated at 37°C, 5% C02 in a humidified atmosphere for 3h. Cells were then
60
detached from their well by treatment with 1 x trypsin-EDTA solution (0.05% 
trypsin (v/v), 0.02% EDTA (w/v) in PBS) and re-suspended in 0.9 mL PBS, and 
Trypan-blue added to a final concentration of 1 mg / mL (w / v). Macrophages 
were then counted using a hemocytometer, viable cells possess intact cell 
membranes that exclude Trypan-blue, appearing colourless, whereas dead 
cells do not, appearing blue under microscopic examination.
2.10 STATISTICAL ANALYSIS
All statistical analysis was performed using StatsDirect software (StatsDirect 
v2.3.1; Sale, UK). Independent sample groups were assessed for normality 
using the Shapiro-Wilk W test [Shapiro et al. 1965]. Samples with a normal 
distribution were tested for equality of variance using Levene's test [Brown 
1974]. Data sets consisting of multiple treatments which were found to be 
both normally distributed and of equal variance were analysed using the 
parametric one-way analysis of variance (ANOVA), followed by pair-wise 
comparisons of treatment means; data sets consisting of 2 samples were 
analysed using Student's t-test. Multiple treatment data sets found to be 
either non-normally distributed, or displaying unequal variances were 
analysed using non-parametric one-way (Kruskal-Wallis) ANOVA [Critchlow 
1991], significance of data was determined using Conover tables [Conover 
1999]; Mann-Whitney U was used when data consisted of only 2 samples. In 
the ANOVA, Student's t-test, Kruskal-Wallis and Mann-Whitney U test, 
differences were considered significant when P < 0.05. All data presented 
within this thesis is expressed as mean ± standard error of the mean (SEM), 
unless otherwise stated.
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Chapter 3
Adherence and Invasion of 
Crohn's Disease AIEC to 
Caco2 and Caco2-cll cells, and 
Inhibition by Plantain NSP
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3.1 HYPOTHESIS
Crohn's disease and control patient AIEC isolates are able to invade Caco2 and 
Caco2-cll cells; the AIEC also adhere to these cells. This invasion and adhesion 
can be inhibited by the presence of soluble plantain fibre.
3.2 AIMS
1. Assess adhesion to and invasion into Caco2 and Caco2-cll cells by a 
panel of Crohn's disease and control patient AIEC.
2. Determine if soluble plantain fibre can prevent this invasion and 
adhesion.
3.3 INTRODUCTION
It is well accepted due to work by several independent groups that there are 
increased numbers of mucosa-associated bacteria, particularly E. coli, in tissue 
samples taken from the colonic mucosa of Crohn's disease patients [Swidsinski 
et al. 2002; Martin et al. 2004] and from the ileal mucosa of Crohn's disease 
patients, both adult [Darfeuille-Michaud etal. 1998] and paediatric [Conte etal. 
2006]. These E. coli, being either intra-mucosal or mucosa-associated, have 
been shown to have invasive properties in Crohn's disease patients by several 
independent groups [Darfeuille-Michaud et al. 2004; Martin et al. 2004; 
Baumgart et al. 2007; Sasaki et al. 2007; Eaves-Pyles et al. 2008].
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One hypothesis is that in vivo, these E. coli, termed 'adherent-invasive 
Escherichia coli' [Boudeau et al. 1999; Darfeuille-Michaud 2002] adhere to and 
invade epithelial cells, initiating an inflammatory cascade which gives rise to the 
characteristic inflammation observed in Crohn's disease. Indeed, in vitro, these 
AIEC have been shown to adhere to, and invade into intestinal cell lines 
[Darfeuille-Michaud 2002; Martin et al. 2004]. Cell lines investigated so far 
include intestine-407 (1407) [Martin et al. 2004], HT-29, an in vitro cell line 
models of epithelial colorectal adenocarcinoma [Martin et al. 2004] and 
differentiated Caco2 cells [Darfeuille-Michaud et al. 1998]. Levels of adhesion 
and invasion of these AIEC to these cell lines has been shown to be both strain 
and isolate dependent [Darfeuille-Michaud et al. 1998; Martin et al. 2004]. 
Published work to date show that invasion of AIEC strains is most predominant 
in 1407 cells, whilst for many strains invasion in HT-29 cells in very low or absent 
[Martin et al. 2004].
The Liverpool £  coli isolates (denoted HM—), unlike isolates from other 
independent groups had not been tested for their ability to invade Caco2 cells, 
knowing this would allow for greater understanding of the invasive properties 
of the Crohn's disease £  coli isolates. Additionally, since Caco2-cll cells, a sub­
clone of Caco2 cells, are commonly used to investigate bacterial translocation 
assays across epithelial layers, and are used in the generation of in vitro M-cells, 
it would be beneficial to know if Crohn's disease £  coli isolates are able to 
adhere or invade into this Caco2-cll cell line.
Previous studies have shown that adhesion of Crohn's disease £  coli isolates 
can be inhibited by the soluble plant fibre plantain NSP [Martin et al. 2004]. 
This work was carried out using the 1407 cell line; it is important that this be 
tested further on a true intestinal epithelial cell line as it potentially could be 
used a prophylactic therapy for Crohn's disease patients.
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3.4 METHODS
A panel of E. coli were selected (see Appendix 1) consisting of seven Crohn's 
disease AIEC, six control patient AIEC, ileal Crohn's disease AIEC LF82, and 
control E. coll K12. These strains were selected to encompass both 
haemagglutinating and non-haemagglutinating strains within the control and 
disease group. All strains were investigated for their ability to invade into Caco2 
and Caco2-cll cells. Three Crohn's disease AIEC displaying the ability to invade 
Caco2-cll cells, ileal Crohn's disease AIEC LF82 and control E. coli K12 were then 
selected for further investigation into the effect that soluble plantain fibre has 
upon E. coli adhesion and invasion into Caco2-cll cells. Detailed methods for 
detection of AIEC invasion and adhesion to Caco2 and Caco2-cll can be found 
within Chapter 2, as can details of the assays using plantain fibre.
Briefly, Caco2 or Caco2-cll cells in culture were infected with Crohn's disease or 
control patient AIEC isolates, for 4 hours, to allow bacterial internalisation, 
followed by extracellular gentamicin treatment to kill extracellular organisms 
for 1 hour for invasion studies. Parallel studies in the absence of gentamicin 
were performed to assess for adhesion. Experiments were conducted with and 
without incubation with soluble plantain fibre, prior to the addition of bacteria. 
Cells were lysed, followed by enumeration of invasive or adherent AIEC 
following overnight growth of the lysate on LB agar.
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3.5 RESULTS
3.5.1 AIEC invade Caco2 and Caco2-cll cells in vitro.
Invasion of the control E. coli K12 was found not to be significantly different for 
Caco2 and Caco2-cll cells. All of the AIEC isolates investigated were found to 
invade into Caco2 cells (Fig 3.1). Of the six control patient AIEC tested, five were 
found to be more invasive than E. coli K12 (being 2.79 -  22.53 fold more 
invasive than E. coli K12). Of the seven Crohn's disease AIEC tested, three were 
found to invade Caco2 cells to a greater extent than E. coli K12 (2.74 -  15.92 
fold more invasive). Whilst still invasive, the other strains investigated invaded 
Caco2 cells less than f. coli K12. The classic AIEC LF82 was found to invade 
Caco2 cells more than K12 (LF82, 2.01 ± 0.83 fold).
All of the AIEC strains investigated were found to invade Caco2-cll cells to a 
greater extent than E. coli K12 (Fig 3.2) (2.72 -  25.55 fold more invasive). E. coli 
LF82 was also more invasive than E. coli K12 (1.58 ± 0.06 fold). The E. coli strains 
appeared to be more invasive in the Caco2-cll cell line than the Caco2 cells line, 
as all strains investigated were more invasive of Caco2-cll than E. coli K12.
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30 * * *
E. coli isolates
Figure 3.1 AIEC invasion into Caco2 cells
Invasion here is defined as the absolute number of E. coli enumerated from within epithelial 
cells following epithelial cell infection with E. coli, gentamicin treatment and cell lysis, and is 
expressed relative to K12. Significant differences from E. coli K12 invasion are as follows: *, P < 
0.05; **, P < 0.01; and ***, P < 0.001 (ANOVA) (n=5).
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Figure 3.2 AIEC invasion into Caco2-cll cells.
Significant differences from E. coli K12 invasion are as follows: *, P < 0.05; **, P < 0.01; and 
***, P< 0.001 (ANOVA) (n=5)
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3.5.2 Bacterial invasion of Caco2-cll cells is inhibited by plantain NSP
Plantain NSP at 50 mg / mL was found to significantly inhibit E. coli K12 invasion 
into Caco2-cll cells (49.12 ± 15.37% inhibition) (Fig 3.3A). For all of the Crohn's 
disease AIEC isolates investigated, invasion to Caco2-cll cells was inhibited in a 
dose-dependent fashion (Figure 3.3 B -  E); statistically significant inhibition was 
observed at 50 mg / mL plantain NSP, and also at the lower concentration of 5 
mg / mL plantain NSP; inhibition of invasion was also seen at 0.5 mg / mL 
plantain NSP, although this was not statistically significant. Whilst invasion of all 
Crohn's disease AIEC isolates into Caco2-cll was inhibited by plantain, E. coli 
HM605 and E. coli HM615 appeared most sensitive to the presence of plantain, 
with approximately 90% and 80% of invasion inhibited respectively by plantain 
at 50 mg / mL.
£. coli K12
Figure 3.3 (A) -  Plantain inhibits bacterial invasion of Caco2-cll cells
Invasion of all of the AIEC Isolates Investigated Is Inhibited by the presence of plantain NSP at 
5 mg / mL and 50mg / mL. For E. coli K12, Inhibition of Invasion is only observed at 50 mg / mL 
plantain NSP. *, P < 0.05; •*, P < 0.01; and ***, P < 0.001 (ANOVA) (n=3)
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Figure 3.3 (B -  D) -  Plantain inhibits bacterial invasion of Caco2-cll cells
Invasion of all of the AIEC isolates Investigated Is inhibited by the presence of plantain NSP at 
5 mg/mL and 50mg / mL. For E. coli K12, inhibition of invasion is only observed at 50 mg / ml. 
plantain NSP. *, P < 0.05; **, P < 0.01; and ***, P < 0.001 (ANOVA) (n=3)
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Plantain mg/ml
Figure 3.3 (E) -  Plantain inhibits bacterial invasion of Caco2-cll cells
Invasion of all of the AIEC isolates investigated is inhibited by the presence of plantain NSP at 
5 mg / mL and 50mg / mL. For E. coli K12, inhibition of invasion is only observed at 50 mg / mL 
plantain NSP. *, P < 0.05; **, P < 0.01; and ***, P < 0.001 (ANOVA) (n=3)
3.5.3 Bacterial adhesion of Caco2-cll cells is inhibited by plantain NSP
The ability of the Crohn's disease AIEC isolates to adhere to the surface of 
Caco2-cll cells was similar to that of E. coll K12 -  there was no significant 
difference in levels of adhesion to Caco2-cll cells between any of the isolates 
investigated (Fig 3.4).
Plantain NSP, at 50mg / mL, and 5mg / mL was found to inhibit E. coli adhesion 
to Caco2-cll cells (Fig 3.5). At 5 mg / mL plantain, inhibition of adhesion of all E. 
coli strains investigated was in the range of 41 -  46 % inhibition, with the 
exception of Crohn's disease E. coll HM615 which was inhibited by
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approximately 60 %. Plantain at 50 mg / mL was found to be more inhibitory of 
adhesion, with the Liverpool strains (HM—) being inhibited in the region of 65 -  
71 %, whilst inhibition of E. coli K12 at 48 % was relatively unchanged by the 
higher plantain concentration, as was AIEC LF82, with an increased inhibition of 
1.5 %, despite the 10 fold higher plantain concentration..
16
u ■
K12 LF82 HM580 | HM605 HM615
Ileal CO AIEC CD AIEC
E. coll Isolates
Figure 3.4 E. coli isolate adhesion to Caco2-cll cells.
Adhesion of E. coli K12 is similar to that of the Crohn's disease AIEC Isolates investigated (n=3).
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Figure 3.5 (A -  C) -  Plantain inhibits bacterial adhesion to Caco2-cll cells
Adhesion of all of the AIEC isolates investigated and E. coli K12 is inhibited by the presence of 
plantain NSP at 5 mg / mL and 50mg / mL, although not statistically significantly in all cases, 
despite a 40% inhibition of adhesion. *, P < 0.05; **, P < 0.01; and ***, P < 0.001 (ANOVA) 
(n=3)
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Figure 3.5 (D -  E) -  Plantain inhibits bacterial adhesion to Caco2-cll cells
Adhesion of all of the AIEC isolates investigated and E. coli K12 is inhibited by the presence of 
plantain NSP at 5 mg / mL and 50mg / mL, although not statistically significantly in all cases, 
despite a 40% inhibition of adhesion. *, P < 0.05; **, P < 0.01; and ***, P < 0.001 (ANOVA) 
(n=3)
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3.6 SUMMARY OF RESULTS
1. Control patient and Crohn's disease AIEC invade into Caco2 and Caco2- 
c ll cells to different extents. Invasion does not appear to correlate 
disease status of the patient from whom the isolates were derived. Some 
AIEC strains invade Caco2 cells to a lesser extent than control E. coli K12; 
all AIEC invade Caco2-cll cells to a greater extent than E. coH K12.
2. Plantain NSP at 0.5, 5 and 50 mg / mL inhibits E. coli invasion into Caco2- 
c ll cells
3. Of the limited number of Crohn's disease AIEC investigated, adherence 
to Caco2-cll cells does not differ to the level of adhesion E. coli K12 
achieves.
4. Plantain NSP at 5 and 50 mg / mL inhibits E. coli adhesion to Caco2-cll 
cells
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3.7 DISCUSSION
The initial cause of inflammation in Crohn's disease is unknown. Reports of the 
increased prevalence of intra-mucosal and mucosa-associated E. coli within the 
tissue of Crohn's disease patients suggest bacterial involvement. These E. coU 
were found in close proximity to the surface of the epithelial lining of the gut, 
and suggest that microbial-host interactions at this point may be important in 
the inflammatory process. Indeed, it is possible that bacterial adhesion to, or 
invasion into host epithelial cells may act as a trigger in the inflammatory 
response.
The data presented here confirms that of several other published manuscripts 
[Boudeau et al. 1999; Sasaki et al. 2007; Eaves-Pyles et al. 2008], showing that 
Crohn's disease E. coli isolates are able to adhere to and invade into Caco2 
intestinal epithelial cells in vitro. The Crohn's disease and control patient E. coli 
isolates described here invade into Caco2 and Caco2-cll cells, and adhere to 
Caco2-cll cells.
Co-incubation of Crohn's disease f. coli isolates with HT-29 or T84 cells 
stimulates production of the proinflammatory chemokine 11-8, providing a firm 
link between Crohn's disease E. coli isolates, epithelial cells and the 
inflammatory response [Subramanian et al. 2008]. It is at least a plausible 
hypothesis that this may be relevant in vivo. Indeed, if this is the case, 
preventing E. coli -  epithelial cell interaction has the potential to prevent or 
lessen inflammation which may be of therapeutic benefit. Previous studies have 
shown that plantain NSP is able to inhibit Crohn's disease E. coli isolate 
adhesion and invasion to 1407 cells [Martin et al. 2004], and here to Caco2-cll 
cells.
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Adherence of diarrheagenic E. coll strains (enteropathogenic E. coli (EPEC), 
enterohemorrhagic E. coll (EHEC), enterotoxigenic E. coli (ETEC), 
enteroaggregative E. coli (EAEC), enteroinvasive E. coli (EIEC), and diffusely 
adhering E. coll (DAEC)) to epithelial cells is a critical early stage in diarrheal 
infections caused by pathogenic E. coll strains. This adherence has been shown 
to be mediated by lectin-carbohydrate interactions on several independent 
occasions [Torres et al. 2005].
If Crohn's disease E. coll isolates also adhere to epithelial cells via lectin- 
carbohydrate interactions, then it is possible that complex oligosaccharides may 
interfere with these lectin-carbohydrates interactions, and may result in 
decreased adherence of Crohn's disease E. coll to the epithelia. Soluble plantain 
NSP is a complex mixture consisting of uronic acids (26.8 %), glucose (25.2 %), 
mannose (18.7 %) arabinose (9.0 %), galactose (8.6 %), xylose (6.7 %), fucose 
(2.6%) and rhamnose (2.4 %). It is possible that complex oligosaccharides 
structures within plantain NSP prevent bacterial -  host cell interactions, and a 
diet supplemented with plantain NSP may be of therapeutic benefit. Boiled 
green bananas, similar to plantains, were shown in a controlled study in 
Bangladesh to be effective in a reducing the severity of a variety of diarrhoeal 
diseases [Rabbani et al. 2001].
Despite these in vitro findings showing Crohn's disease E. coll isolate adhesion 
and invasion of Caco2 and Caco2-cll cells, in vivo, E. coli have not been 
observed within normal epithelial cells. In Crohn's disease tissue, the presence 
of E. coli has been most clearly observed within macrophage cells distributed 
within the lamina propria, beneath ulcers and in granulomas, in the germinal 
centres of mesenteric lymph nodes, and in giant cells along fissures [Cartun et 
al. 1993; Liu et al. 1995; Ryan étal. 2004].
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It is probably not surprising that E. coli have not been observed within normal 
epithelial cells since in vivo accessibility to the epithelial cell surface for 
bacterial species is somewhat reduced compared with the in vitro cell. In vivo, 
intestinal epithelial cells are coated with relatively thick mucus layer which 
overlies the glycocalyx which consists of a matrix of polysaccharides which 
serve to prevent bacterial-host cell interaction. Indeed, the in vivo epithelial cell 
surface is normally relatively sterile. This does question the validity of in vitro 
adhesion and invasion data to the in vivo situation. It is possible that in vivo, E. 
coli adhesion and invasion of the normal epithelial cells is rare, and that other 
cells types within the gut may be the main site of interaction for Crohn's 
disease E. coli isolates.
Within the intestine there are a variety of cell types which may potentially 
interact with AIEC. In vivo, E. coli or E. coli antigens have been identified within 
macrophages (by immunohistochemistry [Lui et al. 1995] and by laser capture 
microdissection [Ryan et al. 2004]) and within the lamina propria and 
surrounded inflamed tissue (including ulcers, fissures and in granulomata) 
[Cartun etal. 1993]. More recently, biopsies from Crohn's disease patients were 
found, following in vitro infection with E. coli K12 and HB101 to have an 
accumulation of these E. coli within dendritic cells underlying the follicle 
associated epithelium (FAE) [Keita etal. 2008; Salim etal. 2009].
This raises the possibility that AIEC may interact with macrophages or dendritic 
cells in vivo. Additionally, since the FAE contains M-cells, which are capable of 
taking up antigen from the lumen and then delivering it to the intestinal 
lymphoid system [Kraehenbuhl et al. 1992; Neutra et al. 1996; Neutra et al. 
1996], it is possible that AIEC may interact with M-cells in vivo. In this way, the 
M-cells may serve as a route by which the AIEC gain entry to macrophages 
resident within the lamina propria.
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Chapter 4
Modelling M-cells In Vitro, 
and Bacterial Translocation across 
this Specialised Epithelium
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4.1 HYPOTHESIS
It is possible to model, in vitro, cells which structurally and functionally 
resemble intestinal M-cells. Translocation of Crohn's disease E. coli isolates 
will be increased across these M-cells compared with translocation across 
control Caco2-cll cells.
4.2 AIMS
1. To model intestinal M-cells of the follicle-associated epithelium (FAE) 
in vitro, demonstrating biochemically, functionally and structurally 
that they are M-cells
2. To establish and characterise translocation of Crohn's disease E. coli 
isolates across these in vitro M-cells
4.3 INTRODUCTION
Aphthoid lesions of Crohn's Disease mainly occur within the follicle- 
associated epithelium (FAE) of the gut [Morson 1972; Rickert et al. 1980; 
Fujimura et al. 1996]. In Crohn's disease of the large bowel, aphthoid lesions 
frequently occur over lymphoid aggregates within the FAE [Fujimura et al. 
1996], whilst in Crohn's disease of the small bowel, these lesions typically 
occur over Peyer's patches [Rickert et al. 1980; Rutgeerts et al. 1984; Olaison 
et al. 1992; Shikuwa et al. 2007], structured collections of lymphoid follicles 
within the FAE [Van Kruiningen etal. 2002].
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The FAE overlies the mucosa-associated lymphoid tissue (MALT), situated just 
below the epithelium, and is the location of M-cells ('membranous' or 
'microfold' cells) [Owen et al. 1974]. These M-cells are the major site of both 
antigen and microorganism sampling in the gut -  they are able to internalise 
macromolecules and microorganisms, and deliver them to the underlying 
lymphoid tissue, providing a portal from which an immune response can be 
mounted [IMeutra 1999; Gullberg et al. 2000]. They are a major site for 
pathogen invasion and uptake, including Salmonella Typhimurium and 
Shigella spp. [Siebers et al. 1996; Jensen et al. 1998; Jepson et al. 2001]. Since 
the initial lesions observed in Crohn's disease occur at Peyer's patches it is 
possible that AIEC, like Salmonella spp. and Shigella spp., are translocated by 
intestinal M-cells and subsequently delivered to the underlying macrophage 
cells, where they have been observed in vivo [Liu et al. 1995; Ryan et al. 
2004],
4.4 METHODS
Detailed methods can be found in chapter 2. Briefly, the reproducible 
generation of M-cell cell enriched monolayers from Caco2-cll cell 
monolayers was obtained by growth of Caco2-cll cells for 14 -  16 days on 
Transwell® filters, followed by 6 days of basolateral co-culture with Raji B 
cells beneath the Transwell® filters. In this way, M-cell enriched monolayers 
were generated, with maintenance of monolayer integrity assessed through 
monitoring transepithelial electrical resistance (TEER).
Following successful M-cell generation, M-cells and control Caco2-cll cells 
were infected apically with various bacterial species to assess translocation 
across M-cell monolayers and Caco2-cll monolayers. Bacterial species
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utilised in this study were Salmonella Typhimurium LT2, Shigella sonnei, 
control E. coli K12, E. coll XLl-Blue, probiotic E. coli Nissle 1917, the classical 
French ileal AIEC LF82, seven Liverpool Crohn's disease E. coll isolates, and 
five Liverpool control subject E. coll isolates. To assess translocation, bacterial 
species were added apically to Transwells® at a multiplicity of infection (MOI) 
of 10 (10 bacteria added per cell); following a 4 hour infection, basolateral 
media containing translocated bacteria was serially diluted, plated onto LB 
agar in triplicate, and grown overnight at 37°C. Colony forming units (CFU), 
assumed to originate from a single, viable, translocated bacteria were then 
counted, and translocated expressed per cm2 epithelial monolayer. (M-cell 
monolayers which had been generated by Raji B co-culture for 4 -  8 days 
(rather than the optimal 6 days) were also investigated for their ability to 
translocate bacterial species using this method).
Assays to establish the time-course of translocation across both M-cells and 
Caco2-cll cells were conducted in the same way using the Liverpool Crohn's 
disease E. coll isolate HM605 -  aliquots of the basolateral media were 
removed at set times post infection, and translocated CFU quantified.
The method by which E. coll HM605 was grown was investigated in relation 
to translocation across M-cells. HM605 was grown by overnight culture on 
solid LB agar, by overnight culture in liquid LB broth, or by overnight culture 
in liquid LB broth followed by 48 h suspension in sterile PBS. Following apical 
infection of the M-cell monolayers at an MOI of 10, aliquots of the 
basolateral media were removed and translocated CFU quantified.
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In addition, Caco2-cll and M-cell monolayers were processed for 
transmission electron microscopy (TEM) analysis. This was to allow 
examination of the cell structure of the monolayers, particularly the 
distribution of microvilli on the apical cell surface. TEM analysis was also used 
to examine the presence of bacterial species within the cells of the 
monolayer.
Western blot analysis was conducted to determine expression levels of 
alkaline phosphatase, previously reported to be down-regulated in M-cells 
[Brown et al. 1990; Clark et al. 1994; Tyrer et al. 2002]. Aleuria aurantia lectin 
binding was also investigated as it had been previously reported to be able to 
selectively target M-cells [Roth-Walter et al. 2005].
4.5 RESULTS
4.5.1 TEER increases during Caco2-cll and M-cell monolayer formation
In the absence of a thin Matrigel™ layer on the Transwell® filter, background 
resistance readings were in the range of 40 -  50 Qcm2; following addition of 
Matrigel™, background resistance readings were in the range of 66 - 78 
Qcm2; monolayer TEER was calculated as the additional TEER generated by 
the presence of Caco2-cll cells above this Matrigel™ background.
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During the course of Caco2-cll cell culture, monolayer TEER steadily 
increased (Figure 4.1). During days 0 to 14 -  16, monolayer TEER typically 
Increased from 0 Qcm2 to 300 Qcm2, Indicating the generation of fully 
confluent differentiated monolayers. Only those monolayers which had TEER 
values in excess of 300 Qcm2 after 16 days of growth were used. Caco2-cll 
monolayers which were co-cultured with Raji B cells during the following 4 -  
6 days formed M-cell monolayers. Those without Rajl B co-culture formed 
Caco2-cll monolayers. In both cases, TEER continued to Increase (Figure 4.1). 
At the end of culture, typically 20 -  22 days, Caco2-cll monolayers had 
slightly higher TEER values than M-cell monolayers. In an assay by assay basis, 
this difference was always present, although it was typically less than 50 
Qcm2.
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Figure 4.1 A typical production of in vitro derived M-cells.
Monolayer TEER steadily increases during culture, indicating formation of fully confluent, 
differentiated monolayers (TEER values in excess of 300 Qcm2). Monolayer incubation with 
Raji B cells occurred on day 16 (dashed line) and continued for the following five days, 
leading to the formation of M-cells, whilst control Caco2-cll monolayers formed in the 
absence of Raji B cells. The TEER of the control Caco2-cll monolayers continued to increase 
over the following five days of incubation (days 16 -  21; closed boxes), as did the TEER of 
the M-cells (open boxes), although to a lesser extent. (Data represents n = 35 culture 
Transwells® for each group (Caco2-cll and M-cell))
In addition to TEER, monolayer integrity was also monitored visually. During 
early culture, typically days 0 - 5 ,  the monolayer could clearly be seen to 
have numerous gaps within it (Figure 4.2A). By day 8, these gaps within the 
monolayer persisted, although were much fewer in number, implying that 
the gaps had been filled through cell growth and cell division (Figure 4.2B). By 
day 11, the gaps were no longer visible by light microscopy (Figure 4.2C).
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A ~ 40 Qcm2 (day 3)
B ~ 130 Qcm2 (day 7)
C ~220 Qcm2 (day 11)
Figure 4.2 TEER increases as cell confluency increases
(A) During the first days of culture, various gaps between Caco2-cll cells were visible (black 
arrows). (B) During days 5 - 9, fewer gaps between Caco2-cll cells were visible (black 
arrows), and there was an increase in monolayer TEER. (C) After day eleven of culture, 
visibly intact Caco2-cll monolayers are observed, and gaps between cells could not be 
detected. Again there was an increase in TEER.
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4.5.2 In vitro generated M-cells have a characteristic M-celi structure
Following culture of Caco2-cll and M-cell monolayers, transmission electron 
microscopy (TEM) revealed the M-cells to be structurally different from 
Caco2-cll cells in their microvilli distribution. All of the Caco2-cll monolayer 
examined had homogeneous microvilli expression on the apical surface of the 
cells; microvilli appeared to be uniform length, and of uniform distribution 
across the apical cell surface (Figure 4.3A). In contrast, M-cell monolayers 
were characterised by both regions containing apical cell surface microvilli 
expression, and regions absent of microvilli expression (Figure 4.3B). This was 
characteristic of all cultures (n = 3) which were examined by TEM. High- 
magnification images of the apical cell surface of these representative M-cell 
productions can be seen in Figure 4.4.
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Figure 4.3 TEM reveals structural differences between Caco2-cll and M-cell monolayers
(A) TEM image of a Caco2-cll monolayer. Closely packed microvilli can clearly been seen on 
the apical aspect of the cells. (B) TEM Image of an M-cell monolayer. The apical surface of 
the cells Is heterogeneous for microvilli expression; lack of microvilli expression Is Indicated 
by black arrows. In both Images, the Transwell® filter support can be seen on the lower 
portion of the Image, as can the 3pm pores within the filter (Indicated by white arrows). Bar 
= 10pm
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Figure 4.4 (A -  C) -  Apical surfaces of Caco2-cll and M-cells
(A -  C) TEM images of the apical surface of Caco2-cll monolayers, showing closely packed 
microvilli at the apical cell surface (white arrows). Bar= 1pm
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Figure 4.4 (D -  F) -  Apical surfaces of Caco2-cll and M-cells
(D -  J) TEM reveals a large variation in M-cell apical surface. Bar = 1pm
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Figure 4.4 (G -  J) -  Apical surfaces of Caco2-cll and M-cells
(D -  J) TEM reveals a large variation in M-cell apical surface. Bar = lpm
4.5.3 In vitro generated M-cells display biochemical variations compared to 
Caco2-cll cells
Western blotting revealed that there was an increase in Aleuria aurantia 
lectin (AAL) total binding to M-cell lysates compared with total binding to 
Caco2-cll cell lysates (Figure 4.5); densitometry analysis of Western blots 
revealed this increase to be approximately 15.4 ± 1.5 % in M-cells compared 
to Caco2-cll monolayers (n = 4). Binding of AAL appears non-specific, as can 
be seen from the diverse number of bands of binding of different molecular 
sizes. There does however seem to be an increase of AAL binding to proteins 
with a higher molecular weight than smaller proteins. AAL binds to Fucal- 
2Gal(3l-4(Fucal-3/4)Gal(3l-4GlcNAc and R2-GlcNAcpl-4(Fucal-6)GlcNAc-R1; 
heavily fucosylated proteins may not migrate on the SDS-PAGE gel as 
effectively as non fucosylated proteins, giving them a falsely high protein 
molecular weight -  thus perhaps accounting for the increase of AAL binding 
of higher molecular weight proteins.
Alkaline phosphatase expression was also investigated. It was found that M- 
cell monolayers had a lower total expression of alkaline phosphatise than 
Caco2-cll monolayers (Figure 4.6); densitometry analysis of Western blots 
revealed this decrease to be approximately 21.6 ± 4.1 % in M-cells compared 
to Caco2-cll monolayers (n = 4)
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~ 39 kDa -» 
~ 32 kDa ->
~ 17 kDa ->
~ 42 kDa Actin
A: Caco2-cll monolayer 
B: M-cell monolayer
Figure 4.5 Aleuria aurantia lectin binding
Representative Western blot showing an increase in Aleuria aurantia lectin binding to M- 
cell monolayer cell lysates compared to Caco2-cll cell monolayer lysates (representative of 
4 individual M-cell productions).
93
~ 60 kDa Alkaline Phosphatase
~ 42 kDa Actin
A: Caco2-cll monolayer 
B: M-cell monolayer
Figure 4.6 Alkaline Phosphatase expression
Representative Western blot showing a decrease of alkaline phosphatase protein 
expression in M-cell monolayers compared to Caco2-cll cell monolayers (representative of 
4 individual M-cell productions).
4.5.4 Translocation of Salmonella Typhimurium LT2 is increased across M- 
cell monolayers
Translocation of Salmonella Typhimurium LT2 from the apical side to the 
basolateral side of the monolayer was established. Translocation through M- 
cell monolayers was significantly higher than translocation through Caco2-cll 
monolayers following a 4 hour infection (Figure 4.7).
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Figure 4.7 Salmonella Typhimurium LT2 translocates through In vitro M-cells
Translocation of Salm onella Typhimurium LT2 was approximately 80 fold higher than 
through Caco2-cll cells. ***, P < 0.001 (ANOVA) (n = 3)
Monolayer TEER decreased slightly in response to infection with Salmonella 
Typhimurium LT2 (Figure 4.8). After a 4 hour infection with S. Typhimurium 
LT2, Caco2-cll monolayer TEER decreased by 8.91 ± 1.47 %, whilst M-cell 
monolayer TEER decreased by 11.96 ± 4.89 %.
Translocation of Salmonella Typhimurium LT2 across an individual well was 
found not to correlate to the TEER of that well (Figure 4.9). In each assay 
conducted, there is overlap between Caco2-cll monolayer TEER and the M- 
cell TEER; the highest translocation of CFUs was always seen across M-cell 
monolayers. This however did not always correlate to wells with the lowest 
TEER values, indicating that TEER was not a direct measure of translocation, 
and that lower TEER values do not absolutely correlate higher translocation 
levels.
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Figure 4.8 TEER decreases in response to Salmonella Typhimurium LT2
Monolayer TEER for both Caco2-cll monolayers and M-cells monolayers decreased during 
the course of a 4 hour Salm onella  Typhimurium LT2 infection, although the decrease was 
not statistically significant, (n = 5)
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Figure 4.9 TEER and Translocation of Salmonella Typhimurium LT2
A, B and C show three individual assays to assess Salm onella Typhimurium LT2 translocation 
across Caco2-cll and M-cell monolayers -  they indicate that translocation of Salm onella  
Typhimurium LT2 was independent of the TEER of the monolayer following a 4 hour 
infection (multiplicity of infection (MOI) = 10).
97
4.5.5 Translocation of Shigella sonnei is increased across M-cell monolayers
As with Salmonella Typhimurium LT2, translocation of Shigella sonnei is 
increased across M-cell monolayers compared to Caco2-cll monolayers by 
approximately 8 fold (Figure 4.10). Again, this increase in translocation was 
not connected to the TEER of the monolayer (Figure 4.11).
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Figure 4.10 Shigella sonnei translocates through in vitro M-cells
Translocation of Shigella sonnei was approximately 8 fold higher than through Caco2-cll 
cells. **, P < 0.01 (ANOVA) (n = 3)
98
Figure 4.11 TEER and Translocation of Shigella sonnel
An individual assay to assess Shigella sonnel translocation across Caco2-cll and M-cell 
monolayers -  it indicates that translocation of Shigella sonnel LT2 was independent of the 
TEER of the monolayer after a 4 hour infection (MOI = 10).
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4.5.6 Translocation of control E. coli K12, £. coli XLl-Blue and probiotic E.coli 
Nissle 1917 are not increased across M-cell monolayers
Unlike Salmonella Typhimurium LT2, translocation of control E. coll K12, E. 
coll XLl-Blue and probiotic E. coll Nissle 1917 are not significantly increased 
across M-cell monolayers compared to Caco2-cll monolayers (Figure 4.11). 
Translocation of these strains did not affect TEER during infection, with a less 
than 5 % change in TEER for each strain during a 4 hour infection.
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Figure 4.11 Translocation of control E. coli across Caco2-cll and M-cell monolayers
E. coli K12 does not significantly translocate through in vitro M-cells any more so than 
through Caco2-cll cells (n = 8). The laboratory E. coll strain XLl-Blue does not appear to be 
translocated through in vitro M-cells (n=3), whilst numerically, translocation of Probiotic 
Nissle 1917 was reduced through M-cells compared to its translocation through Caco2-cll 
cells. The difference in translocation across Caco2-cl and M-cell monolayers for each 
control E. coli strain was not significant (ANOVA) (n=3)
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4.5.7 Characterising the M-cell model using Crohn's disease E. coli HM605 - 
effect of TEER upon translocation
Crohn's disease AIEC HM605 was used initially to establish experimental 
conditions to investigate translocation across M-cells. Both Caco2-cll and M- 
cell monolayers were generated with TEER in the range of 0 -  800 Qcm and 
0 -  450 Qcm2 respectively. Following a 5 minute infection with HM605, 
monolayers with TEER values < 100 Qcm2 showed in excess of 10% of the 
initial HM605 inoculum passing through both Caco2-cll and M-cell 
monolayers (equivalent to ~ 1.6 x 106 CFU / cm2). Both Caco2-cll and M-cell 
monolayers with TEER > 180 Qcm2 did not show any translocation of HM605 
during this 5 minute infection (Figure 4.12A). There is a very distinct gap 
between those monolayers which do not translocate HM605 within a 5 
minute infection, and those that do, which appears closely linked to the 
monolayer TEER.
Following a 30 minute infection, both Caco2-cll and M-cell monolayers with 
TEER < 200 Qcm2 were found to have HM605 within the basolateral 
compartment, with approximately 1 -  10 % of the initial inoculum having 
transferred from the apical to the basolateral chamber. Those monolayers 
with TEER > 200 Qcm2 showed limited transfer of HM605 from the apical to 
basolateral chamber (M-cell monolayer, 0.04 ± 0.06 %; Caco2-cll monolayer, 
0.005 ± 0.009 %) (Figure 4.12B). These findings confirm the decision to regard 
TEER > 300 Qcm2 as being fully confluent monolayers.
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Figure 4.12 TEER and translocation of Crohn's disease AIEC HM605
Passage of Crohn's disease AIEC HM605 across Caco2-cll and M-cell monolayers following a 
(A) 5 minute Infection and (B) a 30 minute Infection.
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4.5.8 M-cell translocation is affected by the length Raji B cell co-culture with 
Caco2-cll monolayers
During the first six days of co-culture of Caco2-cll monolayers with Raji B 
cells to generate M-cells, the TEER of the monolayer increases slightly, 
although to a lesser extent than the TEER of control Caco2-cll monolayers. By 
the eighth day of co-culture, the TEER of the M-cell monolayers falls 
significantly to below 300 Qcm2, whilst the TEER of Caco2-cll monolayers 
remains, on average, in excess of 600 Qcm2 (Figure 4.13).
Figure 4.13 TEER changes during co-culture
The TEER of both Caco2-cll and M-cell modolayers increases slightly during the first 6 days 
of co-culture. By day 8 of co-culture, the TEER of the M-cell monolayer has fallen to less 
than 300 Qcm2, and Is significantly lower than the Caco2-cll monolayer TEER, which 
remains in the region of 600 Qcm2 (n = 5). ***, P < 0.001
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Following a 4 hour infection with HM605, M-cell translocation was found be 
significantly higher than translocation through Caco2-cll cells following co­
culture lasting for 4, 6 and 8 days (Figure 4.14). Flowever, it should be noted 
that translocation on day 8 of co-culture was not always across wells with 
TEER > 300 Qcm2. Following HM605 infection, monolayer TEER was reduced. 
Following infection, the TEER of both Caco2-cll and M-cell monolayers 
decreased on average by less than 10 % from the initial pre-infection TEER, 
when the length of co-culture was between 0 and 6 days. By the eight day of 
co-culture, TEER reduction following HM605 infection was greatest at 20.26 ± 
4.58 % for Caco2-cll monolayers, and 15.79 ± 5.19 % for M-cell monolayers 
(Figure 4.15).
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Figure 4.14 Translocation increases with length of co-culture
Translocation of Crohn's disease AIEC HM605 across Caco2-cll cells remains constant, 
whilst translocation across M-cell monolayers increases with the length of co-culture. *, P < 
0.05; **, P < 0.01; and ***, P < 0.001 (ANOVA) (n = 3)
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Figure 4.15 Reduction in TEER following infection
Following a 4 hour infection with HM605, the TEER of both Caco2-cll and M-cell 
monolayers decreased on average by less than 10 % from the initial pre-infection TEER, 
when the length of co-culture was between 0 and 6 days, whilst the TEER in monolayers 
cocultured for 8-days was reduced by more than 15%. *, P < 0.05; (ANOVA) (n = 5)
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It was observed following several individual assays that HM605 translocation 
across across M-cell monolayers was increased compared to translocation 
across Caco2-cll cells when the Raji B cells used to generate the M-cell 
monolayers were of a low passage number (Figure 4.16A). As the passage 
number of the Raji B cells increased, the ability of HM605 to translocate 
through the M-cell monolayer decreased, and whilst translocation was still 
higher than through Caco2-cll monolayers, the difference in translocate 
levels was lower, perhaps indicting that Raji B cells lose or have a decreased 
ability to transform Caco2-cll cells into M-cells as they become older. The 
effect of Caco2-cll cell passage number upon M-cell transformation 
appeared to have a less pronounced effect upon M-cell transformation 
(Figure 4.16B)
4.5.9 Raji B and Caco2-cll passage number alter translocation rates
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Figure 4.16 Fold increase in translocation of E. coli HM605 across M-cell monolayers 
compared with Caco2-cll monolayers
(A) HM605 translocation across M-cells was increased compared to translocation across 
Caco2-cll monolayer when the Raji B cells used were of a lower passage number (** P < 
0.01, indicating significant correlation between Raji B passage number, and the fold 
increase in translocation of M-cells : Caco2-cll cells). (B). The passage number of the Caco2- 
c ll cells used to generate Caco2-cll and M-cell monolayers appeared not to correlate with 
increased translocation through M-cell monolayer compared to Caco-2cll monolayer 
translocation, (n = 27, individual M-cell productions.)
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It was observed that E. coli HM605 translocation across M-cell monolayers 
was dependent upon the method by which HM605 had been grown. HM605 
grown overnight in LB broth translocated across M-cells much more readily 
than HM605 grown on LB agar, or LB agar followed by 48 h suspension in 
PBS, during an 8 hour infection period (Figure 4.17A). There appeared to be 
no difference between translocation of HM605 grown on LB agar, or LB agar 
followed by 48 h suspension in PBS across M-cell monolayers over the same 8 
hour infection period (Figure 4.17B). Following a 24 hour infection, there was 
no difference between the translocation across M-cells and the growth 
condition of HM605 (Figure 4.17C). There was however a significant 
reduction in M-cell monolayer TEER following infection with LB broth grown 
HM605 at all time points investigated (Figure 4.18A), and following 24 hours 
of infection, a significant reduction in M-cell monolayer TEER for all HM605 
growth conditions (Figure 4.18B), indicating monolayer disruption may be a 
contributing factor in increased translocation rates. LB agar grown HM605 
saw least disruption to TEER, indicating it is a suitable growth condition for 
future studies.
4.5.10 E. coli HM605 growth conditions affects translocation across M-cells
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Figure 4.17 Method of growth of HM605 alters translocation across M-cell monolayers
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Figure 4.17 (continued) Method of growth of HM605 alters translocation across M-cell 
monolayers
(A) HM605 grown in LB broth overnight translocates across M-cells to a greater extent than 
HM605 grown on solid LB agar overnight, or grown on LB agar followed by 48 hour 
suspension in sterile PBS. Translocation at the time points investigated, 4 h and 8 h, is 
significantly higher than translocation at 0 h. (B). Data from panel A redrawn for greater 
clarity. There appears to be no difference in translocation between HM605 grown on solid 
LB agar which has been left for 48 h in PBS, and those which have not. Translocation is 
significantly higher at all time points investigated than translocation at 0 h. (C) Following 24 
hours of infection, there was no difference between the levels of translocation across M- 
cell monolayers and the method by which HM605 was grown. *, P < 0.05; **, P < 0.01; and 
***, P < 0.001 (ANOVA) (n = 3)
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Figure 4.18 TEER alterations in response to differently grown HM605
(A) HM605 grown in LB broth led to a significant reduction in TEER following 4 hours and 8 
hours of infection. (B) Following 24 hours of infection, there was a significant reduction in 
M-cell monolayer TEER for all HM605 growth conditions. *, P < 0.05; **, P < 0.01; and ***, 
P < 0.001 (ANOVA) (n = 3)
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4.5.11 HM605 translocation across M-cell monolayers occurs sooner than 
translocation across Caco2-cll monolayers
Translocation of HM605 across Caco2-cll monolayers was detectable 30 
minutes post infection, at low levels. Translocation across M-cell monolayers 
was detectable within 15 minutes post-infection (Figure 4.19A). Monolayer 
TEER was not affected by infection (Figure 4.19B).
4.5.12 HM605 translocation is not dependent upon TEER
Translocation of HM605 across both Caco2-cll and M-cell monolayers 
following a 4 hour infection was found to be independent of monolayer TEER 
(Figure 4.20), providing TEER > 300 Ocm2.
4.5.13 HM605 was detected within M-cell monolayers
Translocation of HM605 through rather than between cells of the M-cell 
monolayer was confirmed by TEM. HM605 was observed within M-cell 
monolayer cells, but could not be detected either within Caco2-cll 
monolayers, or between cells of the monolayer (Figure 4.21).
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Figure 4.19 Translocation occurs sooner across M-cell monolayers than across Caco2-cll 
monolayers
(A) Translocation across M-cell monolayers was first quantifiable within 15 minutes post 
infection, whilst translocation across Caco2-cll monolayers could not be detected until at 
least 30 minutes post infection. (B) In this assay, TEER remained above 300 Ocm2 
throughout the course of infection. Monolayer TEER was slightly elevated following 4 hour 
infection with HM605. (n>5). *, P < 0.05; **, P < 0.01; and ***, P < 0.001 (ANOVA) (n = 3)
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Figure 4.20 Translocation is independent of TEER
(A) Caco2-cll translocation of Crohn's disease AIEC HM605 was independent of TEER, when 
TEER > 300 Qcm2, (n > 60). (B). M-cell translocation of Crohn's disease AIEC HM605 was 
independent of TEER, when TEER > 300 Qcm2 (n > 60).
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Figure 4.21 HM605 within M-cell monolayers
(A -  E) TEM analysis of E. coli HM605 within M-cell monolayers, indicated by white arrows 
in A, B and E. (F) An enlargement of image E, showing HM605 more clearly. E. coli HM605 
was not observed within Caco2-cll monolayers. Bar = 0.5(im
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4.5.14 Translocation of Crohn's disease E. coli is increased across M-cell 
monolayers
Eight Crohn's disease AIEC were tested for their ability to translocate through 
M-cell monolayers. Each translocated through M-cell monolayers much more 
so than through Caco2-cll monolayers. Four of these isolates, HM580, 
HM605, HM615 and LF82 translocated through M-cells more significantly 
than E. coli K12 (P < 0.05), whilst four strains did not (HM95, HM154, HM413, 
HM419) (Figure 14.22). Interestingly, those isolates, with the exception of 
LF82, which did translocate through M-cells more than E. coli K12 were those 
isolates which has previously been shown to agglutinate red blood cells, 
whilst those that did not translocate through M-cells more than E. coll K12 
were also found not to agglutinate red blood cells.
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Figure 14.22 Translocation of Crohn's disease AIEC
Crohn's disease E. coli isolates are translocated through M-cell monolayers more readily 
than through Caco2-cll monolayers (n>3). *, P < 0.5; **, P < 0.01; and ***, P < 0.001 
(ANOVA).
118
4.5.15 Translocation of control patient E. coli is increased across M-cell 
monolayers
A panel of five control patient E. coli Isolates (Irritable bowel syndrome / 
sporadic polyposis) were tested for their ability to translocate through Caco2- 
c ll and M-cell monolayers. Two of the strains investigated, HM488 and 
HM456 were found to significantly translocate through M-cell monolayers 
much more readily than through Caco2-cll monolayers, and more so than 
control E. coli K12 (Figure 4.23). TEERS were in excess of 300 Ocm2 for each E. 
coli isolate investigated throughout the course of the 4 hour infection, 
indicating that monolayer integrity was maintained throughout infection.
Figure 4.23 Translocation of control patient AIEC
Control patient (irritable bowel syndrome / sporadic polyposis) mucosal adherent and 
invasive E. coli isolates are translocated through M-cell monolayers more readily that 
through Caco2-cll monolayers, with the exception of E. coli HM463 (n>3), following a 4 
hour infection. *, P < 0.5; and **, P < 0.01 (ANOVA).
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4.6 SUMMARY OF RESULTS
4.6.1 Features of in vivo M-cells validated in an in vitro M-cell model
1. In vitro derived M-cells have a varied expression of apical microvilli, 
unlike Caco2-cll cells which have a regular expression of apical 
microvilli.
2. In vitro derived M-cells have increased binding of Aleuria aurantia 
lectin, and decreased expression of total alkaline phosphatase 
protein.
3. M-cell monolayers translocate Salmonella Typhimurium LT2 and 
Shigella sonnei 80-fold and 8-fold more than Caco2-cll monolayers 
respectively, independently of monolayer TEER.
4.6.2 Characterisation of translocation of E. coli HM605 across M-cells and 
Caco2-cll cells
1. The length of Caco2-cll monolayer co-culture with Raji B cells affects 
translocation of E. coli HM605, and the resultant TEER of the 
monolayer, both prior to, and during infection. The optimal length of 
Caco2-cll co-culture with Raji B cells is between 4 - 6  days.
2. Following a 30 minute infection, M-cell monolayers with TEER > 200 
Qcm2 were found only to translocate very low numbers of HM605 
(less than 0.1 % of the initial inoculum), whilst monolayers with TEER 
< 200 Qcm2 saw much higher numbers of HM605 passing through 
the monolayer (1 -  10 %).
120
3. Raji B cells with a lower passage number co-cultured with Caco2-cll 
monolayers generally led to the formation of M-cell monolayers 
which had a higher rate of translocation of E. coli HM605 when 
compared to Caco2-cll monolayer translocation.
4. The method by which E. coli HM605 is grown appears to affect both 
translocation rates and monolayer TEER during infection. The 
optimal growth condition appears to be overnight growth on LB 
agar.
5. HM605 translocation across M-cell monolayers (when TEER > 300 
Qcm2) is just detectable at 15 minutes, and then increases steadily 
over time, without significant disruption to the monolayer integrity. 
Translocation across Caco2-cll cells was just detectable after 30 
minutes, and again, translocation increased over time. Translocation 
was not dependent upon TEER when TEER > 300 Qcm2.
6. HM605 was detected within cells of M-cell monolayers by TEM, but 
not in Caco2-cll monolayers, or between cells.
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4.6.3 Translocation of E. coli across M-cells
1. Translocation of E. coli K12, E. coli XLl-Blue and probiotic E. coli 
Nissle 1917 across M-cell monolayers does not appear to be 
significantly different to translocation across Caco2-cll monolayers.
2. All Crohn's disease AIEC investigated translocated through M-cell 
monolayers to a greater extent than through Caco2-cll monolayers.
3. Two of the five control subject AIEC E. coli translocated through M- 
cell monolayers to a greater extent than through Caco2-cll 
monolayers
4.7 DISCUSSION
The generation of in vitro M-cells was confirmed structurally by the use of 
transmission electron microscopy. Caco2-cll monolayers which had been co­
cultured with Raji B cells to form M-cells were found to have a distinct lack of 
microvilli when compared to Caco2-cll monolayers alone, indicating the lack 
of a brush boarder on M-cells compared to Caco2-cll cells. This type of 
structural alteration has previously been reported by Kerneis et al. [Kerneis et 
al. 1997] and Gullberg et al. [Gullberg et al. 2000].
Functionally, these in vitro derived M-cells were able to translocate 
Salmonella Typhimurium LT2 and Shigella sonnei from the apical to 
basolateral aspect of the cell monolayer; these findings have also been 
observed in vivo [Jepson etal. 2001].
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Total alkaline phosphatase expression was also reduced in this in vitro M-cell 
model, by 21.6 ± 4.1 % compared to Caco2-cll cell monolayers. This is 
consistent with the work of Gullberg et at. who also reported a decrease in 
apical alkaline phosphatase activity of ~ 35 % [Gullberg et al. 2000]. It is also 
consistent with the reported downregulation of alkaline phosphatase activity 
of M-cells seen in vivo [Owen et al. 1983; Farstad et al. 2002].
The increased binding of Aleuria aurantia lectin (AAL) to M-cell monolayers 
compared with Caco2-cll monolayers is interesting as it supports the 
hypothesis that AAL could be used to target M-cells in vivo [Roth-Walter et al. 
2004; Roth-Walter et al. 2005].
The use of Crohn's disease E. coli to characterise translocation across M-cell 
monolayers revealed some interesting findings. Translocation occurred 
within 15 minutes across M-cell monolayers but was only detected at 30 
minutes for Caco2-cll monolayers
This work demonstrates that the in vitro M-cell model can be used to 
establish bacterial translocation of Crohn's disease and control patient E. coli 
across cell monolayers in vitro. Translocation of all Crohn's disease E. coli 
isolates investigated was consistently higher across M-cells than Caco2-cll 
cells, whilst 5 / 6  control subject E. coli were translocated across M-cells to a 
greater extent than across Caco2-cll cells. Translocation was also noticed to 
occur sooner across M-cells than Caco2-cll cells; translocation was first 
quantifiable 15 minutes post infection for M-cells, but only at 30 minutes, 
and to a much lower extent, in Caco2-cll cells.
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The cause for this increased translocation across M-cells is unclear; the lack 
of microvilli in M-cells would certainly allow E. coll interaction with the cell 
surface without the physical barrier that the microvilli normally provide. 
Increased access of E. coli to the M-cell surface would perhaps in turn lead to 
an increase in bacterial uptake and translocation. It is also plausible that the 
E. coli themselves are somehow targeted to the M-cell rather than Caco2-cll 
cells, through expression of surface fimbri or other adhesion molecules not 
yet fully understood.
It is interesting that the three Crohn's disease E. coli which translocate across 
M-cells to the greatest extent (HM580, HM605, HM615) are also all able to 
haemagglutinate red blood cells (Appendix 2) [Martin 2004; Martin et al. 
2004]. The non-haemagglutinating Crohn's disease E. coU (HM95, HM154, 
HM413) all translocate across M-cells more readily than across Caco2-cll 
cells, but the absolute level of translocation across M-cells is lower than that 
of the three haemaggutinating strains. HM419, a Crohn's disease 
haemagglutinating strain was the exception -  it's translocation across M-cells 
was similar to that of the non-haemaglutinating strains. Interestingly, the 
classical AIEC LF82, a non-haemagglutinating strain, was translocated across 
M-cells to a greater extent than HM95, HM154 and HM413, and at a 
comparible level to the haemagglutinating strains HM580, HM615 and 
HM615.
It is also interesting that the Crohn's disease E. coli belonging to the B2 and D 
phylotype (HM580, HM605, HM615, LF82) were translocated through M-cells 
to a greater extent than the Crohn's disease E. coli belonging to the A and B1 
phylotype (HM95, HM154). (The B2 and D phylotype is associated with 
uropathic, avian and extraintestinal virulent E. coli strains (Uropathogenic
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(UPEC), avian pathogenic (APEC) and Extraintestinal pathogenic (ExPEC)) 
[Kotlowski et al. 2007].)
Two control patient AIEC were translocated across M-cells more significantly 
than across Caco2-cll cells, both of these strains (HM488 and HM456) 
belonged to the B2 phylotype, but one (HM456) was a haemagglutinating 
strain, whilst HM488 was a non-haemagglutinater.
Whilst these observations are based on only small numbers of E. coli strains, 
it does indicate that translocation of Crohn's disease E. coli isolates across M- 
cells might be subject to the unique properties of each individual E. coll. 
Additionally, the presence of increased translocation across M-cells does 
support the hypothesis that E. coli transport at this site in vivo might be 
involved in Crohn's disease pathogenesis. Indeed, ex vivo work conducted 
with macroscopically normal Crohn's disease FAE biopsies show increased 
numbers of adherent bacteria compared to control patient on the FAE [Keita 
et al. 2008]. It is plausible that increased bacterial load at M-cells could be 
important in the development of Crohn's disease.
Under normal circumstances, microbota passing through the intestinal 
barrier would be expected to be cleared by a robust phagocytic system. In 
Crohn's disease however, there is evidence for a defective innate immune 
system as documented by evidence of impaired neutrophil recruitment 
[Marks et al. 2006]. This leads to the hypothesis that AIEC gain entry via the 
M-cells, are inadequately cleared by neutrophils, and become ingested by 
macrophages where they replicate within endophagolysosomes and 
stimulate granuloma formation. The replication of the typical ileal AIEC 
isolate LF82 has already been observed with macrophages [Glasser et al. 
2001].
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Despite the findings presented here that Crohn's disease E. coli isolates are 
translocated across in vitro M-cells, it does not prove categorically that these 
E. coli have a causative role in the pathogenesis of Crohn's disease. Whilst the 
correlation between Crohn's disease E. coli translocation across M-cells and 
the location of the initial lesions observed in Crohn's disease would imply 
that E. coli might be a cause of the initial lesion, it is also perfectly possible 
that E. coli translocation at M-cells is a perfectly normal intestinal occurrence, 
and not related to the initiation of the disease itself. It is estimated that M- 
cells account for only 0.01 % of the total intestinal epithelium [Jepson et al. 
2001]. Bacterial invasion at the site of M-cells is thus restricted to a relatively 
small proportion of the total cells within the intestinal epithelium, implying 
that they're impact upon Crohn's disease may be small.
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Chapter 5
Impact of Dietary Factors upon 
Bacterial Translocation across 
Caco2-cll and M-cell monolayers
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5.1 HYPOTHESIS
Soluble plant fibres such as plantain, leek, apple and broccoli NSP will inhibit 
bacterial translocation across in vitro derived M-cells. In contrast, food 
emulsifiers such as polysorbate-60 and polysorbate-80 will lead to increased 
bacterial translocation across in vitro derived M-cells.
5.2 AIMS
1. To determine the effect of plant NSPs upon bacterial translocation
2. To determine the effect of common food emulsifiers upon bacterial 
translocation
5.3 INTRODUCTION
Crohn's disease is accepted as being due to a combination of genetic and 
environmental factors. The genetic factors include mutations that affect 
handling of bacteria by the innate immune system [Hugot et al. 2001; Ogura 
et ol. 2001; 2007; Hampe et al. 2007; Levine et al. 2007; Parkes et al. 2007; 
Zhernakova et al. 2008], but the environmental factors, aside from smoking 
[Calkins 1989; Cottone et al. 1994], are poorly understood. There are marked 
geographical variations in Crohn's disease incidence, with lower prevalence in 
underdeveloped countries, and a rapid recent rise in Japan that has 
paralleled the introduction of a 'Western diet' [Sakamoto et al. 2005]. It is 
therefore a plausible hypothesis that dietary factors may modulate the 
relationship between the host epithelia and the intestinal microbiota.
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The adhesion and invasion of AIEC to intestinal epithelial cells is inhibited by 
soluble plantain fibre [Martin et al. 2004]. It is interesting that in parts of the 
World such as Africa, India and Central America where plantain form an 
important part of the staple diet, have low rates for inflammatory and 
malignant colonic disease. It is theoretically possible that other soluble plant 
based fibres may have similar effects upon bacterial invasion and adhesion.
The lactulose/mannitol test measures the ratio of urinary excreted 
lactulose:mannitol following oral ingestion [Soderholm et al. 1999], it 
demonstrates that intestinal permeability is increased in both Crohn's disease 
patients [Benjamin et al. 2008], and in their unaffected relatives [Katz et al. 
1989; Soderholm et al. 1999; D’lnca et al. 2006]. It is possible that 
environmental factors may lead to this increased intestinal permeability 
[Breslin et al. 2001]. The increase in Crohn's disease incidence seen in Japan 
correlates with increased fat intake there -  and so increased consumption of 
emulsifiers within food. It is plausible that emulsifiers within the diet may 
lead to increased intestinal permeability.
5.4 METHODS
Control Caco2-cll cell monolayers and M-cell monolayers were generated as 
described previously. Detailed descriptions for each assay can be found 
within Chapter 2. Briefly, the apical surface of cell monolayers were pre­
treated with plant NSP (0.05 -  50 mg / mL) or food emulsifiers (in the range 
0.0001 -  0.1 % v/v), prior to bacterial infection. Post infection, translocated 
bacteria were quantified from the basolateral aspect of the monolayer. Data
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are presented as translocated CFU per cm2 monolayer; where this is not 
possible, data are presented as relative translocated CFU, where the 
translocated CFU are expressed relative to either translocation of E. coli K12 
(set at 1), or translocation in the absence of plant fibres or emulsifiers (also 
set at 1).
5.5 RESULTS
5.5.1 Plantain NSP inhibits HM605 translocation across M-cell monolayers
In the absence of plantain NSP, translocation of HM605 was approximately 
20 fold higher through M-cell monolayers compared to Caco2-cll 
monolayers, indicating successful generation of M-cell monolayers. Following 
plantain treatment at 5 and 50 mg / mL, translocation of FIM605 across M- 
cells was inhibited (percentage inhibition in translocation, 5 mg / mL; 82.6 ±
7.2 %; 50 mg / ml, 86.2 ± 11.6 %) (Figure 5.1A). Translocation of FIM605 
across Caco2-cll monolayers was not significantly inhibited by the presence 
of plantain at the investigated doses of 0.05 -  50 mg / mL plantain (Figure 
5.IB). Plantain treatment at all concentrations did not affect monolayer TEER 
(Figure 5.2).
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Figure 5.1 Plantain NSP affects E. coli HM605 translocation across M-cells, but not across 
Caco2-cll cells
(A) E. coli HM605 translocation through M-cells is inhibited by the presence of plantain NSP 
at the investigated concentrations of 5 mg / mL and 50 mg / mL. (ANOVA) (n = 6) (B) 
Plantain NSP does not affect HM605 translocation across Caco2-cll monolayers. **, P < 
0.01; and ***, P < 0.001 (ANOVA) (n = 3)
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Figure 5.2 Effect of Plantain NSP upon monolayer TEER
(A) TEER for M-cell monolayers (n = 6) and (B) Caco2-cll monolayers (n = 3), is unaffected 
following 30 minute plantain incubation on the apical monolayer surface.
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Translocation across M-cell monolayers was significantly inhibited by the 
presence of plantain at 5 mg / mL for K12 (59.0 ± 11.1 %), LF82 (61.6 ± 13.0 
%), HM580 (67.4 ± 1.7 %) and HM615 (45.3 ± 3.3 %) (Figure 5.3A). As for 
HM605, TEER was not affected by the presence of plantain NSP in either 
Caco2-cll or M-cell monolayers. Plantain NSP, at 5 mg / mL, appears able to 
inhibit the translocation of some E. coli strains across Caco2-cll monolayers 
(Figure 5.3B). Whilst inhibition of translocation across Caco2-cll monolayers 
was observed for E. coli K12 (56.7 ± 13.8 %), LF82 (40.1 ± 13.0 %), HM580 
(48.6 ± 14.4 %), and HM615 (80.1 ± 7.5 %), only data for HM615 
demonstrated significant inhibition of translocation.
5.5.2 Plantain inhibits translocation of control E. coli K12 and Crohn's
disease E. coli across M-cells
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Figure 5.3 Plantain affects E. coli translocation across M-cell and Caco2-cll monolayers
(A) Plantain treatment (5 mg / mL) inhibits translocation of all E. coli strains across M-cell 
monolayers and (B) inhibits HM615 translocation across Caco2-cll monolayers. *, P < 0.05; 
**, P < 0.01; and ***, P < 0.001 (ANOVA) (n = 3).
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The inhibitory effect of plantain upon E. coli translocation was found to 
extend to other bacterial species. Translocation of Salmonella Typhimurium 
LT2 across M-cell monolayers was inhibited by plantain at 50 mg / mL (92.8 ±
1.7 %) (Figure 5.4). Translocation of Shigella sonnei across Caco2-cll 
monolayers was unaffected by the presence of plantain, whilst translocation 
across M-cell monolayers was inhibited at a concentration of 5 mg / mL (46.4 
± 7.7 %) (Figure 5.5).
5.5.3 Inhibitory effect of plantain NSP is not limited to E. coU
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Figure 5.4 Plantain NSP inhibits Salmonella Typhimurium LT2 translocation across M-cells
Plantain inhibits translocation across M-cells of Salm onella  Typhimurium LT2 at 50 mg / mL. 
**, P<0.01(ANOVA)(n = 5).
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Figure 5.5 Plantain NSP inhibits Shigella sonnel translocation across monolayers
Plantain inhibits translocation of Shigella sonnei across M-cell monolayers at 5 mg / ml, but 
not across Caco2-cll cell monolayers. *, P < 0.05; and ***, P < 0.001 (ANOVA) (n = 4)
5.5.4 Broccoli NSP inhibits HM605 translocation across M-cells
Broccoli NSP was found to inhibit the translocation of HM605 across both 
Caco2-cll (Figure 5.6A) and M-cell monolayers (Figure 5.6B), in a dose 
dependant manner, without any significant effect upon monolayer TEER. 
Inhibition of translocation across Caco2-cll by broccoli NSP was at follows; 
0.5 mg / mL, 84.5 ± 2.9 %; 5 mg / mL, 78.3 ± 11.9 %; and 50 mg / mL 75.7 ± 
11.6 %. For M-cells, inhibition of translocation by broccoli NSP was 0.5 mg / 
mL, 49.4 ± 13.5 %; 5 mg / mL, 62.5 ± 7.3 %; and 50 mg / mL 68.7 ± 5.7 %.
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Figure 5.6 Broccoli NSP affects translocation across monolayers
HM605 translocation through Caco2-cll monolayers (A) and M-cell monolayers (B) Is 
Inhibited by the presence of broccoli NSP at the Investigated concentrations of 0.5, 5 and 
50 mg / mL. *, P < 0.05;**, P < 0.01; and ***, P < 0.001 (ANOVA) (n = 3).
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5.5.5 Leek NSP does not inhibit HM605 translocation across M-cells
Leek NSP did not significantly affect translocation across either M-cell (Figure 
5.7A) or caco2-cll monolayers (Figure 5.7B) at any does investigated. There 
was a general trend downwards indicating inhibition of translocation at 
higher leek NSP concentrations across M-cell monolayer, but this was not 
seen to be statistically significant. As with plantain and broccoli, the addition 
of leek NSP had no significant effect upon monolayer TEER.
5.5.6 Apple NSP does not inhibit HM605 translocation across M-cells
As with leek NSP, apple NSP was found not affect translocation of HM605 
across Caco2-cll or M-cell monolayers (Figure 5.8), and TEER was not 
affected by the addition of apple NSP to the apical monolayer surface.
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Figure 5.7 Leek NSP has little effect upon E. coli HM605 translocation
Leek NSP does not significantly inhibit HM605 translocation across M-cell (A) or Caco2-cll 
monolayers (B). ***, P < 0.001 (ANOVA) (n = 5)
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Figure 5.8 Apple NSP has little effect upon translocation
Apple NSP does not significantly inhibit HM605 translocation across M-cell (A) or Caco2-cll 
cell (B) monolayers. *, P < 0.05 (ANOVA) (n = 5)
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Polysorbate-80 treatment led to increased HM605 translocation across 
Caco2-cll and M-cell monolayers at different concentrations. Polysorbate-80 
treatment at 0.01%, initially the highest concentration investigated, led to a 
statistically significant sixty fold increase in HM605 translocation across 
Caco2-cll monolayers (Figure 5.9A). Across M-cells, polysorbate-80 at 0.01% 
did not alter translocation of HM605; however, at the tenfold higher 
concentration of 0.1%, fivefold more HM605 were translocated across the 
monolayer (Figure 5.9B).
5.5.7 Polysorbate-80 treatment affects translocation of HM605 across both
M-cells and Caco2-cll cells
Figure 5.9 Polysorbate-80 increased E. coli translocation across monolayers
(A) Polysorbate-80 at 0.01% v/v causes increased translocation of E. coli HM605 across 
Caco2-cll monolayers. (B) Polysorbate-80 at 0.1% v/v Increases translocation across M-cells 
cells. *, P < 0.05 (ANOVA) (n = 5).
141
The TEER of untreated Caco2-cll monolayers fell during the 30 minute 
incubation period in which other wells were treated with polysorbate-80. The 
TEER of Caco2-cll monolayers was significantly decreased at 0.001% and 
0.01% v/v polysorbate-80, whilst TEER at 0.0001% was unaffected (Figure 
5.10A). Across M-cell monolayers, there was a numerical, although not 
statistically significantly relevant, decrease in monolayer TEER in response to 
polysorbate-80 treatment at all concentrations investigated; in addition, 
there was a decrease in untreated M-cell monolayer TEER (Figure 5.10B).
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Figure 5.10 Polysorbate-80 and affect upon monolayer TEER
(A) Caco2-cll monolayer. Polysorbate-80 induces a decrease in Caco2-cll monolayer TEER 
at 0.01% and 0.1% v/v. However, it should be noted that there is also a decrease in TEER in 
the wells not receiving polysorbate-80 treatment, and whilst not statistically significant, it 
does cast some doubt on validity on the TEER reduction seen in the treated wells. (B) M-cell 
monolayer. TEER numerically decreases during polysorbate-80 incubation, although not 
statistically so; there is also an observable numerical decrease in TEER of the untreated M- 
cell monolayers. *, P < 0.05 (ANOVA). (n = 5)
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For polysorbate-60, a fourteen fold increase in HM605 translocation across 
Caco2-cll monolayers was observed at 0.1% v/v (Figure 5.11A), however, no 
observable increase in translocation across M-cells was detected at all 
concentrations investigated (Figure 5.11B).
The TEER of Caco2-cll monolayers significantly increased in both the 
polysorbate-60 treated and untreated wells (Figure 5.12A); a similar, 
although not statistically significant pattern was observed for M-cell 
monolayer TEER (Figure 5.12B)
5.5.8 Polysorbate-60 affects translocation of HM605 across both M-cells
and Caco2-cll cells
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Figure 5.11 Polysorbate-60 increases E. coli translocation across Caco2-cll monolayers
Polysorbate-60 at 0. 1% v/v causes increased translocation of E. coli HM605 across Caco2-cl 
cells (A). Polysorbate-60 does not lead to increased bacterial translocation across M-cells 
(B). *, P < 0.05 (ANOVA) (n = 5).
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Figure 5.12 Polysorbate-60 and affect upon monolayer TEER
(A) M-cell monolayer TEER numerically Increases during polysorbate-80 incubation, 
although not statistically so; there is also an observable numerical increase in TEER of the 
untreated M-cell monolayers. (B) Polysorbate-60 induces a statistically significant increase 
in Caco2-cll monolayer TEER at 0.001%, 0.01% and 0.1% v/v. However, it should be noted 
that there is also a statistically significant increase in TEER in the wells not receiving 
polysorbate-60 treatment. *, P < 0.05 (ANOVA) (n = 6)
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5.6 SUMMARY OF RESULTS
1. Translocation of control E. coli K12, Crohn's disease AIECs LF82, 
HM580, HM605, HM615 and Shigella sonnei at 5 mg / mL, and 
Salmonella Typhimurium LT2 at 50 mg / mL, was significantly inhibited 
across M-cell monolayers by plantain NSP.
2. Translocation of all investigated E. coli, Shigella sonnei and Salmonella 
Typhimurium LT2 through control Caco2-cll monolayers was not 
affected by the presence of plantain NSP, with the notable exception 
of E. coli HM615 which was found to inhibited at the investigated 
concentration of 5 mg / mL.
3. Translocation of HM605 through both Caco2-cll and M-cell 
monolayers was significantly inhibited by broccoli NSP at 0.5, 5 and 50 
mg / mL.
4. Translocation of HM605 across Caco2-cll and M-cell monolayers was 
not affected by the presence of either leek or apple NSP at the 
investigated concentrations.
5. The presence of plantain, broccoli, leek or apple NSP did not 
significantly affect the TEER of either Caco2-cll or M-cell monolayers.
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6. Polysorbate-80 at 0.01% v/v and polysorbate-60 at 0.1% v/v led to 
increased translocation of HM605 across Caco2-cll monolayers; 
polysorbate-80 at the tenfold higher concentration 0.1% v/v led to 
increased translocation across M-cell monolayers, whilst polysorbate- 
60 treatment had no effect upon translocation at the investigated 
concentrations.
7. The TEER of Caco2-cll and M-cell monolayers did not conclusively 
alter as a direct result of either polysorbate-80 or polysorbate-60 
treatment.
5.7 DISCUSSION
If translocation of E. coli across M-cells is important in Crohn's disease 
pathogenesis, then inhibiting this process could be of therapeutic benefit.
Inhibition of Crohn's disease E. coli translocation across M-cells occurred in 
the presence of soluble plantain NSP and soluble broccoli NSP at 5 and 50 mg 
/ mL. In terms of an effective dose for humans, the lower concentration of 5 
mg / mL soluble NSP could be readily achieved in the lumen of the human 
digestive tract through a daily dose of 10 g soluble NSP per day, assuming 
that 75% of the soluble NSP ingested is digested.
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Plantain NSP at 5 and 50 mg / mL was also found to inhibit E. coli adhesion 
and invasion of Caco2-cll cells in vitro, is plausible that a diet rich in plant 
NSPs could inhibit bacterial adhesion to the in vivo epithelia, or translocation 
across it, as has been seen here in vitro. This has potential relevance not only 
to Crohn's disease, but other disease known or thought to be involved with 
irregular bacterial -  host epithelial interactions, including colon cancer 
[Martin et al. 2004], or diarrhoeal disorders.
The effect of food emulsifiers on E. coli translocation is less clear. 
Polysorbate-80 at 0.1 % (v/v) led to 5-fold increased translocation across M- 
cells, but at the lower concentration of 0.01 % across Caco2-cll cells, a 54- 
fold increase in translocation was observed, both without any negative effect 
on monolayer TEER.
Increased translocation of E. coli in the presence of polysorbate-60 across 
Caco2-cll cells was only observed at 0.1 % (v/v), 10-fold higher than the 
effective concentration of polysorbate-80 causing increased translocation 
across the same cells.
Arguably, the relative lack of effect of polysorbates upon M-cell bacterial 
translocation possibly argue against a role of dietary emulsifiers in Crohn's 
disease. However, there increased in bacterial translocation across Caco2-cll 
cells is interesting. Polysorbate-80 has been shown to integrate within cell 
membranes [Zordan-Nudo et al. 1993] resulting in a change of membrane 
microviscosity [Friche et al. 1990]. It is possible that alterations in the 
membrane fluidity could alter bacterial adhesion and translocation through 
epithelial cells.
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The data presented here indicate that Caco2-cll cells are more susceptible to 
the effects of polysorbate-80 than M-cells, and that both cell types are more 
susceptible to the effects of polysorbate-80 than polysorbate-60. The 
increase in bacterial translocation across Caco2-cll seen with these 
emulsifiers may have important implications for Crohn's disease treatment. 
Enteral nutritional feeding with elemental or whole protein feed as either 
primary or adjuvant therapy for Crohn's disease is common [Ricour et al. 
1977; Morin et al. 1982], if these feeds were to contain emulsifiers they could 
have harmful effects when used in sick patients where intestinal permeability 
is already impaired.
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Chapter 6
Replication of Crohn's Disease 
Escherichia coli Isolates within 
Macrophages and their 
Susceptibility to Antibiotics
151
6.1 HYPOTHESIS
Crohn's disease colonic mucosa-associated AIEC are internalised into, and 
then subsequently survive and replicate within macrophages. Antibiotics can 
be used to kill internalised E. coli.
6.2 AIMS
1. To determine survival and replication of Crohn's disease AIEC within 
macrophages.
2. To determine the effectiveness of clinically relevant antibiotics against 
internalised Crohn's disease AIEC
6.3 INTRODUCTION
In Crohn's disease tissue, the presence of E. coli has been most clearly 
observed within macrophages through the use of immunohistochemistry 
against an E. coli antigen [Liu et al. 1995] and by laser capture 
microdissection followed by DNA extraction and PCR amplification of E. coli 
DNA [Ryan et al. 2004]. In addition to this, E. coli antigens have been 
identified in macrophages within the lamina propria, in granulomas, and in 
the germinal centres of mesenteric lymph nodes in patients with Crohn's 
disease [Cartun et al. 1993; Liu et al. 1995]. The Crohn's disease ileal E. coll 
isolate LF82 has been shown to replicate within the mature phagolysosomes 
of macrophages in vitro [Bringer et al. 2006] and to induce giant cell 
formation [Meconi et al. 2007].
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In controlled trials, single antibiotics such as ciprofloxacin [Prantera et al. 
1996], metronidazole [Prantera et al. 1996], clarithromycin [Leiper et al. 
2008] and rifaximin [Prantera et al. 2006] have showed some limited benefit 
as a potential Crohn's disease treatment. It is also known that metronidazole 
[Rutgeerts et al. 1995] and ornidazole [Rutgeerts et al. 2005] are effective 
against postoperative recurrence of Crohn's disease. In the clinic, 
corticosteroids are commonly used as an initial treatment. Studies co­
administering the corticosteroid budesonide with the ciprofloxacin or 
metronidazole showed no improvement compared to treatment with 
budesonide alone [Steinhart et al. 2002]. Without a known cause, or primary 
location of activity, the choice of antibiotic treatment is currently 
uninformed. If Crohn's disease AIEC are found in macrophages within Crohn's 
disease tissue as the literature would suggest, a more targeted antibiotic 
treatment can be sought.
6.4 METHODS
Detailed methods for detection of AIEC replication within macrophages, and 
the efficacy of antibiotics against these internalised AIEC can be found within 
Chapter 2, as can details of TEM analysis.
Briefly, murine macrophages (J774-A1) in culture were infected with control 
or Crohn's disease AIEC isolates, for 2 hours, to allow bacterial 
internalisation, followed by extracellular gentamicin treatment for 1 hour. 
Macrophages were incubated for a further 3 hours to allow internalised 
bacteria to replicate. Cells were lysed, and fold replication calculated by 
overnight growth of the lysate on LB agar.
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The effect of a range of antibiotics upon killing of internalised Crohn's disease 
AIEC HM605 was tested, both as individual antibiotics, and in combination, to 
establish if antibiotics could be used to eradicate Crohn's disease AIEC from 
infected macrophages.
6.5 RESULTS
6.5.1 Crohn's disease AIEC replicate inside J774-A1 macrophages
Following 3 hours of replication time, all seven Crohn's disease AIEC isolates 
tested were better able to replicate inside J774-A1 macrophages than the 
laboratory strain E. coli K12 (P < 0.0001, ANOVA) (Figure 6.1). The French 
ileal Crohn's disease AIEC LF82 replicated at a level (6.8 ± 0.8-fold) similar to 
that of the other seven Liverpool Crohn's disease isolates (6.36 ± 0.7-fold) in 
comparison to E. coli K12, which did not appear to replicate within 
macrophages (1.0 ± 0.1-fold). Six mucosal E. coli strains isolated from control 
patients (IBS / polyposis) showed greater replication (5.2 ± 0.25-fold) within 
macrophages than E. coli K12 (P < 0.0001, ANOVA) (Figure 6.1). On average, 
across all strains, these six control isolates showed significantly less 
replication than the eight Crohn's disease isolates tested (P = 0.006, Kruskal- 
Wallis ANOVA).
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Figure 6.1 Crohn's disease and control adherent-invasive E. coli (AIEC) replicate effectively
inside J774-A1 macrophages.
Replication of E. coli strains isolated from colonic Crohn's disease (n = 7) and control 
patients (n = 6) within J774-A1 murine macrophages (mean ± standard error of the mean) 
compared to the nonpathogenic reference strain E. coli K12. Replication is shown as the 
relative change after 3 h of growth within macrophages. Significant differences from E. coli 
K12 replication rates are as follows: *, P < 0.05; **, P < 0.01; and ***, P < 0.001 (ANOVA) 
(n=3).
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6.5.2 Crohn's disease AIEC isolates replicate within macrophage vacuoles
TEM analysis revealed the cellular morphology and intracellular structure of 
J774-A1 macrophages prior to infection (Figure 6.2A). Three hours after 
infection, HM605 was observed inside vacuoles within J774-A1 macrophages 
(Figure 6.2B). No internalized bacteria were observed free in the cytoplasm. 
The presence of bacteria within vacuoles did not affect the nuclear or 
cytoplasmic membrane morphology, and the macrophages retained an 
otherwise normal appearance. Infected cells often contained large vacuoles 
with the appearance of phagolysosomes (Figure 6.2C), some of which had 
fused, or were in the process of fusing (Figure 6.2D). Bacteria were detected 
that appeared to be undergoing replication (Figure 6.2E and Figure 6.2F). 
Upon closer inspection, it was observed that HM605 reside in membrane 
bound vacuoles within J774-A1 cells (Figure 6.3).
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Figure 6.2 Crohn's disease AIEC HM605 replicates within vacuoles of J774-A1 cells.
(A) TEM analysis reveals that uninfected J774A.1 cells have large vacuoles, with a regular 
cell surface membrane, containing frequent membrane protrusions. (B) Cells infected with 
Crohn's disease AIEC HM605 retain this regular structure; internally, the HM605 can be 
found within both large and small vacuoles. (C) Heavily infected cells contained multiple 
vacuoles which resemble phagolysosomes. (D) Small vacuoles containing HM605 fused with 
much larger vacuoles to form phagolysosomes. (E) Crohn's disease AIEC HM605 replicates 
within structures which resemble phagolysosomes (filled arrows). (F). Crohn's disease AIEC 
HM605 also replicates within smaller vacuoles (filled arrows). A -  C, Bar = 5pm; D -  F, Bar = 
lpm.
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Figure 6.3 Crohn's disease AIEC HM605 is found in membrane bound vacuoles.
(A) Low magnification image of HM605 within J774-A1 macrophages. The black box 
represents the higher magnification image seen in figure B. (B) High magnification image of 
HM605 within membrane bound vacuoles (black arrows). Bar = 1pm.
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6.5.3 Susceptibility of Crohn's disease AIEC HM605 within J774-A1 cells to 
single antibiotics
The effect of a range of antibiotics upon killing of internalised HM605 in J774- 
A1 was investigated at Cmax, the commonly observed peak serum 
concentration seen in patients receiving conventional doses of each 
antibiotics, and at 10% of Cmax. The commonly observed Cmax values seen in 
patients receiving conventional doses of the antibiotics used in this study are 
listed in Table 6.1 (modified from [Subramanian etal. 2008]).
At Cmax, significant intracellular killing was observed for all antibiotics 
investigated, with the exception of gentamicin, which did not lead to 
significant killing of internalised HM605, but which did kill all extracellular 
HM605 (100 ± 0 % killing in 3h). The most potent antibiotic was found to be 
ciprofloxacin (99.5 ± 0.3 % killing); TEM analysis revealed internalised HM605 
in the process of being killed (Figure 6.4).
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Table 6.1 Typically observed Cmax values seen in patients receiving conventional doses of 
antibiotics, and the efficacy of these antibiotics against internalised Crohn's disease AIEC
HM605 in J774-A1 macrophages.
A n tib io t ic D o se  (m g  [ro u te ])3 C m a x
(p g / m l)b
R e fe re n ce %  In tra ce llu la r  H M 6 0 5  
k illin g  a t C max (m e a n  ± 
S E M )C
C ip ro flo x a c in 4 0 0  (i.v) 4 [S a ra v o la tz  et al. 2 0 05] 9 9 .5  ± 0 .3
C la r ith ro m y c in 5 0 0  (p .o ) 3 [L o h itn a v y  et al. 2 0 0 3 ] 7 3 .4  ± 3 .2
R ifa m p in 6 0 0  (p .o ) 10.5 [P e lo q u in  et al. 1999] 9 4 .4  ± 1 .0
T e tra c y c lin e 2 5 0  (p .o ) 1.7 [O ch s  et al. 1978] 5 5 .9  ± 4 .4
T r im e th o p r im 160 (p .o ) 2.3 [Stu rg ill é ta l.  1999] 6 4 .3  ±  8 .4
G e n ta m ic in 0 18 [G illb e rt 2000] 7 .8  ±  15.2
3 p .o ., o ra lly ; i.v ., in tra ve n o u sly .
b C o n c e n tra t io n s  co rre sp o n d in g  to  th e  p e a k  se ru m  le ve ls  o f  th e  re sp e ctive  a n tib io t ic s  fo llo w in g  a d m in is tra t io n  
o f  co n v e n tio n a l d o se s  In h u m a n s b ased  on  p u b lish e d  lite ra tu re  -  see  [S u b ra m a n ia n  et al. 2 0 0 8 ]. 
c A ll a n t ib io t ic s  sh o w  s ig n if ic a n tly  m o re  H M 6 0 5  k illin g  co m p a re d  to  a n tib io t ic -fre e  su rv iv a l rates, P < 0 .0 0 1  
(A N O V A ). T h is  s in g le  a n tib io tic  d a ta  at C max is th e  w o rk  o f D r S re e d h a r S u b ra m a n ia n , U n iv e rs ity  o f L iv e rp o o l, 
L iv e rp o o l, U K  [S u b ra m a n ia n  et at. 2 0 0 8 ].
dln c lu d e d  in ta b le  fo r  co m p a riso n  p u rp o se s. G e n ta m ic in  w a s  u sed  to  kill e x tra ce llu la r  at 20 p g  /  m L w ith o u t 
a ffe c t in g  in te rn a lise d  H M 6 0 5 .
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Figure 6.4 Internalised Crohn's disease AIEC HM605 within J774-A1 macrophages, treated 
with ciprofloxacin, apparently in the process of being killed.
(A) low power magnification and (B) high power magnification of HM605 undergoing killing 
within J774-A1 macrophages (black arrows) as a result of ciprofloxacin treatment at 0.1 pg / 
mL for 3 hours following an initial 3 hour infection period, as indicated by the presence of 
dark granular matter within the HM605 containing vacuole. Bar = 1 pm
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6.5.4 Susceptibility of Crohn's disease AIEC HM605 within J774-A1 cells to 
combination antibiotics
Combination antibiotic treatment at Cmax did not lead to significantly higher 
killing than single antibiotics treatment (ciprofloxacin alone, 99.1 ± 0.2 % 
killing; ciprofloxacin, trimethoprim and tetracycline, 99.1 ± 0.3 % killing; 
ciprofloxacin, trimethoprim and rifampin, 99.6 ± 0.1 % killing, mean ± SEM) 
(Figure 6.5).
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Figure 6.5 Antibiotic combinations at Cmax do not result in significantly higher killing of 
internalised HM605.
When antibiotics are used at Cmax there is no increase in killing of internalised HM605 when 
ciprofloxacin is used alone, or when used in combination with trimethoprim and 
tetracycline or rifampin, (n = 4)
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Triple antibiotic treatment at the highest concentrations used did not lead to 
toxic effects upon the macrophages any more so than single antibiotic 
treatment, as estimated by viable macrophage cell counting (Figure 6.6).
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Figure 6.6 Triple antibiotic administration to macrophages does not lead to a decrease in 
the number of viable cells
Without antibiotic treatment, there were 157.3 ± 6.4 macrophages / ml_; the addition of a 
single antibiotic at Cmax resulted in 152 ± 4.7 macrophages / mL, whilst the use of the triple 
antibiotic combination ciprofloxacin, trimethoprim and tetracycline at Cmax led to 144.3 ± 
8.2 macrophages / mL; ciprofloxacin, trimethroprim and rifampin at Cmax led to 147.5 ± 11.7 
macrophages / mL, so no differences were observed, (n = 3)
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At 10% of Cmax/ four different antibiotic combinations were investigated, 
using 5 different antibiotics. There was no difference in killing between the 
single antibiotic ciprofloxacin (92.4% ± 0.9% killing) and the combination 
treatment consisting of ciprofloxacin, trimethoprim and rifampin (94.0% ± 
1.2% killing). Significantly higher levels of HM605 killing were observed with 
double antibiotic treatment, consisting of ciprofloxacin and tetracycline 
(96.4% ± 0.7% killing, P < 0.05 ANOVA). In the triple antibiotic treatment 
groups, significantly higher killing was seen for ciprofloxacin, tetracyclin and 
clarithromycin (98.3% ± 0.2%; P < 0.01 (ANOVA)) and for ciprofloxacin, 
tetracycline and trimethoprim (97.2% ± 0.4%; P < 0.05 (ANOVA)) (Figure 6.7).
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Figure 6.7 At 10% Cmax, intracellular killing of HM605 can be increased by using 
combination antibiotic treatment.
At 10% Cmax, intracellular killing of HM605 by ciprofloxacin was 94.1% ± 0.8%. In all cases, 
the addition of the antibiotic tetracycline led to significantly higher killing of HM605 than 
when ciprofloxacin was used alone; ciprofloxacin with tetracycline, 96.4% ± 0.7%; 
ciprofloxacin with tetracycline and clarithromycin, 98.3% ± 0.2%; ciprofloxacin with 
tetracycline and trimethoprim, 97.2% ± 0.4%. Treatment with ciprofloxacin, trimethoprim 
and rifampin (94.0% ± 1.2%) did not lead to an Increased in HM605 killing compared to 
milling with ciprofloxacin alone. *, P < 0.05; and **, P < 0.01 (ANOVA) (n=4)
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6.6 SUMMARY OF RESULTS
1. The six control patient AIEC and seven Liverpool colonic mucosa- 
associated Crohn's disease AIEC are better able to survive and 
replicate within J774-A1 macrophages than the laboratory strain E. coli 
K12, as is the ileal Crohn's disease AIEC LF82.
2. AIEC HM605 survives and replicates within membrane bound 
structures which resemble phagolysosomes.
3. At Cmax/ combination antibiotic treatment using ciprofloxacin, 
trimethoprim and either tetracycline or rifampin confers no increase in 
bacterial killing compared with ciprofloxacin treatment alone.
4. At 10% Cmax, using ciprofloxacin with tetracycline leads to increased 
bacterial killing compared to ciprofloxacin treatment alone. The most 
effective intramacrophage killing of HM605 at 10% Cmax was seen using 
the antibiotic combination of ciprofloxacin with tetracycline and 
clarithromycin.
6.7 DISCUSSION
The colonic mucosa-associated Crohn's disease AIEC described here are able 
to survive and replicate more readily than the laboratory control E. coli K12. 
In addition these AIECs are also able to replicate within vacuoles within 
macrophages, without any apparent toxic effect on the macrophage itself. In 
this respect, the colonic mucosa-associated AIEC described here are similar in 
that they replicate at a level already observed previously with the
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characterised ileal Crohn's disease E. coli isolate LF82 [Glasser et al. 2001]. In 
addition, the colonic mucosa-associated Crohn's disease AIEC replicate within 
structures which resemble phagolysosomes [Subramanian et al. 2008], as 
previously reported for LF82 [Bringer et al. 2006].
As with Crohn's disease AIEC, AIEC from healthy control patients (isolated 
from IBS / polyposis colonic mucosa tissue) are able to survive and replicate 
better within macrophages than E. coli K12. This could be accredited to a 
comparatively unaggressive phenotype of E. coli K12; however there is 
extensive overlap between replication rates of Crohn's disease AIEC and 
control patient AIEC within macrophages, demonstrating that individual 
strains of AIEC do not absolutely correspond to their disease / healthy status 
in terms of replication inside macrophages in vitro. In vivo, however, E. coli 
have been identified within the macrophage tissue of Crohn's disease by 
immunohistochemistry [Liu et al. 1995], and by PCR demonstration of 
ribosomal DNA in laser-dissected granulomas [Ryan et al. 2004], but have not 
been identified in healthy control patient macrophage tissue.
These finding here raise the possibility that, in vivo, it is not the pathogenic 
nature of the AIEC themselves which cause an increased presence in Crohn's 
disease macrophages, but rather a problem with the macrophages of Crohn's 
disease being unable to clear the bacterial contents, which does not occur in 
healthy individuals.
Indeed, macrophages are not the first line of defence in fighting bacterial 
species which have escaped the intestinal lumen and breach the intestinal 
barrier [Allen 2003]. These bacteria will first come into contact with various 
antimicrobial peptides, such as defensins [Wehkamp et al. 2005; Nuding et al. 
2007], and then with neutrophils [Allen 2003], and subsequently, bacteria
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which had evaded elimination would come into contact with macrophages, 
with are generally poorer at bacterial killing than neutrophils [Allen 2003].
In Crohn's disease, there is some evidence that the tissue itself has lower 
antimicrobial activity [Nuding et al. 2007]. There is also evidence of 
neutrophil dysfunction in Crohn's disease; following trauma to the rectum, 
ileum or skin, there is abnormally low neutrophil accumulation and a 
reduction in IL-8 production [Marks et al. 2006]. In addition, the rare 
inherited conditions chronic granulomatous disease [Huang et al. 2004] and 
glycogen disease type lb  [Couper et al. 1991] are both associated with well 
characterised defects in bacterial killing by neutrophils, and in addition, are 
associated with Crohn's disease-like intestinal disease.
If neutrophils fail to clear AIEC, it is likely that those AIEC would be taken up 
by intestinal macrophages, where they have previously been seen in vivo [Liu 
et al. 1995; Ryan et al. 2004]. The presence of AIEC within macrophages could 
then initiate an inflammatory cascade, resulting in either elimination of the 
AIEC, or further facilitating bacterial invasion [Aderem 2003]. If, in vivo, the 
AIEC are not killed by the macrophages, and do not induce apotosis or 
macrophage toxicity, as the In vitro data presented here and elsewhere 
would suggest [Glasser et al. 2001], it is possible that a chronic 
granulomatous reaction, typical of that seen in Crohn's disease, would result.
Successful eradication of bacteria by antibiotics is dependent on a number of 
pathogen-, drug-, and patient-related factors. For the antibiotics tested here, 
efficacies against Crohn's disease E. coll isolates at Cmax as well as at 10% Cmax 
were assessed. Ciprofloxacin, clarithromycin, tetracycline, and trimethoprim 
exhibit significant bacterial killing of AIEC internalised in macrophages at 
much lower concentrations than Cmax. Apart from ciprofloxacin, none of the
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other antibiotics studied achieved close to complete killing at conventionally 
seen Cmax levels. When tested at 10% Cmax, ciprofloxacin exhibited significant 
antibacterial effects, which were compounded when the antibiotic was used 
in conjunction with tetracycline, or with tetracycline and clarithromycin or 
trimethoprim.
Based on the data presented here, clinical trials in Crohn's disease using 
combinations of antibiotics could be possible. The combination of antibiotics 
chosen should probably include ciprofloxacin because of its superior in vitro 
efficacy, with perhaps tetracycline, as these two antibiotics in combination 
led to significant bacterial killing at 10% Cmax, more so than ciprofloxacin 
alone. Even though there are theoretical objections to using a bacteriostatic 
antibiotic (tetracycline) in combination with bactericidal antibiotics 
(ciprofloxacin), doxycycline-rifampin combinations have been used with good 
effect in treating brucellosis [Agalar et al. 1999]. However, is should be 
acknowledged that antibiotic combinations could lead to an increase of 
resistant bacterial strains, and the reduction of some possibly beneficial 
bacteria.
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7.1 SUMMARY OF KEY FINDINGS
1. Control patient and Crohn's disease AIEC invade into Caco2 and Caco2- 
c ll cells to different extents. Invasion does not correlate with disease 
status of the patient from whom the isolates were derived. Some AIEC 
strains invade Caco2 cells to a lesser extent than control E. coli K12; all 
AIEC invade Caco2-cll cells to a greater extent than E. coli K12.
2. Plantain NSP at 0.5, 5 and 50 mg / mL inhibits E. coli invasion into 
Caco2-cll cells, and at 5 and 50 mg / mL, inhibits E. coli adhesion to 
Caco2-cll cells.
3. In vitro derived M-cells have a varied expression of apical microvilli, 
unlike Caco2-cll cells which have a regular expression of apical 
microvilli. M-cells have increased binding of Aleurla aurantia lectin, 
and decreased expression of alkaline phosphatase compared with 
Caco2-cll monolayers.
4. M-cell monolayers translocate Salmonella Typhimurium LT2 and 
Shigella sonnel 80-fold and 8-fold more than Caco2-cll monolayers 
respectively, independently of monolayer TEER.
5. HM605 translocation across M-cell monolayers (when TEER > 300 
Qcm2) is just detectable at 15 minutes, and then increases steadily 
over time, without significant disruption to the monolayer integrity. 
Translocation across Caco2-cll cells was just detectable after 30 
minutes, and again, translocation increased over time. Translocation 
was not dependent upon TEER when TEER > 300 Qcm2.
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6. HM605 was detected within cells of M-cell monolayers by TEM, but 
not in Caco2-cll monolayers, or between cells.
7. Translocation of E. coll K12, E. coll XLl-Blue and probiotic E. coli Nissle 
1917 across M-cell monolayers does not appear to be significantly 
different to translocation across Caco2-cll monolayers.
8. All Crohn's disease AIEC investigated translocated through M-cell 
monolayers to a greater extent than through Caco2-cll monolayers. 
Two of the five control subject AIEC E. coli translocated through M-cell 
monolayers to a greater extent than through Caco2-cll monolayers.
9. The translocation across M-cell monolayers of control E. coli K12 and 
Crohn's disease AIECs LF82, HM580, HM605 and HM615 was 
significantly inhibited by the presence of plantain NSP at 5 mg / mL. 
Plantain NSP also inhibited translocation of Shigella sonnel at 5 mg / 
mL, and Salmonella Typhimurium LT2 at 50 mg / mL across M-cell 
monolayers. Translocation of all investigated E. coli, Shigella sonnel 
and Salmonella Typhimurium LT2 through control Caco2-cll 
monolayers was not affected by the presence of plantain NSP, with the 
notable exception of E. coli HM615 which was found to be inhibited at 
the investigated concentration of 5 mg / mL. Plantain did not affect 
monolayer TEER.
10. Translocation of HM605 through both Caco2-cll and M-cell 
monolayers was significantly inhibited by broccoli NSP at 0.5, 5 and 50 
mg / mL. Translocation of HM605 across Caco2-cll and M-cell 
monolayers was not affected by the presence of either leek or apple 
NSP at the investigated concentrations. The presence of broccoli, leek
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or apple NSP did not significantly affect the TEER of either Caco2-cll or 
M-cell monolayers.
11. Polysorbate-80 at 0.01% v/v and polysorbate-60 at 0.1% v/v led to 
increased translocation of HM605 across Caco2-cll monolayers; 
polysorbate-80 at the tenfold higher concentration 0.1% v/v led to 
increased translocation across M-cell monolayers, whilst polysorbate- 
60 treatment had no effect upon translocation at the investigated 
concentrations. Monolayer TEER was not significantly affected by the 
presence of polysorbates.
12. Colonic mucosa-associated control patient AIEC and Crohn's disease 
AIEC are better able to survive and replicate within J774-A1 
macrophages than the laboratory strain E. coli K12, as is the ileal 
Crohn's disease AIEC LF82. AIEC HM605 survives and replicates within 
membrane bound structures which resemble phagolysosomes.
13. At Cmax, combination antibiotic treatment using ciprofloxacin, 
trimethoprim and either tetracycline or rifampin confers no increase in 
bacterial killing compared with ciprofloxacin treatment alone. At 10% 
Cmax/ using ciprofloxacin with tetracycline leads to increased bacterial 
killing compared to ciprofloxacin treatment alone. The most effective 
intramacrophage killing of HM605 at 10% Cmax was seen using the 
antibiotic combination of ciprofloxacin with tetracycline and 
clarithromycin.
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8.1 CONCLUDING DISCUSSION
The pathogenesis of Crohn's disease is incompletely understood. The 
increased presence of mucosa-associated Adherent and Invasive E. coli (AIEC) 
in Crohn's disease has now been well documented [Darfeuille-Michaud et al. 
2004; Martin et al. 2004; Ryan et al. 2004; Mylonaki et al. 2005; Swidsinski et 
al. 2005; 2006; Baumgart et al. 2007; Kotlowski et al. 2007; Sasaki et al. 
2007]. A causative role for these AIEC has not been established; certainly in 
vitro, they have been shown to adhere and invade epithelial cells, such as in 
Caco2-cll cells used here (Chapter 3), but how this correlates to the in vivo 
situation is unclear.
These AIEC are also now shown to translocate across in vitro derived M-cells, 
as a result of the work contained in this thesis. Whilst translocation of AIEC at 
M-cells correlates well with the location of the initial aphthoid ulcers 
observed in Crohn's disease patients, implying they are important in disease 
initiation, it is not evidence that AIEC cause the aphthoid ulcers characteristic 
of the disease.
E. coli have been observed in vivo in macrophages [Liu et al. 1995; Ryan et al. 
2004]. In vitro, the replication of the typical ileal AIEC LF82 and several 
Liverpool colonic mucosa-associated AIEC isolates have already been 
observed with macrophages [Glasser et al. 2001; Subramanian etal. 2008].
Under normal circumstances, microbiota passing through the intestinal 
barrier would be expected to be cleared by a robust phagocytic system. In 
Crohn's disease however, defects in several cell types involved in the innate 
immune system have been reported to be associated with the disease. Cell 
types implicated include goblet cells [Podolsky et al. 1983; Van der Sluis et al.
175
2006], neutrophils [Nikolaus et al. 1998], eosinophils [Furuta et al. 2005], 
mast cells [He et al. 2004], Paneth cells [Wehkamp et al. 2004], macrophages 
[Marks et al. 2006] and dendritic cells
Paneth cells express NOD2 which is involved in the recognition of the 
bacterial peptidoglycan component muramyl dipeptide [Hugot et al. 2001; 
Lara et al. 2003; Ogura et al. 2001]; mutations in NOD2 have been implicated 
in Crohn's disease. Upon bacterial stimulation, Paneth cells produce 
antimicrobial molecules such as a-defensins [Ayabe et al. 2000]. Kobayashi et 
al. demonstrated that NOD2-deficient mice showed impaired Paneth cell 
responses upon challenge with muramyl dipeptide, and a failure to eradicate 
certain pathogens [Kobayashi et al. 2005]. Additionally, Crohn's disease 
patients have a diminished expression of a-defensins which is most 
pronounced in those with a NOD2 mutation [Wehkamp et al. 2004; 
Wehkamp et al. 2005]. A reduction in functional antimicrobial activity has 
also been reported for colonic biopsies isolated from Crohn's disease patients 
[Nuding etal. 2007].
In Crohn's disease, a reduction in function of macrophages has been 
reported, as has evidence of impaired neutrophil recruitment [Marks et al. 
2006]. Monocyte-derived macrophages from Crohn's disease patients with a 
NOD2 mutation have been found to produce less of the chemoattractant IL-8 
following stimulation with muramyl dipeptide, which in turn may lead to 
delayed recruitment of neutrophils and to suboptimal clearance of bacteria 
from the intestine, which has been reported by Marks etal.
Taken together, these findings lead to the hypothesis that, In vivo, AIEC are 
inadequately cleared by translocated across the epithelial barrier via the M- 
cells, are inadequately cleared by neutrophils, and become ingested by
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macrophages where they replicate within endophagolysosomes and 
stimulate granuloma formation.
8.2 IMPLICATIONS FOR FUTURE STUDIES
Whilst the data presented here clearly show that Crohn's disease E. coli 
isolates are able to invade Caco2-cll cells, and work by others has shown 
these E. coli to lead to IL-8 release from epithelial cells in vivo [Subramanian 
et al. 2008]. The mechanism by which these E. coli invade epithelial cells is 
currently unknown. For LF82, type 1 pili-mediated adherence has been 
implicated in invasion [Boudeau et al. 2001], as has expression of bacterial 
flagella [Carvalho et al. 2008]. Deletion of the yfgL gene in strain LF82 
resulted in a decreased ability to invade intestinal epithelial cells and a 
decreased release of outer membrane vesicles [Rolhion et al. 2005], as does 
deletion of the Nlpl gene, which encodes a lipoprotein [Barnich et al. 2004]. 
The yfgL gene is involved in the synthesis and / or degradation process of 
peptidoglycan and in the susceptibility of E. coli strain K-12 to killing by 
glycolipid derivatives of vancomycin [Eggert et al. 2001]. To date, no 
biological role has been described for the Nlpl lipoprotein.
Entry into intestinal mucosa by enteric pathogens Salmonella spp. and 
Shigella spp. is through the activation of host small Rho family GTPases Rac, 
Cdc42 and Rho. Rho-GTPase activation, via downsteam signalling events, 
results in a variety of host cell responses notably the formation of filopodia, 
lamellipodia and stress fibres. It is the regulation and reorganisation of the 
actin cytoskeleton in this way which results in phagocytosis [Jaffe et al. 2002]. 
It is possible that Crohn's disease AIEC also invade host-epithelia by a similar 
mechanism -  my own preliminary data (submitted for the degree of M.Res,
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2005) indicates that colonic mucosa-associated Crohn's disease E. coli isolate 
HM605 activates Rac-GTPase and Cdc42-GTPase in 1407 cells, with a peak 
activation observed at 4 hours. Crohn's disease E. coli isolate HM427 
activates Ras-GTPase in HT-29 cells within 5 minutes and sustains this 
activation for up to 60 minutes. This preliminary data suggests that 
therapeutic intervention using modulators of small GTPase activity may be 
beneficial to prevent bacterial uptake in the gut.
Understanding the mechanism by which AIEC invade epithelial cells in vitro 
may provide insight into their role in Crohn's disease in vivo.
The inhibition of translocation of AIEC across M-cells by plantain NSP is 
interesting, but raises the question of what exactly it is about the plantain 
NSP which inhibits the translocation of AIEC. It is probable that specific 
oligosaccharide structures within the plantain NSP interfere with bacteria -  
host cell interactions, and identifying these structures could lead to increased 
specificity to prevent bacterial translocation at M-cells. Mannose, a 
component sugar of plantain NSP (18.7% by wt), has already been shown to 
prevent LF82 adhesion to isolated Crohn's disease enterocytes but not 
control patient enterocytes when used at 2% (w / v) [Barnich et al. 2007].
That data presented here also have implications for diseases other than 
Crohn's disease. Plantain NSP has been shown to block adherence of Crohn's 
disease E. coli isolates to Caco2-cll cells in vitro, and to inhibit the 
translocation of Crohn's disease E. coli isolates across M-cell monolayers in 
vitro. Translocation of Salmonella Typhimurium LT2 and Shigella sonnei 
across M-cell monolayers is also blocked by plantain NSP in a dose-dependent 
fashion. Whilst work to date has focussed on Gram-negative organisms, the 
broad range of bacteria whose epithelial adhesion and M-cell translocation is
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inhibited by soluble plantain IMSP suggest the possibility that it may also be 
effective at preventing the adhesion to colonic epithelial cells or translocation 
across M-cells by Gram-positive bacteria.
One organism of particular interest is Clostridium difficile, a major cause of 
antibiotic-associated diarrhoea and colitis in humans. C. difficile is often 
considered to be a 'superbug' as it is notoriously difficult to eliminate. The 
cause of C. difficile-induced infection is considered to local release of 
enterotoxin (toxin A) and cytotoxin (toxin B) by C. difficile [Bordello et al. 1988; 
Lyerly et al. 1988; Riegler et al. 1995; Pothoulakis 1996; Taha et al. 2007]. Close 
proximity of C. difficile to the host epithelium is almost certainly necessary to 
produce toxic effects [Bordello et al. 1988], and preventing these interactions 
should therefore be of therapeutic benefit.
The prevention of adhesion of pathogenic bacteria to the intestinal 
epithelium by ingested soluble plant fibres seems likely to represent an 
important protective mechanism that has previously been overlooked.
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APPENDIX 1 -  BACTERIAL CHARACTERISTICS OF STRAINS SELECTED FOR
STUDY WITHIN THIS THESIS
Bacterial Strain Disease Group PatientNumber Isolated from
E. coli HM95 Crohn's disease 15
Epithelial cell- 
associated
E. coli HM154 Crohn's disease 30 Intracellular
E. coli HM413 Crohn's disease 59 Mucus-associated
E. coli HM419 Crohn's disease 59
Epithelial cell- 
associated
E. coli HM580 Crohn's disease 71 Mucus-associated
E. coll HM605 Crohn's disease 73 Mucus-associated
E. coli HM615 Crohn's disease 74 Mucus-associated
E. coli LF82 Crohn's disease — —
E. coli HM428 Control(IBS/Polyposis) 60
Epithelial cell- 
associated
E. coli HM454 Control(IBS/Polyposis) 60 Mucus-associated
E. coli HM456 Control(IBS/Polyposis) 60 Mucus-associated
E. coll HM463 Control(IBS/Polyposis) 62 Mucus-associated
E. coli HM484 Control(IBS/Polyposis) 65
Epithelial cell- 
associated
E. coli HM488 Control(IBS/Polyposis) 65 Mucus-associated
E. coll K12 — — —
E. coli Nissle 1917 — — —
Salmonella 
Typhimurium LT2
— — —
Shigella sonnei — — —
233
Bacterial Strain API 20E 1 Haemagglutination status 2 Induces IL-8 3
E. coli HM95 5144552 - +
E. coli HM154 5104572 - +
E. coli HM413 7144552 - n/a
E. coli HM419 5044552 + n/a
E. coli HM580 4044512 + +
E. coli HM605 5144552 + +
E. coli HM615 5144152 + +
E. coli LF82 n/a - n/a
E. coli HM428 5144512 + +
E. coli HM454 5144512 + n/a
E. coli HM456 5144512 + n/a
E. coli HM463 5144572 - n/a
E. coli HM484 7144552 - +
E. coli HM488 5144552 - n/a
E. coli K12 n/a n/a n/a
E. coli Nissle 
1917 n/a n/a n/a
Salmonella
Typhimurium
LT2
n/a n/a n/a
Shigella sonnei n/a n/a n/a
n/a -  data not available
1 Gram-negavtive bacteria identified by API 20E bacterial identification 
system (BioMerieux, Marcy L'etole, France) [Martin 2004]
2 Determined by the ability to haemagglutinate red blood cells (taken from 
[Subramanian etai. 2008]
3 Significant increase in IL-8 release from HT-29 colon epithelial cells 
compared to basal IL-8 release [Subramanian e ta i 2008].
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Bacterial Strain Afa/Dr cluster4
Curli
fimbriae 5
Adherence to 
1407 cells
Invasion of 
1407 cells
E. coli HM95 - + + +
E. coli HM154 - + + +
E. coli HM413 n/a n/a + +
E. coli HM419 n/a n/a + +
E. coli HM580 + - + +
E. coli HM605 - + + +
E. coll HM615 - + + +
E. coli LF82 n/a n/a + +
E. coli HM428 n/a n/a + +
E. coli HM454 - + + +
E. coli HM456 - + + +
E. coli HM463 + +
E. coli HM484 n/a n/a + +
E. coli HM488 - - + +
E. coli K12 n/a n/a + +
E. coli Nissle 1917 n/a n/a + +
Salmonella 
Typhimurium LT2 n/a n/a +
+
Shigella sonnei n/a n/a + +
4 Data from [Martin et al. 2004]
5 Data from [Subramanian et al. 2008]
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Bacterial Strain
Adherence to 
HT-29 cells
Invasion of 
HT-29 cells
E. coll HM95 + +
E. coli HM154 + -
E. coli HM413 + +
E. coli HM419 + +
E. coli HM580 + +
E. coli HM605 + -
E. coli HM615 + -
E. coli LF82 n/a n/a
E. coli HM428 n/a n/a
E. coli HM454 n/a n/a
E. coli HM456 n/a n/a
E. coli HM463 + -
E. coli HM484 + +
E. coli HM488 n/a n/a
E. coli K12 n/a n/a
E. coli Nissle 1917 n/a n/a
Salmonella 
Typhimurium LT2
n/a n/a
Shigella sonnei n/a n/a
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Bacterial Strain
Invasion into Caco2 
cells 6
Invasion into Caco2-cl 
cells7
E. coli HM95 < 1 2.72 ±0.52
E. coli HM154 < 1 4.27 ± 1.22
E. coli HM413 n/a n/a
E. coli HM419 4.39 ± 1.37 4.19 ± 1.74
E. coli HM580 < 1 3.64 ±0.29
E. coli HM605 15.92 ±2.74 10.04 ±0.65
E. coli HM615 2.16 ±0.11 3.32 ± 1.21
E. coll LF82 2.01 ±0.83 1.58 ±0.06
E. coli HM428 8.85 ±2.82 12.29 ± 1.99
E. coli HM454 17.29 ±3.18 11.71 ± 1.57
E. coli HM456 5.89 ±0.92 8.45 ±0.20
E. coli HM463 22.53 ±3.92 25.55 ± 1.74
E. coli HM484 < 1 5.86 ±0.57
E. coli HM488 2.79 ± 1.09 4.85 ±0.34
E. coli K12 1 1
E. coli Nissle 1917 n/a n/a
Salmonella 
Typhimurium LT2
> 1 > 1
Shigella sonnei > 1 > 1
6 Data expressed as invasion relative to E. coli K12
7 Data expressed as invasion relative to E. coli K12
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Bacterial Strain
Invasion of Caco2-cl 
cells inhibited by 50 
mg / mL plantain NSP
Adhesion to Caco2-cl 
cells inhibited by 5 or 50 
mg / mL plantain NSP
E. coli HM95 n/a n/a
E. coli HM154 n/a n/a
E. coli HM413 n/a n/a
E. coli HM419 n/a n/a
E. coli HM580 + +
E. coll HM605 + +
E. coli HM615 + +
E. coli LF82 + +
E. coll HM428 n/a n/a
E. coli HM454 n/a n/a
E. coll HM456 n/a n/a
E. coli HM463 n/a n/a
E. coli HM484 n/a n/a
E. coll HM488 n/a n/a
E. coli K12 + +
E. coli Nissle 1917 n/a n/a
Salmonella 
Typhimurium LT2
+ +
Shigella sonnei + +
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Bacterial Strain Phylotype 8
Replication within 
macrophages
E. coli HM95 A +
E. coli HM154 B1 +
E. coli HM413 n/a +
E. coli HM419 n/a +
E. coli HM580 D +
E. coli HM605 B2 +
E. coli HM615 B2 +
E. coli LF82 B2 +
E. coli HM428 n/a +
E. coli HM454 B2 +
E. coli HM456 B2 +
E. coli HM463 n/a +
E. coli HM484 n/a +
E. coli HM488 B2 +
E. coli K12 n/a +
E. coli Nissle 1917 n/a n/a
Salmonella 
Typhimurium LT2
n/a n/a
Shigella sonnei n/a n/a
8 Phylotype data from [Subramanian et al. 2008], analysis based on the 
findings of [Kotlowski et al. 2007].
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APPENDIX 2 -  SOLUTIONS
10% Resolving Polyacrylamide Gel (Immunoblotting)
21.6 mL Distilled water
11.25 mL Acrylamide/bis-acrylamide, 40% solution (SIGMA)
11.25 mL 1.5 M Tris buffer (pH 8.8)
450 pL 10% (w/v) SDS
450 pL 10% (w/v) Ammonium persulfate
45 pL TEMED
4% Stacking Polyacrylamide Gel (Immunoblotting)
18.9 mL Distilled Water
3 mL Acrylamide/bis-acrylamide, 40% solution (Sigma Ltd)
7.5 mL 1.5 M Tris buffer (pH 8.8)
300 pL 10% (w/v) SDS
300 pL 10% (w/v) Ammonium persulfate
30 pL TEMED
Luria Burtani agar
5g Yeast extract
lOg Tryptone
lOg NaCl
15g Agar
1L Distilled water
Luria Burtani culture broth
5g Yeast extract
10g Tryptone
10g NaCI
1L Distilled Water
Phosphate Buffered Saline (PBS)
8g NaCI
0.2 g KCl
1.44 g Na2HP04
0.24 g kh2po4
1 L Distilled Water
Adjust pH to 7.4 
Reynards Lead Citrate
1.33 g Lead nitrate
1.76 g Sodium citrate
8 mL 1M NaOH
42 mL Distilled water
Uranyl Aceteate
1.25g Uranyl acetate
12.5 mL Ethanol
12.5 mL Distilled water
SDS-PAGE running buffer
1 L Distilled water
14.4 g Glycine
3.03 g Tris base
l g Sodium dodecyl sulphate
SDS-PAGE transfer buffer
800 mL Distilled water
14.4 g Glycine
3.03 g Tris base
200 mL Methanol
5x SDS-PAGE sample buffer
4 mL Distilled water
1 mL 0.5 M Tris-HCI
0.8 mL Glycerol
1.6 mL 10% SDS
0.4 mL Beta-mercaptoethanol
0.2 mL 0.05% (w/v) bromophenol blue
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